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 Biomechanics plays a key role in the development and maintenance of biological 
tissue. It is well known that biological tissue grows and remodels in response to varying 
mechanical loads. Arteries and lymphatic vessels share many similar mechanical loads 
such as luminal pressure, axial force, and fluid shear force on the endothelium. Diseases 
of these vascular systems have frequently been associated with deviations from a 
hypothesized “preferred” homeostatic mechanical environment and maladaptive growth 
and remodeling. Changes in mechanical loading such as hypertension and disturbed flow 
have been shown to lead to well known preclinical markers of cardiovascular disease 
including arterial stiffening, increased thickness of the arterial wall, and endothelial 
dysfunction as diagnosed by a decrease in flow-mediated dilation. Similarly, although the 
progression of lymphedema is less understood, lymphatic dysfunction has been 
associated with changes in luminal and/or interstitial pressure and tissue remodeling that 
includes thickening of the lymphatic wall.  
 Mechanically-mediated disease development affects many populations, but 
developing nations face challenges that are unique due to disease burdens that are 
specific to the regions. Treatment strategies for HIV have resulted in HIV-positive 
patients living longer lives, but these patients also suffer from non-AIDS-related 
comorbidities including accelerated progression of cardiovascular disease. Such 
progression may occur via mechanisms that differ from traditional pathways leading to 
cardiovascular disease in the developed world. Developing nations, specifically those in 
sub-Saharan Africa, carry the majority of the burden of HIV infection and, consequently, 
its associated comorbidities, making the characterization of HIV-associated 
 xxi
cardiovascular disease a critical step in the treatment and care of a large population. 
Similarly, lymphedema is a common side effect of lymphatic filariasis, a condition 
characterized by parasitic infection that occurs preferentially in tropical areas. Again, 
sub-Saharan Africa carries a significant portion of the burden of lymphatic filariasis and 
suffers from significant disability burden due to the lack of treatment options for 
lymphedema associated with lymphatic filariasis. The overall goal of this project is to 
develop novel experimental and theoretical frameworks for the study of mechanically-
mediated diseases of the arterial and lymphatic vasculature that are commonly seen in 
developing nations with the ultimate intention of identifying key parameters that 
contribute to tissue growth and remodeling that underlie disease progression. 
 In this study, we investigated the progression of two primary pathologies: HIV-
associated cardiovascular disease and mechanically-mediated progression of lymphatic 
dysfunction. First, we investigated the role of efavirenz (EFV), a commonly used 
antiretroviral for HIV treatment, in the progression of early markers of cardiovascular 
disease. We characterized EFV-associated vascular remodeling and dysfunction in adult 
and pediatric HIV-1-positive Ethiopian populations. Arterial stiffness was quantified via 
pulse wave analysis and pulse wave velocity with applanation tonometry, and carotid 
intima-media thickening and impairment of brachial flow-mediated dilation were 
quantified using non-invasive ultrasound. We found that adult patients infected with 
HIV-1 who were taking EFV-containing treatment regimens had increased aortic stiffness 
as measured by pulse wave velocity compared to NVP-containing treatment regimens (a 
similar drug of the same class of antiretrovirals) as well as decreased brachial flow-
mediated dilation and increased normalized carotid intima-media thickness (cIMT) 
 xxii
compared to HAART-naïve controls and NVP-treated subjects, indicating endothelial 
dysfunction and maladaptive vascular remodeling due to EFV treatment. Correlation and 
regression analysis revealed that current EFV use was an independent predictor for 
increased pulse wave velocity and increased normalized cIMT. 
 Additionally, we developed a novel experimental and theoretical paradigm to 
quantify lymphatic mechanical function and mechanically-mediated growth and 
remodeling to highlight key parameters that may be contributing to the onset of 
lymphedema. We quantified the ex vivo passive and active mechanical properties of rat 
thoracic ducts using a microstructurally-motivated constitutive model and incorporated 
the theoretical framework and experimentally-determined parameters into a lumped 
parameter model to predict the mechanical environment of a lymphatic vessel during 
active and passive lymph transport. Using this predictive model, we then developed a 
novel framework for prediction of lymphatic growth and remodeling and identified 
potential parameters involved in the progression of lymphedema. This study serves to 
identify possible contributors to mechanically-mediated lymphatic dysfunction using a 
novel mathematical framework and consequently provide direction for future 
investigations of lymphatic dysfunction. 
 This dissertation demonstrates the utility of modeling and biomechanics in the 
investigation of disease progression in understudied populations using applied 
biomechanics concepts in clinical, experimental, and theoretical contexts. The application 
of biomechanics to the study of arterial and lymphatic dysfunction in this study has 
successfully identified potential parameters involved in the progression of cardiovascular 
disease associated with HIV treatment as well as the progression of mechanically-
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mediated lymphatic dysfunction. This work can be utilized in future studies as we 









                                                              CHAPTER 1 
INTRODUCTION 
Medical advances over the past century have dramatically improved both life 
expectancy and quality of life for many global populations. However, it is well known 
that the benefits of medical advancement are strikingly different between people groups. 
Results from the Global Burden of Disease study recently reported healthy life 
expectancy (i.e. years of life without disability) for all nations in 2010. Countries in sub-
Saharan Africa dominated the bottom of the list for both men and women, with values as 
low as 38 years in the Central African Republic [1].  Compare this to the 70+ year 
healthy life expectancy in Japan, and the disparity between public health burdens 
becomes obvious.  
In order to effectively combat such a staggering statistic, it is critical that we first 
understand the problem before providing a solution. Sub-Saharan Africa has been 
devastated in recent years by the AIDS epidemic [2], and while the advent of HAART 
has transformed HIV from a death sentence into a chronic and manageable disease, many 
still suffer from the large number of co-morbidities associated with HIV infection and 
treatment. Such co-morbidities include neurological disorders, nephropathy, diabetes, 
malnutrition, dyslipidemia, and cardiovascular disease (CVD) [3]. More specifically, 
CVD related to HIV has been attributed to both the infection as well as the treatment, 
creating difficulty in understanding the pathology associated with this condition. 
Additionally, diseases such as lymphatic filariasis, while not generally fatal, contribute to 
a substantial portion of the burden of global disability rates. Approximately 40 million 
people worldwide are disfigured or disabled by lymphedema associated with lymphatic 
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filariasis [4], and again sub-Saharan Africa carries a significant portion of the burden [5]. 
As with HIV-induced CVD, the pathological development of lymphedema is not well 
understood.  
Within the past few decades, much research has been dedicated to understanding 
the role of mechanics in disease development, and many important discoveries have been 
made that suggest disease pathology may in many cases be mechanically-mediated [6]. 
This knowledge offers a novel perspective in the search for a solution to disease burden 
in underdeveloped nations, including HIV-induced CVD and lymphedema associated 
with lymphatic filariasis. This dissertation aims to utilize modeling approaches to 
quantify the role of mechanics in the development of these conditions with the ultimate 
goal of supporting long-term efforts at identifying therapeutic targets for the treatment 
and prevention of these and other diseases.  
1.1 Specific Aim 1: Characterize the role of efavirenz in HAART-induced 
mechanically-mediated vascular remodeling in an HIV-positive Ethiopian cohort as 
well as a mouse model of atherosclerosis. 
 Clinical studies have shown an increased incidence of preclinical markers of 
atherosclerosis such as arterial stiffening, endothelial dysfunction, and thickening of the 
arterial wall along with resultant cardiovascular events following the initiation of 
HAART [7]. While most clinical studies addressing cardiovascular-related comorbidity 
with HIV are focused on the developed world, the majority of the burden of HIV 
infection is in sub-Saharan Africa, with 69% of the HIV-infected population residing 
there [2]. Treatment programs in Africa have dramatically reduced HIV-related deaths, 
but disparities in infrastructure inhibit patient access to follow-up treatment and a broad 
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range of combination therapy. Consequently, patients in sub-Saharan Africa remain on 
first-line therapy, which often includes EFV, for a longer period of time.  
 Despite the prevalence of EFV in first line therapy, research addressing its role in 
the development of HAART-related CVD is minimal, with only a handful or recent 
reports quantifying its role in vascular dysfunction [8, 9]. Because treatment involves a 
cocktail of drugs as opposed to a single drug, the use of animal models is a desirable 
route in the effort to characterize the role of EFV in CVD development. Laboratory 
studies of EFV have shown vascular dysfunction [8], mitochondrial dysfunction [10, 11], 
and increased production of ROS [10]. Laboratory studies of other drug classes for HIV 
treatment have demonstrated similar results in addition to arterial stiffening and alteration 
of cathepsin expression and activity [12]. Given the clinical need and available laboratory 
data, our working hypothesis is that EFV will be associated with arterial stiffening and 
vascular remodeling in an Ethiopian cohort of HIV-positive patients and will lead to 
arterial stiffening and aortic intima-media thickening in a mouse model of 
atherosclerosis.  
1.2 Specific Aim 2: Develop an experimental / theoretical paradigm to 
characterize lymphatic dysfunction associated with mechanically-mediated growth 
and remodeling. 
 Lymphatic function is directly dependent on the ability of lymphatic vessels to 
spontaneously and rhythmically contract to transport fluid against an unfavorable 
pressure gradient, a function which, if impaired, leads to lymphedema. Progression of 
lymphedema can be spontaneous (primary or idiopathic lymphedema), or it can occur 
following cancer treatment or parasitic infection. Lymphedema is estimated to occur in 
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12.5% of cases of lymphatic filariasis infection, and sub-Saharan Africa contains 
approximately 40% of the world’s cases of infection, suggesting that approximately 5 
million cases of lymphedema occur in sub-Saharan Africa due to lymphatic filariasis 
alone [5].  
 It is well known that the mechanical environment of lymphatic vessels contributes 
to their contractile function [13, 14]. Consequently, much work has been devoted to 
quantifying the relationship between mechanical cues such as inlet and outlet pressure, 
magnitude and direction of flow, and pressure gradient and lymphatic contractile 
function. In the context of lymphedema, lymphatic contractile function is inhibited to the 
extent that lymph propulsion no longer exists. Mechanically-mediated growth and 
remodeling has been well established in biological tissue (see, for example [15]), and 
given the intimate relationship between mechanical cues and lymphatic function together 
with observed tissue thickening in lymphedema [16], it seems likely that mechanically-
mediated growth and remodeling may be a primary contributor to the loss of contractile 
function that leads to lymphedema. Experimentally-motivated mathematical models 
describing such a process are glaringly absent, and thus the goal of this aim is to develop 
a theoretical paradigm that incorporates experimental data to quantify the relationship 
between mechanically-mediated growth and remodeling and concomitant loss of 





                                                                 CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
2.1 Arterial structure and function 
 Systemic circulation consists of arteries, which are responsible for carrying 
oxygenated blood from the heart to the peripheral tissues, and veins, which are 
responsible for carrying deoxygenated blood from the peripheral tissues to the heart for 
oxygenation. Arteries can be divided into two categories: elastic arteries are generally 
larger arteries that are closer to the heart (e.g. aorta, common carotid arteries), and 
muscular arteries are generally smaller vessels and located closer to peripheral tissues 
(e.g. femoral artery, cerebral artery). The arterial wall consists of three primary layers: 
the intima, the media, and the adventitia [17]. The intima is a single layer of endothelial 
cells lining the luminal face of the vessels and exists to provide a non-thrombogenic 
surface as well as to regulate transport of substances from blood to tissues and vice versa. 
During inflammatory cascades, endothelial permeability is increased to facilitate 
transport of immune cells. Endothelial cells are capable of sensing and responding to the 
local flow environment and thus also assist in the regulation of blood pressure via 
production of nitric oxide (NO) and subsequent relaxation of vascular smooth muscle 
cells [18]. The media is a layer of vascular smooth muscle cells (SMCs) and numerous 
sheets of elastic lamina. In elastic arteries, the vascular smooth muscle is organized into 
concentric layers that are separated by thin fenestrated sheets of elastin. In muscular 
arteries, smooth muscle generally appears as a single layer surrounded by an internal and 
external layer of elastin. Vascular SMCs are capable of communicating with neighboring 
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cells, a function which is critical for maintenance of blood pressure following production 
of signaling molecules by endothelial cells. Finally, the adventitia is the outermost layer 
of the artery wall and is comprised mostly of collagen and fibroblasts. The adventitia is 
the primary load-bearing component of the arterial wall and serves to limit the extent to 
which an artery can extend following systolic contraction of the heart.  
 All constituents of the arterial wall work together to govern both the mechanical 
and biological functions of the systemic circulation. Interruption or alteration of any 
cellular or structural function of any component can inhibit the ability of the vessels to 
function properly, leading to any number of cardiovascular diseases including 
hypertension, coronary artery disease, atherosclerosis, and peripheral arterial disease.  
2.2 Cardiovascular disease 
 Cardiovascular disease (CVD) is currently the leading cause of death in the 
developed world, causing as many as one in three deaths in the United States and killing 
approximately 2200 Americans every day [19].  Most CVD-related deaths are attributable 
to atherosclerosis and eventual ischemia. In 2008, cardiovascular events related to 
ischemic heart disease (i.e. heart attacks and strokes) in the United States were 
responsible for 13.5 million out of 17.3 million deaths worldwide [20]. Atherosclerosis is 
a condition in which lipids accumulate in the arterial wall and eventually form calcified 
plaques. These plaques can rupture, leading to thrombosis and complete occlusion of the 
lumen of a vessel, thus preventing blood flow to critical organs such as the heart and 
brain. Risk factors for CVD are partially behavioral. Tobacco use, physical inactivity, 
unhealthy diet, and alcohol abuse are all primary contributors to CVD [21]. Metabolic 
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risk factors also exist such as hypertension, elevated blood sugar, increased cholesterol, 
and obesity, and still others exist such as ethnicity, age, and gender [21].  
 Atherosclerosis is considered a chronic inflammatory condition due to the 
constant cascade of immune cells and inflammatory cytokines associated with its 
progression [22]. Progression of atherosclerosis begins with activated endothelial cells 
and subsequent endothelial dysfunction marked by an increase in endothelial 
permeability, increased expression of adhesion molecules, and decreased shear-induced 
production of NO [23]. Many have suggested that such endothelial dysfunction is due in 
large part to a change in the hemodynamic environment due to altered or disturbed blood 
flow [24-26], a hypothesis which arose from the discovery that atherosclerotic plaques 
occur preferentially in locations of disturbed flow [27]. Increased expression of adhesion 
molecules attracts circulating monocytes to attach to the vascular endothelium, and 
increased endothelial permeability then allows an influx of monocytes, platelets, and T-
lymphocytes into the arterial wall [22]. Monocytes differentiate to become macrophages 
that ingest lipoproteins and eventually become the lipid-laden foam cells that form the 
characteristic fatty streaks that form in the early stages of atherosclerosis. These cells 
secrete various chemokines that continue to attract additional monocytes and promote a 
positive feedback loop of lipid accumulation in the wall. As lipids accumulate, smooth 
muscle cells begin to change to a synthetic phenotype, a process which results in 
increased production of collagen and decreased vascular compliance [28]. Note, however, 
that arterial stiffening and thickening of the carotid wall are also considered risk factors 
for cardiovascular events that precede plaque progression, so decreased compliance and 
vascular remodeling likely occur prior to plaque accumulation in the wall of the artery 
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[29, 30]. Without behavioral, pharmaceutical, or surgical intervention, atherosclerotic 
plaques will continue to grow until the lumen is mostly occluded, likely resulting in 
plaque rupture, thrombosis, and a subsequent ischemic cardiovascular event. 
 Clinically, there are multiple methods for assessing markers of CVD in order to 
increase awareness and decrease risk of cardiovascular events. Endothelial dysfunction is 
diagnosed via measurement of flow-mediated dilation (FMD) in which blood flow is 
occluded and flow-induced dilation of an artery (usually the brachial artery) is quantified 
using ultrasound following the release of the occlusion. Decreased FMD is interpreted as 
endothelial dysfunction due to the presumed lack of NO production by the endothelial 
cells upon increased blood flow [31]. Increased intima-media thickness (IMT) of the 
carotid artery is another preclinical marker of CVD that can be easily assessed using 
ultrasound [30, 32]. Arterial stiffness can also be quantified using either pulse wave 
velocity (PWV) or pulse wave analysis (PWA) which are quantified using applanation 
tonometry [33]. Lastly, coronary artery calcification can be measured using computed 
tomography in order to quantify the level of calcium deposits in an artery, a metric which 
follows the progression of atherosclerosis.  
2.3 HIV and highly active antiretroviral therapy 
 The Human Immunodeficiency Virus (HIV) was first diagnosed when the Centers 
for Disease Control reported an outbreak of pneumocystis pneumonia in an otherwise 
healthy group of young homosexual males in New York City and San Francisco [34]. By 
1987, the first antiretroviral drug for the treatment of HIV (AZT) was produced. While 
the treatment was somewhat successful, viral mutations resulted in drug resistance that 
led to development of other drugs and eventually a standard treatment consisting of a 
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cocktail of three drugs, now known as highly active retroviral therapy (HAART). The 
result of the development of HAART has been undeniable: HIV has transformed from a 
death sentence to a chronic and manageable disease. Indeed, the introduction of HAART 
led to a decrease in AIDS-related mortality in the United States by 47% in 1997 [35]. 
 HIV is a lentivirus that causes the acquired immunodeficiency syndrome (AIDS). 
HIV infects many different immune cells, but primarily CD4+ lymphocytes, by first 
binding to the cell surface. Binding is promoted by the expression of the CD4 receptor 
and a chemokine receptor, usually CXCR4 or CCR5 [36]. Following fusion with the 
membrane, the virus undergoes a shedding process in which the viral RNA is 
incorporated into the host cell’s DNA via reverse transcription. Viral DNA is then 
integrated into the genome DNA, new viral genes are transcribed, and the RNA is either 
packaged into new virions or translated into viral proteins. Proteins then move close to 
the cell membrane and begin a budding process to form a new virus that contains all of 
the necessary RNA and proteins to repeat the process in another host cell. 
 HAART treatment consists of a daily regimen of three drugs that work together to 
inhibit replication of HIV. Multiple drug types exist and are prescribed in particular 
combinations based on drug-drug interactions as well as patient considerations such as 
age, previous HAART experience, and current viral load or CD4 cell count. Most 
prescribed first-line therapy consists of a backbone of nucleoside reverse transcriptase 
inhibitors (NRTIs) along with either a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI) [37]. 
NRTIs and NNRTIs have similar mechanisms of action in that they both inhibit the 
reverse transcriptase enzyme and thus prevent incorporation of viral RNA into the host 
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cell genome [38]. A dual NRTI backbone is most often prescribed to patients who have 
never undergone HAART therapy, and the most commonly recommended backbone is 
tenofovir disoproxil fumarate (TDF) together with emtricitabine (FTC) [37]. This 
backbone is frequently prescribed with efavirenz (EFV), the most commonly prescribed 
NNRTI. PIs operate differently by inhibiting the protease enzyme that facilitates cleaving 
and final assembly of the mature virus following replication, thus allowing viral 
replication within the cell but preventing the virus from maturing and infecting other cells 
[38]. PIs are also often prescribed with the common dual NRTI backbone. Some common 
PIs include ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), 
and ritonavir-boosted darunavir (DRV/r). INSTIs also inhibit integration of the viral 
RNA into the host cell’s DNA by inhibiting the integrase enzyme [39]. Some INSTIs that 
are recommended for use with a dual NRTI backbone are dolutegravir (DTG) and 
elvitegravir (EVG) [37]. Fusion inhibitors and CCR5 co-receptor antagonists are also 
relatively newly available drug types but are prescribed much less frequently than the 
other drug types listed here. 
2.4  HIV, HAART, and cardiovascular disease 
 The advent of HAART has resulted in patients infected with HIV-1 living much 
longer lives. However, these patients are now suffering from many non-infectious 
comorbidities. HIV-1+ patients suffer from increased incidence of neurological disorders 
such as toxicity of the central nervous system and peripheral neuropathy, diabetes, 
dyslipidemia and lipodystrophy, renal failure, bone fracture, and cardiovascular disease 
[3, 40]. Of particular interest is the association between HIV and CVD. Multiple studies 
have shown that HIV-1+ patients are at increased risk of cardiovascular and 
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cerebrovascular events [7, 41-44], have atherosclerotic lesions [45-47], and present with 
multiple preclinical markers of atherosclerosis including arterial stiffness [48-50], 
increased cIMT [48, 51], and impaired FMD [52, 53]. However, the exact mechanisms 
driving the progression of CVD in HIV-1+ patients are still not fully understood. Some 
studies have implicated the viral infection as a singular cause of CVD, demonstrating 
coronary arteriopathy and atherosclerotic lesions following post-mortem analysis of 
HAART-naïve HIV-1+ patients [54, 55], and many laboratory studies have implicated 
HIV-1 proteins in preclinical markers of atherosclerosis and vascular dysfunction [56-
59]. However, multiple other studies have shown an increase in markers of CVD between 
HAART-naïve and HAART-treated patients [48, 52, 53, 60, 61]. Consequently, many 
laboratory studies have been devoted to understanding the individual roles of HIV-1 
proteins or specific HAART drugs on the development of markers of CVD. 
 Various HIV-1 proteins have been shown to cause markers of CVD via different 
mechanisms. The Tat protein has been linked to endothelial dysfunction in porcine 
coronary arteries via NOS inhibition [62]. The same protein has also been shown to bind 
to endothelial cells and alter secretion of matrix remodeling proteins, cell-cell adhesion, 
angiogenesis, and vascular permeability [63-67]. Parker et al. showed that Tat increases 
expression of matrix remodeling proteins (cathepsin K) in areas of the vasculature with 
low or oscillatory shear stress [58]. Hansen et al. demonstrated a synergistic role of 
multiple HIV-1 proteins in the onset of arterial stiffening in a transgenic rat model [56], 
and Kline et al. demonstrated increased ROS production using the same model [57]. 
Similarly, gp120 and Tat have both been implicated in the production of reactive oxygen 
species in brain endothelial cells by multiple groups [68-70].  
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 While it seems clear that HIV-1 infection alone may contribute to accelerated 
progression of CVD due to the impact of HIV-1 proteins on vascular function and the 
inflammatory cascade initiated by infection, many other studies have also implicated the 
treatment as a primary contributor to vascular dysfunction and CVD. Multiple markers of 
CVD are exacerbated in HIV-1+ patients receiving HAART (compared to HAART-naïve 
patients) including arterial stiffening [71-74], impaired FMD [52, 75-77] (noting 
exceptions in Gupta et al. in which various HAART treatments were different, but not 
compared to HAART-naïve), and increased cIMT [46, 78]. NRTIs have been heavily 
implicated in the development of these markers. In a longitudinal study, van Vonderen et 
al. showed a decrease in carotid arterial stiffness, but increase in femoral artery stiffness 
after 24 months of AZT+3TC+LPV/r treatment (an NRTI-based regimen), with similar 
trends in NVP+LPV/r treatment (an NNRTI-based regimen) [71]. Indeed, laboratory 
studies have corroborated the role of various NRTIs, most commonly AZT, in 
progression of markers of CVD. AZT causes endothelial dysfunction via increased 
production of reactive oxygen species [79-82], intima-media thickening [12, 83], and 
arterial stiffening [12]. Similarly, PIs have been widely implicated class of antiretroviral 
drugs associated with atherosclerosis and have been correlated with increased c-IMT [84, 
85], impaired FMD [86-88], dyslipidemia [89], atherosclerosis [7, 90], and myocardial 
infarction [91], but others have reported contradictory results [92-96]. NNRTIs have been 
associated with elevated cholesterol levels and triglycerides [7], with EFV associated 
with higher total cholesterol and triglyceride levels than NVP [89]. Less is known about 
the association between NNRTIs and c-IMT, FMD, and arterial stiffness. Some 
laboratory studies have implicated EFV in development of endothelial dysfunction in 
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coronary endothelial cells via ROS production [8] as well as mitochondrial dysfunction 
and ROS production in hepatic cells [10, 11]. Others have shown EFV to be cytotoxic in 
Jurkat T cells and peripheral blood monocytes [97]. Mondal et al. reports that EFV alone 
does not contribute to increased leukocyte adhesion [98], so the detrimental effects of 
EFV have still not been fully characterized. Given this plethora of data, there clearly 
exists a need to further elucidate the effects of individual drugs and combined therapy 
and investigate the mechanisms behind HAART-induced cellular dysfunction and disease 
progression. 
2.5 Vascular mechanics and growth and remodeling 
 As early as 1880, Dr. Charles Roy observed that “with animal tissues (excepting 
bone), [Hooke’s Law] does not hold good” [99]. Since then, many have sought to 
accurately characterize the behavior of biological tissue. The mechanical environment of 
blood vessels consists primarily of luminal pressure, axial force, and shear stress on the 
endothelium. Some vessels such as coronary arteries experience a high degree of torsion 
during loading from contractions of cardiac muscle [100], but in general, mechanical 
forces can be simplified to in plane forces excepting fluid shear stress. Previous 
observations have asserted that elastin is the primary load-bearing constituent under low-
loading conditions, whereas collagen supports the majority of the load under high-loading 
conditions [101]. The mechanical environment can be easily quantified using Laplace’s 
Law to calculate the average stresses in the wall of the vessels based on the applied loads 
and the geometry of the vessels. However, such quantification neglects stress 
distributions within the wall of the vessel and does not adequately predict the highly non-
linear, heterogeneous, anisotropic behavior of the tissue. In order to accurately 
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characterize the complex behavior of the vessels, a combination of an accurate strain 
energy function and an appropriate kinematic framework must be considered. 
Appropriate kinematics are generally simplified to include only inflation and extension; 
however, some models have included torsion to account for forces experienced in 
coronary arteries [102]. Additionally, Chuong and Fung identified the presence of 
residual stresses in arteries that became a critical consideration for accurate predictions of 
stress in a 3D framework [103]. Various empirical strain energy functions have been 
proposed that capture the non-linearity of vascular tissue while treating the tissue as 
homogeneous [104-107]. Additional functions have been proposed and utilized that are 
more phenomenological and attempt to account for contributions from the microstructure 
of the vessel [108-110], and other models have moved beyond characterization of the 
passive mechanics to include active stress contributions due to smooth muscle cell 
contraction [111]. Ex vivo testing can be performed in order to acquire data regarding 
mechanical behavior, and non-linear regression analysis can then be performed using any 
of the constitutive models here in conjunction with Laplace’s Law to quantify parameters 
associated with specific tissue. This parameter estimation process provides a wider range 
of parameters describing material behavior (as opposed to a single value such as Young’s 
modulus for linear elastic behavior) and also provides a methodology for quantification 
of differences in mechanical behavior between tissue types [112]. 
 Accurate quantification of the mechanical environment of blood vessels has 
become an important focus since studies have suggested that arteries grow and remodel 
to restore homeostatic values of stress. These studies have shown that arteries have an 
increased radius in response to increased flow in order to restore wall shear stress [113] 
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as well as increased thickness in response to increased blood pressure in order to restore 
circumferential stress [114]. Other studies have shown that axial stress is regulated by 
remodeling of the arterial wall as well [115]. The remodeling described in these studies is 
indicative of the remodeling seen in the progression of preclinical markers of 
atherosclerosis, especially thickening of the arterial wall. Consequently, many have 
sought to quantify the growth and remodeling process in order to identify key parameters 
that drive the process. Such models were initially proposed as volumetric growth, defined 
as uniform growth of infinitesimally small volumes of the arterial wall in response to 
changes in mechanical loading [116, 117]. In these models, growth can be governed 
mathematically by evolution equations containing parameters that drive the rate at which 
the tissue grows in particular directions as well as the stimulus that drives the growth. 
However, these models cannot account for preferential growth of particular constituents 
within the wall. Consequently, constrained mixture models of growth and remodeling 
have been proposed that describe tissue growth in terms of increased production of 
collagen, elastin, and SMCs [118-122]. These models utilize the kinematic assumptions 
and constitutive equations previously detailed as well as new evolution equations that 
govern the unloaded states of newly produced constituents as well as the rate at which 
they are produced. Volumetric models as well as constrained mixture models can support 
either empirical or microstructurally-motivated constitutive models, and all types have 
been utilized extensively to predict growth and remodeling behavior of arteries. 
2.6 Lymphatic physiology and function 
 The lymphatic system is a robust network of vessels and organs that serves 
multiple functions including immune trafficking, lipid transport from the gut to the 
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bloodstream, and tissue fluid balance [123]. Transport of fluid through lymphatics begins 
at the peripheral tissues with fluid uptake into lymphatic capillaries and continues with 
fluid transport into progressively larger lymphatic vessels (precollecting lymphatics and 
collecting lymphatics), eventually returning to the venous circulation through the thoracic 
duct. The lymphatic system is unique from the systemic circulation in that the lymphatic 
system is not a closed circulatory system but rather a one-way conduit for fluid. The 
lymphatic system lacks a central pump to propel fluid forward to its destination, which 
presents a unique challenge given that the system is often working against a negative 
pressure gradient. Consequently, lymphatic vessels are capable of spontaneous and 
rhythmic contraction that provides them with the ability to effectively transport fluid 
against a negative gradient, a function which, if impaired, leads to fluid imbalance and 
lymphedema.  
 Collecting lymphatics have similar structure to arteries in that they are composed 
of an endothelium consisting of a single layer of lymphatic endothelial cells, a middle 
layer consisting of lymphatic muscle cells and elastin, and an outer layer of collagen, 
although mass fractions of these components may differ dramatically from arteries. 
Lymphatic endothelial cells provide similar function as vascular endothelial cells by 
producing NO in response to fluid shear stress on the endothelium and consequently 
reducing tonic contraction of the lymphatic muscle cells [124]. Lymphatic endothelial 
cells are also responsible for cell signaling that affects shear-induced rhythmic 
contraction, a function that does not exist in arteries. Lymphatic muscle cells exhibit 
complementary functions that are similar to vascular smooth muscle as well as skeletal 
muscle due to their ability to maintain tonic contraction and produce spontaneous 
 17
contraction, respectively [125]. Spontaneous contraction begins with pacemaker activity 
originating somewhere in the vessel wall and results from depolarization and sudden 
increases in intracellular calcium levels. Impairment of this function inhibits fluid flow 
along the lymphatic vasculature. Also found in the lymphatic vasculature is a system of 
one-way valves that facilitates forward flow of lymph. Following spontaneous 
contraction from the muscle cells, a proximal valve will close while the distal valve 
opens due to changes in pressure gradients across the valves, and a portion of the fluid in 
the vessel is consequently ejected. These valves are biased to stay open even in the face 
of a small negative pressure gradient [126], and it is therefore critical that contractions of 
lymphatic vessels be coordinated and timed such that backflow is minimized.  
2.7 Lymphatics and cardiovascular disease 
 The lymphatic system has been suggested as a possible mediator of the 
progression of CVD [127]; however, direct evidence of its role is sparse. The transport of 
cholesterol from peripheral tissues to the bloodstream is thought to be a critical process 
that prevents the development of atherosclerotic plaques [128], and given the role of the 
lymphatic system in the transport of lipids, some investigators have hypothesized that the 
lymphatic vasculature plays a role in prevention of atherosclerosis. Indeed, one group has 
demonstrated a correlation between hypercholesterolemia and lymphatic dysfunction in 
mice [129], and the same group later demonstrated a direct role for the lymphatic 
vasculature in reverse cholesterol transport from the aortic wall in mice [130]. Lymphatic 
vessels and lymphangiogenic factors have been identified at sites of atherosclerosis [131, 
132], and others have shown that aortic smooth muscle produces lymphangiogenic 
factors in a mouse model of atherosclerosis [133]. Similarly, other groups have suggested 
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that lymphatic obstruction plays a role in myocardial infarction. Studies have shown that 
experimental obstruction of cardiac lymphatics leads to interstitial edema [134], 
subendocardial edema and hemorrhage [135], increased cardiac collagen synthesis and 
tissue fibrosis [136], and reduced left ventricular contractility [137], while others have 
shown that increased cardiac lymph drainage reduces infarct risk area [138]. Despite 
these data, the role of lymphatic dysfunction in the development of CVD is still unclear 
and requires further investigation. 
2.8 Lymphedema and lymphatic filariasis 
 Lymphedema is characterized by the inability of the lymphatic system to properly 
transport fluid from the peripheral tissues to the central venous system and subsequent 
edema and fibrosis of the tissue. Lymphedema can occur for multiple reasons, many of 
which are related to cancer treatment (e.g. axillary lymph node removal or sentinel node 
biopsy) [139]. Disruption of the lymphatic system following surgical excision of lymph 
nodes and neighboring lymphatic vessels triggers edema in the affected limb by 
mechanisms that are still relatively unknown. Treatment options for cancer-related 
lymphedema (generally following mastectomy) include simple compression therapy by 
which fluid transport is stimulated manually by massage or compression garments [140] 
as well as surgical techniques such as lymphaticovenous anastomosis [139].  
 Another significant contributor to lymphedema is parasitic infection of the 
lymphatic system, termed lymphatic filariasis. The World Health Organization estimates 
that over 120 million people are currently infected by the parasites that lead to lymphatic 
filariasis, and 40 million people are disfigured or incapacitated by lymphedema 
associated with the infection [4]. Lymphatic filariasis is transmitted via mosquitoes 
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whereby the worms are lodged in the lymphatic system following a mosquito bite. The 
worms live for 4-6 years and produce larvae that circulate in the blood. Lodging of the 
worms leads to lymphatic obstruction, and left untreated the obstruction can lead to 
lymphedema and ultimately a condition known as elephantiasis that is characterized by 
extreme disfigurement. 
2.9 Regulation of lymphatic contractile function 
 Regulation of contractility in lymphatic vessels has many factors, but perhaps the 
most studied are the effects of the mechanical environment (e.g. pressure and flow) on 
metrics defining contractility. Metrics such as pumping frequency, contractile amplitude, 
and ejection fraction are commonly quantified as measures for comparison of contractile 
function in vessels. Many studies have shown that changes in pressure gradient have 
marked effects on such metrics. Studies investigating the role of elevated afterload have 
shown that creating a more negative pressure gradient triggers a clear decrease in 
contractile amplitude and stroke volume but an increase in pumping frequency [13]. 
Conversely, a study from the same group investigating preload showed that a more 
favorable pressure gradient has little effect on the contractile amplitude and only a slight 
decrease in ejection fraction [141]. In both cases, experiments were performed with both 
step changes in pressure gradient as well as continuous ramping of pressure gradient in 
order to compare differences. Lymphatic vessels have been shown to demonstrate 
transient changes in contractility following changes in intramural pressure [142], which 
motivates the need to compare step and ramp changes in pressure.  
 Independent of pressure gradient, the luminal pressure also directly affects 
contractile function of lymphatic vessels. Many have reported length-tension 
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relationships of lymphatics, and it has been well established that such behavior is quite 
heterogeneous based on location within the vasculature (i.e. thoracic duct vs. cervical 
lymphatics) [143-146]. One hypothesis explaining this phenomenon is that lymphatic 
vessels adapt to maximize their contractile force based on the local hydrostatic pressure 
conditions, although this hypothesis is unproven. Additionally, magnitude and direction 
of flow have also been implicated in the regulation of contractile activity. One study 
demonstrated that imposed flow reduces frequency depending on the magnitude of flow 
but not the direction and reduces contractile amplitude depending on the direction of flow 
but not the magnitude, and both responses were time-dependent [14]. These changes were 
attributed in part to changes in production of NO. Conversely, another study showed that 
imposed flow leads to a decrease in amplitude but an increase in contractile frequency 
[147]. However, this study was performed in lymphatic vessels from iliac lymph nodes, 
and given the regional heterogeneity established in other studies, the observed differences 
may simply be due to vessel type. Others have demonstrated contractile regulation based 
on flow generated from contractions rather than imposed flow. Gasheva et al. showed 
tonic relaxation in lymphatic vessels due to spontaneous contractions [124]. Aside from 
mechanical factors, there are other biological factors that may also play a role in 
contractile function including but not limited to the presence of metabolites [148], 
regulation of lipids [129], and muscle cell phenotype [149]. These data taken together 
suggest an extremely complex regulation of lymphatic contractility that demands further 
investigation in order to better understand lymphatic dysfunction and subsequent disease. 
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2.10 Mathematical modeling of lymphatic function 
 The ability to predict lymphatic contractile function and consequently bulk 
transport is key to understanding parameters affecting disease development. 
Consequently, many have developed predictive mathematical models attempting to 
capture the salient features of lymphatic function. The problem is inherently complex and 
requires considerations of both the solid mechanical properties of the tissue as well as the 
fluid dynamics of lymph transport through the lumen of these vessels. Investigations of 
the passive mechanical properties of the lymphatic vessel wall as well as the active 
tension generation have been performed in order to develop predictive models of the 
solid mechanical behavior [145, 150-153]. Other studies have modeled the bulk flow 
through vessels exclusively [154]. While a select few of these studies investigated only 
the solid or fluid mechanical properties specifically, many of them sought to incorporate 
both properties into one model, hereafter referred to as a fluid-structure interaction (FSI) 
model. These models have taken on various forms, some focusing on transport through 
the lumen and neglecting contribution of the valves [151, 155], others have focused 
specifically on flow across valves [156, 157], and still others incorporate valve behavior 
into a model of bulk flow through one or multiple lymphangions [152, 158-160]. Many of 
these models have been powerful steps forward in our characterization of lymphatic 
function; however, the models all contain simplifications that limit their predictive 
power. The solid mechanics considerations are often empirical, and those that are not still 
neglect the non-linear, anisotropic behavior that is characteristic of most soft tissue. The 
fluid mechanics in some cases neglect the inertial forces experienced during fluid 
transport, and those that do assume unidirectional and fully-developed flow, which may 
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overlook important minutiae in fluid behavior. Finally, valve behavior has been shown to 
be highly complex [126], and almost all models have dramatic simplifications of valve 
behavior, with the notable exception of a study from Bertram et al. which incorporates a 
tedious study of valve behavior into an FSI model [160]. Regardless of simplifying 
assumptions, these models are critical tools for furthering our understanding of the 
complex mechanical environment in the lymphatic vasculature.  
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                                                                                 CHAPTER 3 
THE ROLE OF EFAVIRENZ IN DEVELOPMENT OF 
MECHANICALLY-MEDIATED VASCULAR REMODELING 
3.1 Introduction 
  Since the advent of highly active antiretroviral therapy (HAART), patients 
infected with HIV-1 are living longer lives. The World Health Organization reports that 
over 35 million people worldwide were living with HIV-1 as of 2012 [161]. 
Consequently, co-morbidities associated with HIV-1 infection and treatment have 
become a prevalent issue. Indeed, non-AIDS related comorbidities associated with 
cardiovascular disease (CVD) including myocardial infarction [43, 44, 162], 
atherosclerotic lesions [45-47], and other subclinical markers of atherosclerosis are 
widely reported among HIV-infected populations.  
  A pressing need remains to better quantify non-AIDS related co-morbidities in 
people living with HIV in sub-Saharan Africa. Most studies of cardiovascular co-
morbidities with HIV represent populations from developed countries; yet, 69% of all 
people living with HIV reside in sub-Saharan Africa. Antiretroviral programs in Africa 
have made a tremendous impact in reducing HIV-related deaths and have been available 
in Ethiopia since 2005; the treatment disparities, however, between the developing world 
and the developed world remain great. People living with HIV in the developing world 
have access to fewer combinations of HAART regimens and patient adherence and 
clinical monitoring of CD4+ cell counts and viral loads in the developing world is well 
below that in the developed countries. As a result, people living with HIV in developing 
nations remain on first line therapy with less follow up. These treatment disparities, 
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combined with differences in demographics, lifestyle, and nutritional status between 
Ethiopian and Western populations, may make this population more susceptible to non-
AIDS related co-morbidities. 
  The individual roles of HIV-1 infection and HAART treatment in the progression 
of atherosclerosis are not well understood. Some studies have implicated the viral 
infection as a singular cause of CVD, demonstrating coronary arteriopathy and 
atherosclerotic lesions following post-mortem analysis of HAART-naïve HIV-1+ patients 
[54, 55], and many laboratory studies have implicated HIV-1 proteins in preclinical 
markers of atherosclerosis and vascular dysfunction [56-59]. Conversely, a multitude of 
studies have shown accelerated progression of atherosclerosis in HAART-treated patients 
compared to HAART-naïve patients, suggesting an additive role of the drugs in disease 
progression. Azidothymidine (AZT) has been shown to cause arterial stiffening [12, 48, 
49], cardiomyopathy [163, 164], and endothelial dysfunction [80, 165, 166]. Similarly, 
endothelial dysfunction has been associated with use of protease inhibitors (PIs) via 
mitochondrial dysfunction, oxidative stress, and ROS [79, 167, 168]. PIs are also known 
to cause an increase in cIMT [169] as well as impairment of FMD [53, 170], but these 
results are controversial due to conflicting evidence [61, 92, 93, 171, 172]. 
  While NRTIs and PIs have both been implicated in the development of preclinical 
markers of CVD, there remains much information to be discovered regarding the 
contributions of non-nucleoside reverse transcriptase inhibitors (NNRTIs), specifically 
efavirenz (EFV), to the progression of CVD in HIV-1 infection. Clinical studies have 
shown that NNRTI-containing regimens are associated with increased markers of CVD, 
particularly alterations of lipid profiles, but have less pronounced changes than those of 
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PI-containing regimens [173, 174]. More recently, EFV was implicated in worsening 
endothelial function over time [9]. In laboratory studies, EFV has been associated with 
increased production of reactive oxygen species and endothelial dysfunction [8] as well 
as progressive mitochondrial dysfunction and associated changes in lipid levels [10, 11]. 
Conflicting data should be noted as another study has shown transient increases in 
cholesterol efflux with EFV treatment, suggesting a beneficial effect in the prevention of 
atherosclerosis [175]. In general, clinical data and the majority of laboratory data seem to 
suggest a role of EFV in the progression of subclinical markers of CVD. 
  The role of mechanics in the development of CVD has been well characterized. 
Arterial stiffening is a commonly used preclinical marker of atherosclerosis and is 
commonly seen in HIV-1+ populations [49, 176]. However, given the combination 
treatment regimen that these patients receive, it is difficult to parse out the roles of 
individual drugs in development of CVD, thus making laboratory studies of significant 
use. Additionally, laboratory studies offer the opportunity for additional endpoints for 
quantification of CVD development beyond the possible clinical endpoints. Alteration of 
axial force behavior is one such indicator [177, 178]. Indeed, previous laboratory studies 
from our lab investigating the role of AZT in the progression of CVD report changes in 
axial force generation in addition to the stiffening normally observed in the 
circumferential direction [12] while other studies have reported axial changes that 
precede circumferential stiffening [179]. Thus, utilization of an animal model offers the 
opportunity to identify contributions of EFV to the development of CVD without 
interference from drug-drug interaction and with higher sensitivity than standard clinical 
measurements. 
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 Taken together, it seems clear that a pressing need exists to quantify the role of 
EFV in the progression of atherosclerosis. The purpose of this paper is to demonstrate the 
role of EFV in the development of subclinical markers of atherosclerosis including 
arterial stiffening and geometric changes as well as early onset plaque development. We 
utilized a common mouse model of atherosclerosis to quantify these tissue level changes 
with long-term administration of EFV in order to provide direction for future studies 
surrounding EFV use in the context of HIV treatment. 
3.2 Hypothesis 1: Treatment with EFV will be associated with accelerated 




 Ethiopian patients 
 To test this hypothesis, adult Ethiopian HIV-1-negative, HIV-1-positive / 
HAART-naïve, and HIV-1-positive / HAART-treated patients as well as pediatric 
Ethiopian HIV-1-positive / HAART-naïve, and HIV-1-positive / HAART-treated patients 
were recruited and evaluated for arterial stiffening using pulse wave velocity and pulse 
wave analysis using applanation tonometry as well as increased carotid intima-media 
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thickness and impaired flow-mediated dilation using non-invasive ultrasound. The goal 
of testing this hypothesis is to investigate the role of a frequently prescribed antiretroviral 
in the development of a common non-AIDS-related comorbidity and shed light on 
possible differences of HAART treatment in an understudied population of HIV-infected 
patients. 
3.2.1 Methods and Materials3 
3.2.1.1 Participant enrollment and baseline data 
 All work was performed in accordance with the Declaration of Helsinki. All 
participants provided written informed consent and this study was approved by the 
Institutional Review Board Committees at Addis Ababa University and Georgia Institute 
of Technology. Eighteen- to 65-year-old HIV-negative, HIV-positive HAART naïve, and 
HIV-positive subjects on EFV-, NVP-, or LPV/r-containing regimens for at least two 
months prior to the exam were recruited from Tikur Anbessa (Black Lion) Specialized 
Referral Hospital in Addis Ababa, Ethiopia to participate in this study. Six- to 17-year-
old subjects who were vertically infected with HIV and HAART naïve or taking EFV-, 
NVP-, or LPV/r-containing HAART regimens for at least two months prior to the exam 




 AWC was responsible for analysis of cIMT data, FMD data, and worked with IKP on quantification and 
analysis of inflammatory blood markers. RLG collected and analyzed PWA and PWV data, collected all 
ultrasound data, oversaw collection of anthropometric and metabolic data, and performed all statistical 
analyses.  
 28
were also recruited. Note that 99% of the pediatric HAART-treated subjects were on 
therapy for 6 months or more and 95% were on therapy for more than 1 year. For subjects 
between 6 and 11 years of age, written informed consent was obtained from the parent or 
guardian of the participant and for subjects between 12 and 17 years of age, written 
informed consent was obtained from both the participant and the parent or guardian of the 
participant. Subjects were excluded if they had active AIDS defining illnesses or diabetes 
mellitus. Subjects fasted and refrained from tobacco products for at least 8 hours prior to 
the test and refrained from exercise in the morning of the test. 
 Participant age, sex, HIV-serostatus, date of first HIV-seropositive test, initial 
CD4+ cell count, last CD4+ cell count, and any viral load determinations, and date of 
initiation of current and all previous HAART regimens were obtained from the 
participants hospital card. Questionnaire-driven interviews were performed by the local 
recruiting nurse at the Black Lion Hospital HIV clinic under the direction of the research 
team. Self-reported personal and familial (mother, father, brothers, or sisters) history of 
heart attack, angina, stroke, kidney disease, diabetes, or lipid disorders and self-reported 
alcohol and cigarette use were recorded. 
3.2.1.2 Body composition 
 Body weight, body height, waist and hip circumference, and skinfold thickness 
(bicep, tricep, suprailiac, and sub scapula) were measured. Skinfold measurements were 
taken in in duplicate on the right and left sides and reported as the average of these four 
values. The ratio of the sum of skin-fold measurements in the suprailiac and sub-scapula 
divided by the sum of those from the bicep and tricep was reported as the Trunk/arm 
ratio. Adult subjects were asked if they observed an ‘increase in fat’, ‘decrease in fat’, or 
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‘no change’ at each of the following locations: face, arms, legs, abdomen, chest, cervical 
fat pad, supraclavicular fat, and across their entire body. 
3.2.1.3 Blood pressure, pulse wave analysis, and pulse wave velocity 
 Brachial artery systolic (B-SBP) and diastolic (B-DBP) blood pressure were 
measured with a digital automatic blood pressure measurement device after the subjects 
rested in a supine position for at least 10 minutes. Pulse wave analysis (PWA) and pulse 
wave velocity (PWV) measurements were subsequently taken with a SphygmoCor CPV 
Clinical System (AtCor Medical) following manufacturer protocol. PWA and PWV 
measurements meeting the manufacturer quality control criteria were collected in 
triplicate and averaged. 
3.2.1.4 Carotid intima-media thickness 
 Ultrasound measurements were collected using a Sonocyte Micromax portable 
ultrasound device with vascular software for two-dimensional imaging, color and spectral 
Doppler, high- frequency (10 MHz) linear transducer, and internal electrocardiogram 
monitor. The right and left common carotid arteries (CCA) were examined with the head 
in the midline position tilted slightly upward and away from the artery being imaged. The 
probe was placed so that the near and far walls were parallel in the acquired image and 
lumen diameter was maximized in the longitudinal plane. Three 6-second clips of each 
artery were collected and stored for analysis. cIMT was reported in systole and diastole 
as the average of the near and far wall measurements from three separate clips from both 
the right and left CCA. Given subject-to-subject variability in the carotid artery size, a 
normalized measure was defined as cIMT
norm
 = cIMT/(/2), where  was the measured 
inner diameter of the CCA. 
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 The linearized cyclic strain ∆ = ∆/, was also reported, where ∆ is the 
difference between the systolic and diastolic luminal diameter and  is the diastolic 
luminal diameter. The Peterson’s modulus (), a common measure of arterial stiffness, 
defined as  = ∆	 = 1/, where  is the pulse pressure and  is the compliance, was 
reported. The medial hoop stress approximated as  = ()/(cIMT) = /cIMTnorm, was 
also reported.  and  in the carotid artery were approximated by the values determined 
for the aorta via PWA. A single analyst, blinded to the patients HIV status and HAART 
regimen, analyzed all images from adult patients. Three analysts, blinded to the patients 
HIV status and HAART regimen, analyzed all images from pediatric patients. 
3.2.1.5 Flow-mediated dilation 
 An appropriately sized sphygmomanometer was placed on the widest part of the 
proximal right forearm ~1 cm distal to the antecubital fossa. Prior to inflation, three 6-
second clips of the brachial artery image and EKG tracings were stored for baseline 
measurements. The sphygmomanometer was inflated at least 50 mmHg above the 
subjects’ systolic blood pressure. Five minutes after occlusion, the cuff was deflated and 
a 6-second clip of the brachial artery image and EKG tracing was stored at 30, 45, 60, 75, 
and 90 seconds after deflation. A single analyst, blinded to the patients HIV status and 
HAART regimen, analyzed all images from adult patients. Three analysts, blinded to the 
patients HIV status and HAART regimen, analyzed all images from pediatric patients. 
Further,  = ( − )/, where  is the brachial artery inner diameter during 
diastole at the time-point of interest and  is the average of the three measurements of 
the brachial artery diameter during diastole at baseline. 
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3.2.1.6 Blood sample analysis 
 Complete blood count, total cholesterol (TC), triglyceride (TG), high-density 
lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and glucose 
analysis were performed at the clinical laboratory at Black Lion Hospital. CD4+ cell 
count and plasma HIV RNA analysis was performed at the International Clinical 
Laboratory (Addis Ababa, Ethiopia). In adult patients, high-sensitivity C-reactive protein 
(hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular 
adhesion molecule-1 (sICAM-1), and leptin analyses were performed on blood serum 
using commercially available ELISA kits (Life Technologies Corporation). Analysis for 
HIV viral load was performed on 70%, hsCRP on 80%, sVCAM-1 on 85%, sICAM-1 on 
80%, and leptin on 80% of the adult subject pool, equally distributed among groups.  
3.2.1.7 Statistical analysis 
 All statistical analyses were performed using MATLAB© (MathWorks). A one-
way analysis of variance (ANOVA) was performed to determine statistical significance 
across groups (p < 0.05) on continuous variables that satisfied Bartlett's test for equal 
variances and Pearson Chi-square test for normality of residuals; a Kruskal-Wallis non-
parametric one-way ANOVA was performed on continuous variables that did not show 
equal variances or normality. For continuous variables with significance across groups, a 
pairwise Wilcoxon rank sum test was performed to detect differences between individual 
groups (p < 0.05). For categorical variables,  analysis was performed to determine 
statistical significance across groups (p < 0.05); for those with significance across groups, 
a pairwise Marascuillo procedure was performed to compare differences in proportions 
between individual groups (p < 0.05). 
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 Correlation analysis was performed and multivariable linear regression models 
were constructed to examine the association of study parameters with PWV for all 
HAART-treated subjects. Relevant study parameters were selected for the inclusion of 
the initial models and the stepwisefit multivariable regression MATLAB 
subroutine, which eliminates (or adds) covariates in a stepwise fashion, was used with the 
criteria p<0.05 for removal from (or inclusion in) the final model. 
3.2.2 Results 
3.2.2.1 Participant characteristics 
 Adult population: CD4+ cell count was lower in all HIV-positive groups, 
compared to HIV-negative subjects, and lower in LPV/r-treated, compared to NVP-
treated subjects (Table 3.1). Plasma HIV RNA levels were lower and percentages of 
subjects with plasma HIV RNA levels below detectable limits (<40 copies/mL) were 
higher in all HAART-treated groups, compared to HAART-naïve subjects. Years since 
first HIV diagnosis was higher in HAART-treated groups compared to HAART-naïve 
and in NVP- and LPV/r-treated compared to EFV-treated subjects. LPV/r-treated subjects 
were on HAART longer than EFV-treated subjects. EFV-treated subjects have been on 
their current regimen longer than LPV/r-treated, but shorter than NVP-subjects. The 
HAART treated groups had similar distributions of NRTI-backbone, with the exceptions 
that less LPV/r-treated subjects had an AZT-3TC backbone compared to NVP-treated 
subjects and more LPV/r-treated subjects had an NRTI-backbone other than AZT-3TC or 
TDF-3TC compared to EFV-treated subjects. The ‘Other’ NRTI backbones included 
stavudine in the NNRTI groups and didanosine, abacavir, or stavudine in the LPV/r 
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group. More LPV/r-treated subjects had taken a previous regimen, which was expected, 
as LPV/r is considered a second-line regimen. 
 
 Less than 3% of the participants in any group reported being current cigarette 
smokers and less than 6% of the participants in any group report drinking more than 4 
drinks per week. Less than 10% and 15% of the subjects from any group reported a 
family history and personal history, respectively, of heart attack, angina, or stroke, kidney 
disease, diabetes, or lipid disorders. 
End-point
(n= 36) (n= 51) (n= 91) (n= 95) (n= 44)
Demographics
Age (yrs) 39 (29 - 45) 38 (32 - 45) 38 (34 - 45) 37 (32 - 42) 39 (35 - 44)
Male ratio [# (%)] 8   (22%) 14   (27%) 23   (25%) 21   (22%) 14   (32%)
HIV / HAART History
CD4+ count 730 (656 - 1047) 395 (182 - 546)
A
349 (232 - 481)
A
390 (271 - 534)
A
285 (147 - 453)
A,e
3.6 (2.2 - 4.7) <1.6 (<1.6 - <1.6) B <1.6 (<1.6 - <1.6) B <1.6 (<1.6 - <1.6) B
Viral Load (% BDL)
B B B
Yrs since diagnosis 1.6 (0.3 - 3.7) 5.7 (3.4 - 7.0)
B
6.0 (5.6 - 7.4)
B,d
6.5 (5.3 - 8.3)
B,d
Yrs on HAART 5.0 (3.2 - 6.2) 5.7 (3.9 - 6.2) 5.9 (4.2 - 6.8)
d
Yrs on Current Regimen 2.5 (1.5 - 4.4) 3.8 (1.9 - 5.7)
d
1.8 (0.7 - 3.2)
E
Current NRTI backbone
TDF+3TC [# (%)] 55   (60%) 38   (40%) 28   (64%)
AZT+3TC [# (%)] 35   (38%) 53   (56%) 7   (16%)
E
Other [# (%)] 1   (1%) 4   (4%)
e
9   (20%)
Previous Regimen
All [# (%)] 39   (43%) 29   (31%) 40   (91%)
D,E
EFV-containing [# (%)] 24   (26%) 5   (5%) 20   (45%)
d,e





] 22 (20 - 26) 22 (20 - 26) 21 (19 - 24) 23 (20 - 25) 22 (18 - 25)
WHR [ ] 0.82 (0.77 - 0.86) 0.84 (0.79 - 0.89) 0.86 (0.81 - 0.91)
A
0.86 (0.81 - 0.92)
A
0.88 (0.82 - 1)
A,b
Skinfold Thickness
Tricep [mm] 12.2 (7.6 - 15.3) 10.8 (5.4 - 14.9)
A
6.7 (3.9 - 9.5)
A,B
6.7 (4.2 - 10.0)
A,b
8.0 (5.2 - 10.6)
A
Bicep [mm] 6.1 (3.3 - 8.8) 6.2 (3.1 - 9.2) 3.1 (2.4 - 5.8)
A,B
3.5 (2.4 - 6.0)
A,B
4.4 (2.7 - 8.1)
Suprailiac [mm] 9.3 (6.4 - 13.7) 7.9 (5.0 - 13.1) 6.2 (4.0 - 8.9)
A,b
7.4 (4.3 - 10.9)
A
7.7 (4.0 - 12.4)
Sub-scapula [mm] 20.9 (16.0 - 27.1) 19.8 (11.7 - 28.4) 15.8 (9.9 - 20.7)
a,b
18.4 (11.2 - 28.2)
d
20.2 (9.8 - 30.4)
d
Trunk:arm [ ] 1.6 (1.4 - 2.0) 1.8 (1.4 - 2.2) 2.1 (1.4 - 2.8)
a,b
2.2 (1.5 - 3.3)
a,b
2.1 (1.5 - 2.6)
a,b
Observed change in fat (% observing decrease in fat / % observing increase in fat)
Face [%] 0%       / 0% 8%       / 4% 27%
A,b
   / 5% 15%
A




   / 11%
Arms [%] 0%       / 0% 4%       / 4% 16%
A  




   / 7%
Legs [%] 0%       / 0% 6%       / 2% 22%
A
    / 5% 17%
A
    / 20%
A,b
25%       / 7%
Abdomen [%] 0%       / 0% 4%       / 6% 1%       / 32%
A,B
1%       / 29%
A,B
2%       / 41%
A,B
Chest [%] 0%       / 0% 4%       / 0% 2%       / 11%
a,b
1%       / 9%
a,b
0%       / 25%
a,b
Buffalo hump [%] 0%       / 0% 4%       / 0% 1%       / 7% 0%       / 9%
a,b
2%       / 14%
Neck [%] 0%       / 0% 4%       / 0% 3%       / 5% 0%       / 8% 2%       / 16%
Body [%] 0%       / 8% 20%
a
    / 14% 14%
A




    / 42%
A,B









-- 18% 87% 81%
--
Viral Load (log10copies/mL) --
92%
HIV-Negative HAART Naïve Efavirenz (EFV) Nevarapine (NVP) Lopinavir/r (LPV/r)
Table 3.1. Baseline characteristics and body composition metrics for HIV-1-negative, 
HIV-1-positive HAART-naïve, and HIV-1-positive HAART-treated adults. Continuous
variables are reported as median (interquartile range). A, a = p<0.005 or p<0.05 versus 
HIV-negative controls, respectively; B, b = p<0.005 or p<0.05 versus HAART-naive, 
respectively; D, d = p<0.005 or p<0.05 versus EFV, respectively; E, e = p<0.005 or 
p<0.05 versus NVP, respectively. 
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 Pediatric population: CD4+ cell count was higher in NVP-treated subjects 
compared to HAART-naïve and EFV-treated subjects, and EFV-treated, compared to 
HAART-naive subjects (Table 3.2). LPV/r-treated subjects were on HAART longer than 
EFV- and NVP-treated subjects and EFV-treated subjects were on HAART longer than 
NVP-treated subjects. LPV/r-treated subjects were on their current regimen for a shorter 
period than EFV-treated subjects. The EFV- and NVP-treated subjects had similar 
distributions of NRTI-backbone, with a majority of subjects taking zidovudine (AZT) + 
lamivudine (3TC) or stavudine (d4T) + 3TC. The majority of LPV/r-treated subjects had 
an NRTI backbone of abacavir (ABC) + didanosine (ddI). The ‘Other’ NRTI backbones 
for the EFV- and NVP-treated subjects were tenofovir (TDF) + 3TC (n=4) and ABC + 
3TC (n=3). The ‘Other’ NRTI backbone for the LPV/r-treated subjects was ABC+3TC. 
3.2.2.2 Body composition and anthropometric measurements 
 Adult population: No differences were observed in BMI across groups. WHR was 
elevated in all HAART-treated groups, compared to HIV-negative subjects and in the 
LPV/r-treated subjects compared to HAART-naïve subjects. Skin-fold thickness 
measurements yielded multiple differences between HAART treated versus HIV-negative 
and HAART-naïve subjects. Trunk/Arm skin-fold thickness ratio was significantly higher 
in all HAART-treated subjects compared to HIV-negative and HAART-naïve subjects. 
The self-reported fat redistribution followed these trends, with HAART-treated subjects 
generally reporting decreased fat in their face, arms, and legs, increased fat in the chest, 
buffalo hump, and neck and increased overall body fat. A significant fraction of NVP-
treated subjects also reported increased fat in their face, arms, and legs. Taken together, 
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WHR, skin-fold thickness measurements, and self-reported observations show that adult 
HAART-treated subjects in Addis Ababa, Ethiopia exhibit lipodystrophy. 
 Pediatric population: No differences were observed in BMI or WHR across 
groups. Bicep skin-fold thickness measurements were lower in EFV- and NVP-treated 
subjects compared to HAART-naïve subjects. 
 
(n = 45) (n = 90) (n = 80) (n = 19)
Demographics
Age (yrs) 11 (9 - 14) 13 (10 - 15) 11 (9 - 14) 13 (11 - 15)




) 16 (15 - 18) 16 (14 - 18) 16 (15 - 18) 16 (15 - 18)
WHR ( ) 0.85 (0.82 - 0.90) 0.85 (0.82 - 0.89) 0.87 (0.83 - 0.91) 0.87 (0.85 - 0.90)
Skinfold Thickness (mm)
Tricep 5.7 (3.8 - 7.2) 5.0 (3.6 - 6.4) 4.7 (4.0 - 6.2) 4.3 (3.5 - 7.1)
Bicep 3.1 (2.6 - 4.0) 2.7 (2.1 - 3.6) a 2.6 (2.1 - 3.3) A 3.1 (2.4 - 4.8)
Suprailiac 3.1 (2.4 - 4.2) 3.3 (2.4 - 4.7) 3.1 (2.4 - 4.0) 3.3 (2.8 - 3.9)
Sub-scapula 6.0 (4.0 - 7.4) 6.2 (4.3 - 9.7) 5.3 (4.0 - 6.7) 5.0 (4.5 - 6.6)
Trunk:arm 1.0 (0.8 - 1.3) 1.2 (1.0 - 1.6) 1.1 (0.9 - 1.5) 1.0 (0.9 - 1.3)
HIV / HAART History
Current CD4+ count 456 (378 - 608) 575 (412 - 744) a 639 (460 - 902) A,b 554 (336 - 776)
Yrs on HAART 4.5 (3.0 - 5.7) 3.4 (1.8 - 5.5) b 6.1 (5.5 - 6.3) B,C
Yrs on Current Regimen 4.2 (2.3 - 5.4) 3.1 (1.7 - 5.5) 3.1 (2.0 - 3.6) b
Current NRTI backbone
d4T+3TC [# (%)] -- 33 (37%) 31 (39%) 2 (11%)
AZT+3TC [# (%)] -- 51 (57%) 48 (60%) 1 (5%)
ABC+DDI [# (%)] 0 (0%) 0 (0%) 15 (79%)
Other [# (%)] -- 6 (7%) 1 (1%) 1 (5%)
Cardiovascular Metrics
Heart Rate (bpm) 81 (71 - 89) 81 (73 - 87) 82 (74 - 91) 69 (65 - 87)
Brachial Artery SBP (mmHg) 103 (96 - 108) 100 (93 - 108) 100 (94 - 107) 105 (99 - 111)
Brachial Artery DBP (mmHg) 62 (58 - 71) 61 (56 - 67) 63 (59 - 68) 63 (57 - 73)
Brachial Artery MP (mmHg) 76 (72 - 82) 74 (69 - 80) 76 (72 - 80) 78 (72 - 83)
Brachial Artery PP (mmHg) 38 (32 - 43) 38 (33 - 44) 37 (30 - 43) 41 (34 - 46)
Pulse Wave Velocity (m/s) 4.6 (4.1 - 5.0) 4.7 (4.3 - 5.3) 4.6 (4.2 - 5.1) 5.2 (4.6 - 5.9) a,b,C
Flow-Mediated Dilation (%) 8.6 (5.4 - 13.6) 6.4 (4.1 - 10.0) 7.9 (4.1 - 12.1) 9.6 (5.0 - 12.2)
cIMT (microns) 45 (42 - 47) 45 (43 - 48) 46 (42 - 50) 47 (45 - 51)
Modulus (kPa) 35 (29 - 42) 38 (30 - 45) 38 (28 - 45) 43 (32 - 51)
Laboratory Analysis
Metabolic Parameters
Glucose (mg/dL) 83 (76 - 87) 86 (79 - 92) a 82 (77 - 87) b 81 (74 - 86)
TC (mg/dL) 128 (110 - 157) 161 (134 - 186) A 157 (135 - 183) A 199 (173 - 244) A,B,C
TG (mg/dL) 90 (71 - 135) 104 (76 - 143) 99 (80 - 127) 146 (120 - 249) A,B,C
HDL-c (mg/dL) 37 (33 - 42) 45 (40 - 52) A 48 (43 - 55) A 40 (33 - 50) c
LDL-c (mg/dL) 70 (59 - 94) 97 (70 - 111) A 91 (75 - 115) A 144 (98 - 174) A,B,C
TC:HDL 3.8 (3.1 - 4.1) 3.5 (3.1 - 4.3) 3.2 (2.7 - 4.1) 4.8 (3.7 - 6.1) A,B,C
HAART Naïve Efavirenz (EFV) Nevarapine (NVP) LPV/r
Table 3.2. Cardiovascular metrics for HIV-1-negative, HIV-1-positive HAART-naïve, 
and HIV-1-positive HAART-treated pediatric patients. Continuous variables are reported 
as median (interquartile range). A, a = p<0.005 or p<0.05 versus HIV-negative controls, 
respectively; B, b = p<0.005 or p<0.05 versus HAART-naive, respectively; D, d = 
p<0.005 or p<0.05 versus EFV, respectively; E, e = p<0.005 or p<0.05 versus NVP, 
respectively. 
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3.2.2.3 Blood pressure, pulse wave analysis, and pulse wave velocity 
 Adult population: The B-SBP was lower in EFV-treated compared to NVP-treated 
subjects and brachial artery pulse pressure (PP) was lower in EFV-treated compared to 
NVP- and LPV/r-treated subjects (Table 3.3). PWA predicted that the aortic PP was 
higher in the NVP- and LPV/r-treated compared to the HAART-naïve and EFV-treated 
subjects; aortic PP was higher in HIV-negative compared to HAART-naïve subjects. 
PWV was significantly lower in NVP-treated compared to EFV-treated and LPV/r-
treated subjects, indicating arterial stiffening of the central vasculature (Figure 3.1). No 
differences were observed in SBP, DBP, MP, or PP across pediatric groups.  
 Pediatric population: No differences were observed in SBP, DBP, MP, or PP 
across groups. PWV was significantly higher in LPV/r-treated subjects compared to all 




3.2.2.4 Flow-mediated dilation 
 Adult population: The peak FMD was observed at 60 seconds post-occlusion (not 
shown). FMD at 60 seconds post-occlusion was reduced in EFV-treated and LPV/r-
treated compared to HAART-naïve subjects and in EVF-treated compared to NVP-
treated subjects.  
Figure 3.1. Preclinical markers of atherosclerosis are elevated in EFV-treated and LPV/r-
treated adult subjects compared to HAART-naïve and NVP-treated. Wilcoxon rank sum 
test p-values are shown. *Note: Although the pairwise Wilcoxon rank sum test showed 
differences in cIMT between EFV- and LPV/r-treated and NVP-treated subject, ANOVA
yielded a p=0.12, which is above the defined criteria of p<0.05 for statistical significance. 
When normalized to carotid artery diameter (cIMT
norm
 = cIMT/(D/2), where D = carotid 
diameter), EFV- and LPV/r-treated subjects exhibited significantly increased values 
compared to NVP-treated and HAART-naïve subject. 
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 Pediatric population: The peak FMD was observed at 60 seconds post-occlusion 
(not shown). FMD was similar across groups. 
3.2.2.5 Carotid artery geometry and properties 
 Adult population: The carotid artery diameter was smaller in NVP- compared to 
EFV- and LPV/r-treated subjects, both in diastole and systole. No significant differences 
in the cIMT were observed across groups. When normalized to diameter, however, 
cIMT
norm
 was significantly increased in EFV- and LPV/r-treated compared to NVP-
treated and HAART-naïve subjects. The medial stress was lower in EFV- and LPV/r-
treated compared to NVP-treated subjects and lower in EFV-treated compared to HIV-
negative and HAART-naïve subjects. No differences were observed in the Peterson’s 
modulus, compliance, or cyclic strain over the cardiac cycle across adult groups.  
 Pediatric population: No differences were observed in cIMT. No differences 
were detected in the Peterson modulus, compliance (not shown), or the distensibility or 
compliance coefficients (not shown) over the cardiac cycle across groups. 
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3.2.2.6 Plasma metabolic parameters 
 Adult population: Fasting glucose was elevated in EFV-treated compared to NVP- 
and LPV/r-treated subjects. Total cholesterol (TC) was elevated in all HAART-treated 
groups compared to HAART-naïve subjects. Triglycerides (TG) were elevated in all 
HAART-treated groups compared to HIV-negative subjects and in LPV/r-treated subjects 
End-point
(n= 36) (n= 51) (n= 91) (n= 95) (n= 44)
Cardiovascular Metrics
Heart Rate 66 (64 - 74) 72 (65 - 79) 70 (65 - 78) 71 (65 - 78) 69 (63 - 73)
Blood Pressure
Brachial SBP [mmHg] 120 (112 - 132) 112 (108 - 123) 112 (104 - 123)
a
117 (107 - 130)
d
119 (105 - 131)
Brachial DBP [mmHg] 73 (68 - 81) 70 (66 - 79) 71 (63 - 78) 72 (67 - 82) 70 (66 - 79)
Brachial MP [mmHg] 90 (83 - 99) 85 (82 - 95) 86 (78 - 95) 89 (82 - 99) 90 (80 - 101)
Brachial PP [mmHg] 46 (40 - 54) 43 (37 - 49) 42 (38 - 46)
a
45 (39 - 52)
d
45 (38 - 56)
d
Pulse Wave Analysis
Aortic SBP [mmHg] 110 (101 - 121) 103 (98 - 114) 103 (96 - 113) 109 (98 - 122) 112 (97 - 123)
Aortic DBP [mmHg] 75 (69 - 82) 71 (67 - 81) 72 (64 - 79) 73 (68 - 83) 71 (67 - 81)
Aortic MP [mmHg] 90 (83 - 98) 85 (82 - 95) 86 (78 - 95) 89 (82 - 99) 90 (80 - 101)
Aortic PP [mmHg] 34 (30 - 42) 32 (26 - 38) 31 (28 - 36)
a
34 (29 - 42)
b,d
34 (31 - 47)
b,d
AP [mmHg] 8 (5 - 13) 8 (6 - 14) 8 (5 - 11) 10 (6 - 14) 10 (6 - 16)
Aix 27 (15 - 34) 25 (20 - 35) 26 (20 - 33) 27 (20 - 35) 28 (21 - 38)
AIx-75 26 (12 - 33) 25 (19 - 35) 26 (17 - 32) 27 (19 - 33) 28 (19 - 34)
Pulse Wave Velocity [m/s] 7.1 (6.3 - 8.4) 7.0 (6.3 - 8.2) 7.4 (6.3 - 8.4) 6.8 (6.0 - 7.5)
D
7.4 (6.8 - 8.7)
E
Baseline Diameter [mm] 3.04 (2.83 - 3.40) 2.87 (2.63 - 3.19) 2.98 (2.75 - 3.26) 3.07 (2.81 - 3.41) 2.88 (2.69 - 2.69)
Dilated Diameter [mm] 3.29 (3.07 - 3.56) 3.22 (2.94 - 2.94) 3.22 (2.99 - 3.51) 3.33 (3.07 - 3.76) 3.20 (2.91 - 2.91)
FMD [%] 6.5 (5.0 - 12.4) 10.0 (7.0 - 13.9)
a
7.7 (4.8 - 11.2)
b
9.2 (6.6 - 12.5)
d
7.6 (4.5 - 12.2)
b
Common Carotid Artery
Diameter [mm] 5.17 (4.94 - 5.52) 5.27 (5.02 - 5.58) 5.16 (4.92 - 5.51) 5.42 (5.08 - 5.69)
D
5.21 (4.90 - 5.49)
e
c-IMT [mm] 0.47 (0.41 - 0.54) 0.47 (0.44 - 0.51) 0.50 (0.44 - 0.54) 0.47 (0.44 - 0.51) 0.50 (0.46 - 0.54)
c-IMT norm [%] 18.0 (16.4 - 19.8) 17.6 (16.6 - 19.3) 19.2 (17.2 - 21.7)
b
17.5 (16.3 - 18.9)
D
19.0 (17.4 - 21.1)
b,E
Medial stress [kPa] 55 (49 - 60) 55 (49 - 61) 50 (45 - 58)
a,b
57 (52 - 62)
D
51 (43 - 59)
e
Properties
Modulus [kPa] 57 (42 - 81) 50 (43 - 74) 52 (43 - 66) 55 (47 - 70) 61 (51 - 75)
Compliance [MPa
-1
] 20 (12 - 24) 20 (14 - 24) 19 (15 - 23) 18 (14 - 22) 17 (14 - 20)
Cyclic strain [ ] 8.3 (7.4 - 9.8) 7.5 (6.7 - 9.2) 8.0 (6.8 - 9.5) 8.4 (7.0 - 10.2) 8.8 (6.9 - 9.7)
Blood Sample Analysis
Metabolic Parameters
Glucose [mg/dL] 93 (85 - 100) 88 (83 - 97) 94 (88 - 103) 89 (83 - 96)
D
89 (83 - 95)
D
TC [mg/dL] 184 (161 - 230) 180 (152 - 206) 195 (175 - 229)
b
201 (175 - 239)
B
216 (181 - 240)
b
TG [mg/dL] 90 (74 - 153) 131 (104 - 155) 147 (109 - 196)
A
146 (102 - 185)
a
208 (149 - 242)
A,B,D,E
HDL-c [mg/dL] 53 (46 - 59) 43 (39 - 54)
A
46 (40 - 56)
a
49 (41 - 60)
b
45 (38 - 53)
A,e
LDL-c [mg/dL] 106 (91 - 149) 108 (91 - 140) 123 (101 - 152) 126 (95 - 155) 129 (108 - 160)
b
TC:HDL ratio 3.5 (3.1 - 4) 4.3 (3.7 - 4.8)
a
4.3 (3.6 - 5.1)
A
4.2 (3.4 - 5.2)
a
4.5 (4.1 - 5.7)
A,b,e
Inflammatory Markers
hs-CRP [ug/mL] 3.1 (1.5 - 6.6) 3.6 (1.8 - 14.9) 8.1 (4.2 - 18.3)
A,b
3.9 (2.0 - 14.8)
d
5.4 (2.4 - 15.9)
a
s-ICAM [ng/mL] 521 (454 - 602) 711 (574 - 937)
A
651 (509 - 914)
A
657 (526 - 914)
A
651 (504 - 843)
A
s-VCAM [ng/mL] 651 (548 - 977) 1114 (768 - 1952)
A
806 (593 - 1036)
B
845 (649 - 1083)
a,b
1011 (606 - 1409)
a
Lepitin [ng/mL] 23 (15 - 31) 23 (16 - 43) 16 (11 - 24)
a,B
18 (12 - 27)
b
18 (14 - 31)
Efavirenz (EFV) Nevarapine (NVP) Lopinavir/r (LPV/r)HIV-Negative HAART Naïve
Table 3.3. Cardiovascular metrics for HIV-1-negative, HIV-1-positive HAART-naïve, 
and HIV-1-positive HAART-treated adults. Continuous variables are reported as median 
(interquartile range). A, a = p<0.005 or p<0.05 versus HIV-negative controls, 
respectively; B, b = p<0.005 or p<0.05 versus HAART-naive, respectively; D, d = 
p<0.005 or p<0.05 versus EFV, respectively; E, e = p<0.005 or p<0.05 versus NVP, 
respectively. 
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compared to all other groups. HDL was lower in HAART-naïve and EFV- and LPV/r-
treated compared to HIV-negative subjects and in HAART-naïve and LPV/r-treated 
compared to NVP-treated subjects. LDL was higher in LPV/r-treated compared to 
HAART-naïve subjects. TC to HDL ratio was elevated in all HAART-treated groups and 
HAART-naïve compared to HIV-negative subjects and in LPV/r-treated compared to 
HAART-naïve and NVP-treated subjects. 
 Pediatric population: Fasting glucose was elevated in EFV-treated compared to 
HAART-naive and NVP-treated subjects. Total cholesterol and LDL were elevated in all 
HAART-treated groups compared to HAART-naïve subjects and further elevated in 
LPV/r-treated versus EFV- and NVP-treated subjects. HDL was elevated in EFV- and 
NVP-treated subjects compared to HAART-naïve subjects and in NVP-treated versus 
LPV/r-treated subjects. TC:HDL ratio and triglycerides were elevated in LPV/r-treated 
subjects compared to all other groups. 
3.2.2.7 Inflammatory markers and adipokines 
 Adult population: hs-CRP was elevated in EFV-treated compared to HIV-
negative, HAART-naïve, and NVP-treated subjects and in LPV/r-treated compared to 
HIV-negative subjects. sICAM-1 was elevated in all HIV-positive groups, compared to 
HIV-negative subjects. sVCAM-1 was elevated in HAART-naïve, NVP-treated, and 
LPV/r-treated compared to HIV-negative subjects and in HAART-naïve subjects 
compared to EFV- and NVP-treated subjects. Leptin was lower in EFV- and NVP-treated 
groups compared to HAART-naïve subjects and in EFV-treated compared to HIV-
negative subjects. 
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3.2.2.8 Complete blood count 
 Adult population: No differences were observed in the number of percentages of 
white blood cells (WBC) or distribution of WBC classes across groups. Red blood cell 
markers suggest a shift towards a more anemic state in HAART-treated and, to a lesser 
degree, HAART-naïve subjects (Table A.1). Namely, red blood cell count was lower and 
mean corpuscular volume, mean corpuscular hemoglobin, and red blood cell distribution 
width-standard deviation were higher in all HAART-treated groups compared to HIV-
negative and HAART-naïve subjects and hemoglobin and hematocrit were lower in all 
HAART-treated groups and HAART-naïve subjects compared to HIV-negative subjects. 
(Note: p = 0.06 comparing hemoglobin between EFV-treated and HIV-negative subjects.) 
Platelet count and plateletcrit were elevated in EFV-treated subjects compared to all other 
HIV-positive groups; platelet count was also higher in EFV-treated and plateletcrit lower 
in NVP-treated subjects compared to HIV-negative subjects. 
3.2.2.9 Correlation and regression analysis 
 Adult population: Multivariable regression of data from all HAART treated 
subjects showed that PWV was associated with age, current EFV and LPV/r use, heart 
rate, B-SPB, triglycerides, LDL, and hsCRP (Table 3.4). FMD was associated with age, 
HIV duration, WHR, and glucose. cIMT was associated with age, current EFV use, 
skinfold thickness, and blood pressure.  
 Pediatric population: Multivariable regression showed that PWV was associated 
with current LPV/r-treatment, age, BMI, heart rate, and FMD (Table 3.5). Note, too, that 
the addition of other potentially important variables, such as total cholesterol, and 
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TC:HDL, which were included in preliminary model analysis, were not shown not to be 
significant, and thus, removed from the final model. 
 
Table 3.4. Correlation analysis and multivariable regression model for PWV, FMD, and 
cIMT versus key study parameters. ρ =  Spearman Rank Correlation Coefficient, P = p-
value for Spearman correlation, β = model parameters, SE(β) = standard error of model 
parameters,  p = p-value for multivariable regression for that parameter.  
ρ P β SE(β) p ρ P β SE(β) p ρ P β SE(β) p
Age 0.531 <0.001 0.0425 0.0151 0.006 -0.163 0.014 -0.00137 0.000564 0.017 0.412 <0.001 0.000240 7.582E-05 0.002
Sex 0.151 0.022 -- -- -- -0.15 0.023 -- -- -- 0.164 0.013 -- -- --
CD4 count -0.154 0.020 -- -- -- 0.0429 0.52 -- -- -- 0.0314 0.64 -- -- --
log10(VL) 0.066 0.32 -- -- -- -0.011 0.87 -- -- -- 0.0531 0.42 -- -- --
Year since HIV+ 0.189 0.004 -- -- -- -0.0105 0.87 -0.00357 0.00167 0.035 0.104 0.12 -- -- --
HAART duration 0.228 <0.001 -- -- -- 0.0119 0.86 -- -- -- 0.140 0.034 -- -- --
Current EFV 0.121 0.067 1.14 0.277 <0.001 -0.0987 0.14 -- -- -- 0.0972 0.14 0.0257 0.0122 0.038
Current LPV/r 0.132 0.047 1.05 0.305 <0.001 -0.0471 0.48 -- -- -- 0.0744 0.26 -- -- --
BMI 0.107 0.11 -- -- -- 0.027 0.68 -- -- -- 0.109 0.1 -- -- --
WHR 0.313 <0.001 -- -- -- -0.187 0.005 -0.15 0.0647 0.023 0.171 0.009 -- -- --
Trunk:Arm 0.140 0.034 -- -- -- -0.152 0.022 -- -- -- 0.105 0.11 0.00138 0.000517 0.009
Heart Rate 0.204 0.002 0.0278 0.0125 0.028 0.0741 0.26 -- -- -- -0.0711 0.28 -- -- --
B-SBP 0.567 <0.001 0.0332 0.00662 <0.001 -0.147 0.026 -- -- -- 0.311 <0.001 6.43E-05 3.14E-05 0.043
AIx75 0.408 <0.001 -- -- -- 0.0978 0.14 -- -- -- 0.146 0.027 -- -- --
PWV -0.113 0.088 -- -- -- 0.337 <0.001 -- -- --
FMD -0.113 0.09 -- -- -- -0.111 0.093 -- -- --
cIMT 0.337 <0.001 -- -- -- -0.111 0.093 -- -- --
Metabolic Parameters
Glucose 0.130 0.05 -- -- -- -0.0671 0.31 -0.000615 0.000288 0.035 0.0915 0.17 -- -- --
TG 0.145 0.03 0.0018 0.000888 0.046 -0.084 0.21 -- -- -- 0.0274 0.68 -- -- --
HDL-c 0.00364 0.96 -- -- -- 0.0049 0.94 -- -- -- 0.0954 0.15 -- -- --
LDL-c 0.259 <0.001 0.0063 0.00311 0.046 -0.0212 0.75 -- -- -- 0.185 0.005 -- -- --
Inflammatory Markers
VCAM -0.125 0.06 -- -- -- 0.0739 0.27 -- -- -- -0.103 0.12 -- -- --
ICAM -0.113 0.09 -- -- -- 0.134 0.042 -- -- -- -0.118 0.0756 -- -- --
Leptin -0.0293 0.66 -- -- -- 0.127 0.055 -- -- -- -0.0282 0.67 -- -- --
hs-CRP 0.300 <0.001 0.0209 0.00799 0.0106 -0.0531 0.42 -- -- -- 0.0820 0.22 -- -- --
Adjusted R2 = 0.604 Adjusted R2 = 0.168 Adjusted R2 = 0.277
Pulse Wave Velocity Flow-mediated Dilation Carotid Intima-media Thickness
Correlation Multivariable Regression Model Correlation Multivariable Regression Model Correlation Multivariable Regression Model
  Demographics
  HIV / HAART History
  Body Composition
  Cardiovascular Metrics




3.2.3.1 Preclinical markers of atherosclerosis 
Adult population 
 There are numerous studies that associate specific antiretroviral drugs with early 
onset of atherosclerosis. Protease inhibitors (PI’s) have been the most widely implicated 
class of antiretroviral drugs associated with atherosclerosis and have been correlated with 
increased c-IMT [84, 85], impaired FMD [86-88], dyslipidemia [89], atherosclerosis [7, 
90], and myocardial infarction [91], but others have reported contradictory results [92-
96]. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been associated with 
ρ P β SE(β) p
Demographics
Age (yrs) 0.402 1.0E-08 0.0822 0.0205 8.8E-05




) 0.342 1.5E-06 0.0609 0.0264 0.023
WHR ( ) -0.017 0.81 -- -- --
Trunk:arm 0.195 0.0073 - - -
HIV/HAART History
Current CD4+ count -0.131 0.072 - - -
Yrs on HAART 0.150 0.039 - - -
Current EFV Treatment 0.024 0.74 -- -- --
Current NVP Treatment -0.146 0.046 - - -
Current LPV/r Treatment 0.199 0.0061 0.572 0.161 0.00051
Cardiovascular Metrics
Heart Rate (bpm) 0.120 0.10 0.0159 0.00384 5.4E-05
Brachial Artery SBP (mmHg) 0.358 4.4E-07 - - -
Flow-Mediated Dilation (%) -0.079 0.28 -2.034 0.942 0.032
cIMT (microns) -0.049 0.50 -- -- --
Blood Metabolic Parameters
Glucose (mg/dL) 0.044 0.55 -- -- --
TG (mg/dL) 0.108 0.14 - - -
HDL-c (mg/dL) -0.001 0.99 -- -- --
LDL-c (mg/dL) 0.215 0.0030 - - -
Adjusted R2 = 0.269
Correlation Multivariable Regression Model
Table 3.5. Correlation analysis and multivariable regression model for pulse wave 
velocity versus key study parameters in a pediatric population. 
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elevated cholesterol levels and triglycerides [7], with EFV associated with higher total 
cholesterol and triglyceride levels than NVP [89]. Less is known about the association 
between NNRTIs and c-IMT, FMD, and arterial stiffness. 
 Increased arterial stiffness is a key predictor of future cardiovascular events [180] 
and is elevated in HIV-positive populations [71-74]. van Vonderen et al. report decreased 
distensibility and compliance coefficients in carotid, femoral, and brachial arteries in 
HIV-positive subjects, with no differences between HAART-naïve and HAART-treated 
subjects. In a longitudinal study, van Vonderen et al. showed a decrease in carotid 
arterial stiffness, but increase in femoral artery stiffness (i.e., a decrease in distensibility 
and compliance coefficients) after 24 months of AZT+3TC+LPV/r treatment, with 
similar trends in NVP+LPV/r treatment [71]. The current report shows that central 
arterial stiffness measured via PWV was higher in adult EFV- and LPV/r-treated 
subjects, compared to NVP-treated subjects. No differences were observed in the carotid 
artery elastic modulus, compliance, or the distensibility or compliance coefficients (not 
shown) across groups. Note that arterial stiffening in aorta, but not CCA’s, is consistent 
with recent findings in a mouse model of AZT treatment [12].  
 Arterial stiffness appears to increase with HAART [71, 73, 74] and is associated 
with immune cell activation and senescence [72] and may be independent of 
lipodystrophy [181].  In the current study, PWV was associated with EFV and LPV/r use, 
traditional cardiovascular risk factors (age, heart rate, B-SBP), dyslipidemia (triglycerides 
and LDL), and systemic inflammation (hsCRP). Taken together, the current study and 
previous studies from the literature suggest that both HIV infection and HAART play a 
role in arterial stiffening, with differing effects at different locations in the vasculature. 
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 Impaired brachial artery FMD is a non-invasive indicator of endothelial 
dysfunction and is associated with elevated cardiovascular risk in the general population
 
[182]. Impaired FMD is also widely reported in HIV-infected populations and appears to 
be associated with both viral RNA levels [183, 184] and HAART [75-77]. Although not 
significantly different than pre-HAART values, Gupta et al. reports a significant decrease 
in FMD in EFV-treated compared to PI-treated subjects after 12-months of treatment 
[77]. Impaired FMD has been associated with lipodystrophy [52]; the association 
between FMD and dyslipidemia with HIV, however, is debatable [75]. Our data show 
that EFV- and LPV/r-treated adult subjects exhibit lower FMD, compared to NVP-treated 
and HAART-naïve subjects. Multivariant regression shows that FMD was associated 
with age, duration of HIV, WHR, and fasting blood glucose levels.  
 Increased cIMT has been widely reported in HIV-infected populations [51, 71, 78, 
183, 185-187], is strongly associated with all-cause death in HIV patients [188], and 
appears to be associated with both HIV infection and HAART regimen [78, 185]. PI’s 
have been implicated [189] as a mediator of increased cIMT, and cIMT has been 
associated with immune cell activation [190, 191], systemic inflammation [188, 191, 
192], and Framingham risk [193]. Our data show nominally higher cIMT in EFV- and 
LPV/r-treated subject; however, increased cIMT only becomes significant when 
normalized to D/2. Multivariant regression showed that cIMT was associated with current 
EFV use, traditional cardiovascular risk factors (age and B-SBP), and lipodystrophy 
(Trunk:Arm).    
 Our results show elevated markers of atherosclerosis in EFV- and LPV/r-treated 
subjects, compared to HAART-naïve and NVP-treated groups. However, there are 
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several compounding factors at play that contribute to this observation. First, the years 
since HIV diagnosis in the HAART-treated group is nearly double that of the HIV-naïve 
group. However, the NVP group had a longer duration of HIV infection, compared to the 
EFV group. Second, more subjects in the EFV- and LPV/r-treated groups were taking an 
NRTI-backbone of TDF+3TC, compared to the NVP-treated group, which had more 
subjects taking AZT+3TC. The role of AZT in arterial stiffening, endothelial dysfunction, 
and cIMT is well documented [12, 82, 194]. We included TDF and AZT in early 
iterations of our multivariable regression model; due to their low association with arterial 
stiffness, cIMT, and FMD, TDF and AZT were considered key predictors of these 
markers and were subsequently eliminated from the final model. Clinical evidence for 
atherosclerosis associated with NRTIs is often indirect and difficult to define because 
NRTIs are typically not prescribed as monotherapy and cardiovascular effects are often 
attributed to other components of HAART (namely PIs). Nevertheless, recent exposure to 
abacavir, didanosine, and tenofovir in adult populations was associated with increased 
risk of heart failure
 
[195-198]; however, these findings are controversial
 
[199]. Abacavir 
has been associated with impaired FMD
 
[52]. Experimental models, including those from 
our group, clearly show that AZT, induces endothelial dysfunction [194, 200] and 
increased c-IMT and arterial stiffness [12]. 
 Data from the literature suggest that HIV, independent of HAART, can induce 
cardiovascular disease
 
[187, 201, 202]. Post-mortem analyses reveal coronary 
arteriopathy
 
[54, 203], pulmonary arteriopathy
 
[203], major atherosclerotic lesions
 
[55, 
203] and cerebral aneurysms
 
[204] in HIV-positive patients not treated with HAART. A 
long-term multi-institution analysis concluded that cessation of HAART in HIV-positive 
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patients increased their short-term risk of developing cardiovascular disease
 
[201]. Viral 
load correlated inversely with endothelium-dependent FMD without any relation to 
HAART regimens
 
[205]; thus, viral load is a significant predictor of impaired FMD
 
[96]. 
HIV infected, HAART-naïve patients exhibited elevated c-IMT and impaired FMD
 
[202] 
and HIV-infected children had significantly reduced FMD and increased arterial stiffness 
of the carotid artery compared to non-infected children, with no significant differences 
between HAART treated and HAART naïve subjects
 
[206]. Lorenz et al. concluded that 
both HAART and HIV-infection are independent risk factors for the development of 
atherosclerosis in adults
 
[207]. They show that c-IMT of the carotid bifurcation was 25% 
higher in HIV positive / HAART-naïve patients compared to uninfected controls, but 
observed significantly greater c-IMT of the carotid bifurcation and the common carotid 
artery due to HAART treatment in HIV positive subjects. Although c-IMT, FMD, and 
arterial stiffening are affected by HIV infection, it appears that HIV infection only 
introduces mild dyslipidemia
 
[202, 208, 209]. 
Pediatric population 
 Increased arterial stiffness and c-IMT and impaired FMD are key predictors of 
future cardiovascular events and are elevated in pediatric HIV-positive populations [192, 
209-212]. Bonnet et al. reported elevated common carotid arterial stiffness and impaired 
brachial artery FMD HIV-infected children (pooled HAART-treated and HAART-naïve), 
compared to HIV-negative controls, with no differences in cIMT; no differences were 
observed between treated and treatment-naïve subjects or between subjects with or 
without dyslipidemia. McComsey et al. and Ross et al. report elevated cIMT among HIV-
infected, HAART-treated subjects, compared to HIV-negative controls and that the 
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duration of HAART, CD4 count, and markers of inflammation were among the key 
predictors of cIMT [192, 211, 212]. Charakida et al. showed the cIMT was elevated and 
FMD reduced in HIV-infected children, particularly those taking a protease inhibitor-
containing regimen [209].  
 The current report shows that central arterial stiffness measured via PWV was 
elevated in LPV/r-treated subjects, compared to HAART-naïve and EFV- and NVP-
treated subjects. Although central arterial stiffness was increased, no differences were 
observed in the common carotid artery elastic modulus, compliance, or the distensibility 
or compliance coefficients. We did not observe differences in cIMT across groups, but 
note a subtle trend of increased cIMT in LPV/r-treated subjects, compared to HAART-
naïve and EFV- and NVP-treated subjects. Given that the primary end-point of the study 
was PWV, this study was not powered for c-IMT or FMD; thus, firm conclusions 
regarding this possible trend in c-IMT cannot be made from these results. No differences 
or trends in FMD were observed across groups.  
 Multivariable regression showed that current LPV/r use was an independent 
predictor of PWV in HAART-treated subjects. Despite no differences in FMD across 
groups, multivariable regression showed FMD as a key predictor of PWV. This was a 
surprising finding, given that the strength of the correlation between FMD and PWV was 
not strong (p=0.28). Note, that when heart rate (or FMD) are eliminated from the model, 
systolic blood pressure arises as a key predictor rather than FMD (or heart rate), 
illustrating the co-linearity of these parameters. PWV was also associated to the 
traditional risk factors, age and BMI. 
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3.2.3.2 Metabolic disorders 
Adult population 
 Alterations in plasma lipid profiles have been reported in both HAART-naïve and 
HAART-treated subjects that are characterized by increased TG’s and decreased HDL; 
increased total cholesterol and LDL are also reported and PI-containing regimens are 
generally associated with a less favorable lipid profile compared to PI-sparing regimens 
[89, 213]. Our results are consistent with these observations, with both HAART-naïve 
and HAART-treated subjects showing less favorable lipid profiles than HIV-negative 
subjects, and PI-treated subjects exhibiting worse lipid profiles than other HIV-positive 
groups.  
 HIV-associated lipodystrophy is characterized by peripheral lipoatrophy and 
central lipohypertrophy, and are often associated with disorders in glucose metabolism, 
insulin resistance, dyslipidemia, altered cytokine and adipokine production, and markers 
of cardiovascular disease [214, 215]. Self-reported observations of fat redistribution in 
the present study suggest similar trends, with a significant fraction of HAART subjects 
reporting observed decreases in peripheral fat and an increase in central fat. In addition, 
NVP-treated subjects reported increase in fat in their face, arms, and legs. Skin-fold 
thickness measurements support these self-reports, with EFV-, NVP-, and LPV/r-treated 
subjects having higher Trunk/arm ratios compared to HIV-negative and HAART-naïve 
subjects. Note that the trunk skin-fold thickness measurement did not suggest central 
lipohypertrophy, as superiliac and sub-scapula values were generally lower or not 




 Dyslipidemia and lipodystrophy [216-221] are widely reported in HIV-infected 
children and adolescents and generally show elevated total cholesterol, LDL, and 
triglycerides and reduced HDL with HAART treatment, with elevated dyslipidemia in 
protease treatment. Our results are consistent with these findings, showing proatherogenic 
lipid profiles with HAART treatment, particularly in the LPV/r group. Our results for 
BMI, WHR, and skin-fold thickness show little evidence of differences in these markers 
of lipodystrophy across HAART-treatment and HAART-naïve groups. 
3.2.3.3 Inflammatory markers and adipokines 
 hsCRP is a key predictor of future cardiovascular events in the general population 
[222-224], is widely reported to be elevated in HIV populations [51, 192, 225-232] 
(noting contradictory reports [72, 183, 233]), and is associated with all-cause death in 
HIV patients [188]. Most studies show little or no HAART dependency [71, 77, 184, 228, 
234] and hsCRP appears to be independent of lipodystrophy [235]. Our results show that 
hsCRP is elevated in EFV-treated subjects compared to HIV-negative, HAART-naïve, 
and NVP-treated subjects and elevated in LPV/r-treated subjects compared to HIV-
negative subjects and that hsCRP is a key predictor of PWV.  
 sVCAM-1 and sICAM-1 are plasma biomarkers that have been associated with 
the initiation and progression of atherosclerosis [236] and are commonly associated with 
HIV infection [228, 232, 233, 237]. Following initiation of HAART, values decrease 
from pre-HAART levels, but remain higher than HIV-negative controls [71, 77, 228, 
238]. Our results are consistent with these findings, with sVCAM-1 and sICAM-1 levels 
elevated in HAART-naïve and, to a lesser degree, in HAART-treated subjects compared 
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to HIV-negative subjects, but no correlation between sVCAM-1 or sICAM-1 levels and 
PWV, FMD, or cIMT were found.  
 Adipokines such as adiponectin and leptin have been studied intensively for their 
relation to obesity, insulin resistance, and hyperglycemia and as potential proatherogenic 
mediators [239, 240]. Low leptin and adiponectin levels are more common in persons 
with HIV and correlate with lipodystrophy [225, 232, 235, 241]. Our results show 
reduced leptin levels with HAART treatment, but no correlation between leptin levels 
and PWV, FMD, or cIMT were found. 
3.2.3.4 Study limitations 
Adult population 
 This study has several limitations. The cross-sectional design of this study does 
not allow for a causal relationship between specific antiretroviral drugs and the markers 
studied. As is often the case, there were challenges in recruiting a representative HIV-
negative control group. Controls were recruited by word of mouth at Black Lion hospital, 
and some recruits may have been referred from the Cardiac clinic. This may explain, in 
part, why the preclinical markers of atherosclerosis were nominally, albeit not 
significantly higher (except for FMD), in the controls versus NVP-treated and HAART-
naïve groups. Although the normalization of the cIMT was motivated to normalize values 
across a broad range of patients and showed significant differences across groups, 
although the more traditional ‘raw’ cIMT data followed similar trends, the raw data did 
not show significant differences. Also, the cIMT images were taken from a single profile 
view, rather than the average of several orthogonal views and the FMD protocol did not 
include nitroglycerine to quantify the endothelial independent vasodilation. Taken 
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together, we believe these limitations do not significantly bias the conclusions of this 
study. 
Pediatric population 
This study has several limitations. The cross-sectional design of this study does 
not allow for a causal relationship between specific antiretroviral drugs and the markers 
studied. The lack of a HIV-negative control group makes it harder to assess the impact of 
HIV infection, itself, versus the role of HAART regimens. The cumulative duration of 
HAART was larger in LPV/r-treated subjects, compared to EFV- and NVP-treated 
subjects. The longer duration of treatment could play a role the observed elevation in 
PWV; note, however, that the multivariable regression did not identify cumulative 
HAART duration as a significant variable. Note, too, that LPV/r is a second line therapy; 
thus, these patients have had some immunologic failure, which may be associated with a 
longer history of systemic inflammation or immune dysfunction that led to the observed 
increase in arterial stiffness. Also, NRTI backbones for the LPV/r-treated subjects were 
primarily ABC and ddI. ABC has been implicated as a potential contributor to 
cardiovascular risk and may be playing a role in the current study [52, 198, 242]. These 
results delineate the need for additional longitudinal studies to confirm such causal 
relationship between specific antiviral treatment and atherosclerosis in this population. 
Taken together, we believe these limitations do not significantly bias the conclusions of 
this study. Note, too, that plasma HIV RNA analysis was performed on 23% of the study 
participants; given this low coverage, viral load was not included in the results.   
 In closure, this report suggests that current LPV/r use (typically in combination 
with ABC and ddI) may play a role in the development of HIV-associated preclinical 
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markers of atherosclerosis in pediatric subjects. The data presented herein are consistent 
with previous results, in that HAART-treated subjects exhibit arterial stiffening, elevated 
cholesterol, LDL, TC:HDL ratio and triglycerides. This cross-sectional study delineates 
the need for additional longitudinal and mechanistic studies to establish a causal 
relationship between LPV/r-treatment and atherosclerosis in this population and the 
underlying mechanisms of atherogenesis and the progression of atherosclerosis. 
3.3 Hypothesis 24: EFV treatment will lead to arterial stiffening but not 
atherosclerotic plaque progression in a mouse model of atherosclerosis 
 To test this hypothesis, ApoE
-/- 
mice were treated with various concentrations of 
EFV or vehicle for either 35 or 70 days, and geometry and mechanical properties as well 
as atherosclerotic plaque progression will be analyzed in the abdominal and thoracic 
aorta, respectively. The goal of testing this hypothesis is to better inform the guidelines 
for treatment and care of HIV-infected patients as well as establish a novel framework for 
future investigations of mechanisms driving HAART-induced vascular remodeling. 
3.3.1 Methods and Materials 
3.3.1.1 Animals and diet 
 Male ApoE
-/-
 mice bred on a C57 background were obtained at 6 weeks of age 
from Jackson Laboratories (Bar Harbor, ME) and kept on a 12-hour light/dark cycle in a 




 Caulk AW, Soler J, Platt MO, Gleason RL. Efavirenz treatment leads to arterial stiffening in 
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temperature-controlled room at 22°C. The animals were housed and cared for according 
to the guidelines set forth the by the National Institutes of Health for the care and use of 
experimental animals. All experimental procedures were reviewed and approved by the 
Georgia Tech Institutional Animal Care and Use Committee (IACUC).  
 Mice were kept on a high-fat diet from Teklad, Inc. (TD88137) consisting of a 
caloric content of 0.15% cholesterol and 42% fat and given water ad libitum. The 
ingredients to the diet are as follows: 195 g high protein casein, 3 g DL-methionine, 
341.46 g sucrose, 150 g corn starch, 210 g anhydrous milkfat, 1.5 g cholesterol, 50 g 
cellulose, 35 g mineral mix (AIN-76), 4 g calcium carbonate, 10 g vitamin mix, and 0.04 
g ethoxyquin. 
3.3.1.2 Drug administration 
Efavirenz (EFV) was obtained from Toronto Research Chemicals, Inc. (catalog 
no. E425000) in powder form. Because EFV has low solubility in water, it is normally 
reconstituted in methanol. However, to prevent unwanted side effects during long-term 
daily administration in mice, EFV was reconstituted in deionized water (1 mg/mL for 1X 
doses and 10 mg/mL for 10X doses) and repeatedly sonicated until the powder was 
visibly evenly distributed throughout the solution. To ensure uniform distribution upon 
administration, the solution was briefly spun in a vortex mixer prior to administration to 
evenly distribute any powder that had settled to the bottom of the solution.  
Mice were administered EFV (n = 6) at 10X relative to the normal human dosage 
(75 mg/kg) or water (n = 6) daily for 5 weeks. To facilitate comparison for concentration- 
and time-dependent evaluation in plaque development, animals were given a 1X dose of 
EFV for 5 weeks (n = 6) or 10 weeks (n = 6). Water controls from the 10X study were 
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used for comparison in the 5 week study as volume of vehicle delivered was equal in 
control and experimental groups, and additional animals were treated with water for 10 
weeks to serve as additional controls (n = 8). In total, 32 animals were used for this study. 
Animals were weighed on a weekly basis, and volumes of EFV were administered based 
on the weekly weight measurements. For example, a mouse weighing 0.020 kg would 
receive 0.15 mL of EFV solution. Note that the dilutions of EFV were achieved in such a 
way as to make volume administrations identical regardless of whether the concentrations 
were 1X or 10X. Control mice were treated with comparable volumes of water. Drug 
administrations were performed using oral gavage. Briefly, the mice were lightly 
anesthetized with gas isoflurane, and a 30 gauge ball-point syringe was inserted into the 
esophagus until reaching the stomach. Once the drug was administered, mice were 
monitored until they regained consciousness to ensure that the airway was not obstructed 
during the administration. 
3.3.1.3 Cylindrical biaxial mechanical testing 
 Following exsanguination, suprarenal abdominal aortas were excised from the 
region approximately 1-2 mm proximal to the celiac artery and immediately distal to the 
renal arteries. Vessels were carefully cleaned of all perivascular tissue, and all branches 
were tied using 8-0 silk suture. Vessels were mounted on a custom biaxial testing device 
[243] and maintained in physiologic buffered saline solution (PBS) containing sodium 
nitroprusside to prevent force generation from the smooth muscle cells and ensure that 
testing was performed in a fully passive state. Unloaded length and diameter were 
determined visually using LabView, and the vessels were preconditioned by ramping the 
luminal pressure from 0 to 160 mmHg at axial stretch values of 1.3, 1.4, 1.5, 1.6, 1.7, and 
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1.8, where the stretch λ is defined by the ratio of the loaded length to the unloaded length. 
Vessels were then subjected to three loading cycles of pressure values from 0 to 160 
mmHg at each of the previously mentioned stretch values in order to generate pressure / 
diameter curves. Fluid level in the bath of the device was monitored to identify the 
presence of leaks in the vessels. Any vessels with substantial leaks were not considered in 
the analysis of vessel mechanical properties, resulting in 4 control samples and 5 EFV-
treated samples being included in stiffness analysis. All mechanical tests were performed 
within 4 hours of excision. Following mechanical testing, aortas were embedded in 
optimum cutting temperature compound (OCT) in an unloaded state and stored for 
histological analysis and quantification of cathepsin activity. 
3.3.1.4 Quantification of compliance and in vivo axial stretch 
 Arterial stiffness was quantified by calculating the compliance, defined as 
 = (∆/)/∆. Diameter measurements were separated into bins by pressure at an 
interval of 10 mmHg and averaged according to each bin. Compliance calculations were 
performed using binned measurements of pressure and diameter.  
 Estimation of the in vivo axial stretch of arteries has previously been performed 
by determining the intersection point of various axial force vs. axial stretch curves under 
isobaric conditions. Data from biaxial mechanical testing of aortas was utilized by 
rearranging the binned data from arterial stiffness calculations such that axial force 
measurements were grouped by pressure rather than axial stretch. Therefore, each 
isobaric curve had at most 6 data points corresponding to a single pressure value and 6 
axial stretch values. Second-order polynomials were fit to all isobaric curves, and the 
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intersection points of all curves were calculated and averaged in order to estimate the in 
vivo axial stretch. 
3.3.1.5 Measurement of intima-media thickness 
 Abdominal aortas were sectioned at a thickness of 7 µm and stained for 
hematoxylin and eosin. Sections were imaged using a Nikon bright-field microscope and 
processed using a custom MATLAB script for determining the thickness of the intima-
media layer. Briefly, each image was loaded into the script, and the adventitia/media 
interface as well as the luminal surface were traced. The average inner and outer diameter 
were then determined from the measured circumferences, and the thickness of the intima-
media was calculated as the difference between the average inner and outer radius. 
3.3.1.6 Determination of plaque coverage 
 Vessels for determination of plaque progression were excised following either 5 
weeks or 10 weeks of EFV administration. Thoracic aortas were removed from just 
below the aortic arch to the diaphragm, carefully cleaned of perivascular tissue, and fixed 
in 10% buffered formalin. Aortic arches were removed from immediately distal to the 
sinus to immediately proximal to the thoracic aorta. Note that one aortic arch from the 
control group was excluded from analysis due to plaque disruption during excision. 
Vessels were cut longitudinally and pinned en face in a petri dish. A digital picture of 
each vessel was acquired using a Marlin F131B camera (Allied Vision Technologies). 
Images were analyzed for plaque coverage using ImageJ software (NIH, Bethesda, MD) 
following previously published methods [244]. Plaque coverage was calculated twice for 
each image by the same observer, and the results were averaged to determine the final 
value of plaque coverage. 
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3.3.1.7 Statistical analysis 
 All data were analyzed using a student’s unpaired t-test with equal variance, and 
significance was determined by p values less than 0.05. Data were expressed as the mean 
± SEM. Additionally, statistical analysis of plaque progression following 5 weeks of 
treatment was performed using a one-way ANOVA followed by a Tukey post-hoc t-test 
to compare control data, 1X, and 10X EFV data. 
3.3.2 Results 
3.3.2.1 EFV treatment alters mechanical behavior in abdominal aortas 
 Suprarenal abdominal aortas from mice treated with water or 10X EFV for 5 
weeks were subjected to biaxial cylindrical mechanical testing in which pressure was 
ramped under fixed length conditions of  = 1.3, 1.4, 1.5, 1.6, 1.7, and 1.8. Diameter and 
axial force measurements from each stretch value were binned according to 
corresponding pressure values at an interval of 10 mmHg. Compliance was quantified for 
each stretch value and for each bin. Diameter measurements and compliance calculations 
revealed a trend towards a slight increase in stiffness at axial stretch values of  = 1.6 and 
above in EFV-treated mice compared to controls (Figure 3.2). 
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Statistical significance was achieved for compliance values at 90 mmHg at λ = 1.6 and 
1.7 as well as 80 mmHg at λ = 1.8. Various stiffness values at pressures between 80 and 
120 mmHg exhibited near significance with p values reaching less than 0.1 at stretch 
values of 1.6 and above. Axial force vs. pressure curves were shifted downward from 
vessels treated with EFV (Figure 3.3). Force values between 0 and 70 mmHg showed 
statistically significant differences (p < 0.05) at all stretch values and in some cases 
reached significance for pressure values of 80 or 90 mmHg. Similarly, axial force vs. 
axial stretch ratio curves were used to determine the in vivo axial stretch of each vessel. 
The average in vivo stretch of control arteries was 1.709 ± 0.017, and the average in vivo 
stretch of EFV-treated arteries was 1.649 ± 0.034. While EFV treatment appeared to 
decrease the in vivo stretch, the differences were not statistically significant (p = 0.186). 
 




























































Figure 3.2. Mechanical testing results from suprarenal abdominal aortas from water-
treated and EFV-treated mice. (Left) Pressure-diameter testing results are shown for an 
axial stretch value of 1.7. (Right) Calculations of compliance for aortas under a range of 
pressure values at a fixed length of  = 1.7. EFV-treated vessels had decreased 
compliance compared to water-treated controls at 90 mmHg. (*) Denotes p < 0.05. 
 60
 
3.3.2.2 EFV treatment does not affect thickness of the aortic wall 
 Suprarenal abdominal aortas from mice treated with water or 10X EFV for 5 
weeks were embedded in OCT following mechanical testing and stained with 
hematoxylin and eosin. Aortic IMT was 22.36 ± 2.44 µm in water-treated mice vs. 21.13 
Figure 3.3. Axial force vs. pressure measurements of suprarenal abdominal aortas from 
water- and EFV-treated mice. (Top left) Axial force vs. pressure of aortas at an axial 
stretch of 1.7 from water- (black) and 10X EFV-treated (grey) mice. Force values are 
significantly lower in the EFV-treated group at pressure values up to 90 mmHg. 
Asterisks denote p<0.05. (Top Right) Force values from all axial stretch conditions are 
reported in black for controls and grey for EFV-treated vessels. Note that the curves are 
shifted downwards for the EFV-treated group. (Bottom) Average axial force vs. axial 
stretch curves depicting in vivo axial stretch values of water- and EFV-treated mice. 
Vertical dotted lines denote the in vivo axial stretch values for each group. Note the 
intersection point of the curves from EFV-treated samples is lower than that of water-
treated samples. 









































































± 1.63 µm in EFV-treated mice (Figure 3.4). The differences were not statistically 
significant. 
 




 mice were treated with water, 1X EFV, or 10X EFV for 5 weeks and 
water or 1X EFV for 10 weeks, and the thoracic aorta and aortic arch were subsequently 
removed, cleaned, and opened en face for imaging. Plaque coverage was determined as a 
percent of the total luminal area. EFV-treated mice had a higher percentage of plaque 
coverage than water-treated mice in the thoracic aorta and the aortic arch after 5 weeks of 
































Figure 3.4. Suprarenal abdominal aorta intima-media thickness measurements 
from mice treated with water or 10X EFV for 5 weeks. No differences were 
observed in aortic IMT between groups. 
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Interestingly, the trend was reversed in both the thoracic aorta and the arch with a 10X 
treatment (Figure 3.5). Differences between EFV-treated vessels and controls were not 
different following 10 weeks of treatment with 1X EFV and water. All results for plaque 








































































Figure 3.5. Percent plaque coverage in various arterial segments from water- and EFV-
treated mice. (Left) Plaque coverage in mice treated with water (n=6, one excluded from 
arch analysis), 1X EFV (n=6), or 10X EFV (n=6) for 5 weeks. Note that the 1X EFV 
group has an increasing trend compared to the control group, but the 10X EFV group has 
less plaque than the 1X group. No significant differences were observed. (Right) Plaque 
coverage in mice treated with water (n=8) or 1X EFV (n=6) for 10 weeks. Plaque 
coverage was increased compared to respective groups treated for 5 weeks, but no 
differences were observed between groups treated for 10 weeks.   
Thoracic aorta plaque coverage (%)
Water-treated 0.79 ± 0.17 0.79 ± 0.17 2.61 ± 0.43
EFV-treated 1.67 ± 0.4 0.95 ± 0.25 2.42 ± 0.32
Aortic arch plaque coverage (%)
Water-treated 3.44 ± 0.69 3.44 ± 0.69 7.98 ± 0.71
EFV-treated 3.86 ± 0.71 2.99 ± 0.58 7.67 ± 1.06
5 week 1X treatment 5 week 10X treatment 10 week 1X treatment
Table 3.6. Calculated values of plaque coverage in thoracic aortas and aortic arches from 
various water- and EFV-treated mice. Note that in the 5-week treatment groups, control 
values for the 1X EFV group were also used as controls for the 10X EFV group because 




 The role of HAART treatment in the development of early onset cardiovascular 
disease has become the focus of much attention given the increased life expectancy and 
increase in non-AIDS-related comorbidities in HIV-positive populations. Various classes 
of antiretroviral drugs have been implicated to different extents in the development of 
precursors of CVD [7]. Of specific interest is the development of arterial stiffening and 
increased vessel wall thickness as these are commonly used subclinical markers of 
atherosclerosis. Clinical studies have shown HAART-induced changes in carotid IMT 
[48], arterial stiffening [49, 176], and progression of endothelial dysfunction in HIV-
positive patients [9, 52, 53]. Our lab has previously shown development of arterial 
stiffening and increased intima-media thickness in mice treated with azidothymidine 
(AZT), one of the most common NRTIs in HIV treatment [12]. Other labs have shown 
similar atherogenic results in mice treated with various antiretroviral drugs [80, 81, 83, 
165, 166]. However, NNRTIs such as EFV have received less attention compared to their 
NRTI relatives. Despite ample clinical implications of NNRTIs in the alterations of lipid 
profiles [7, 173] and recent reports of their role in CVD development [9], only a handful 
of laboratory studies have investigated the role of NNRTIs in the progression of 
atherosclerosis [8, 10, 11, 175]. Consequently, we performed long-term in vivo studies to 
examine the effects of EFV on the development of commonly investigated preclinical 




 mice were given bolus doses of EFV daily via oral gavage for 35 days in 
order to study the effects of the drug on the development of arterial stiffening and 
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thickening of the arterial wall. Compliance values were significantly different at the 
highest stretch values in the range of 80-90 mmHg. Previous studies have suggested that 
in vivo axial stretch values of normal murine carotid arteries lie in the range of 1.6-1.9 
depending on the strain of the mouse [178, 245], thus implicating higher values of axial 
stretch as being the most physiologically relevant in analysis. Our results show 
significant increases in arterial stiffening of the abdominal aorta at physiologic values of 
axial stretch and blood pressure, indicating a possible role of EFV in the development of 
arterial stiffening. This finding corroborates results reported in hypothesis 1 in which 
arterial stiffening was associated with EFV treatment in the aorta but not in the carotid 
arteries. Additionally, axial force values were consistently decreased at pressure values 
between 0 and 70 mmHg, and there was a non-significant trend towards a decreased in 
vivo axial stretch ratio. Although modulus calculations were not different in these ranges, 
the force measurements still suggest a role of EFV in maladaptive vascular remodeling. 
Previous studies have shown that arterial remodeling is dependent on axial length and 
directly affects longitudinal tension in arteries [115, 177, 178]. Indeed, studies have 
shown a decrease in axial force in a mouse model of fibulin-5 deficiency as well as a 
model of AZT treatment [12, 245], and one study demonstrated a decrease in the in vivo 
axial stretch ratio with no accompanied change in pressure-diameter behavior in a mouse 
model of abdominal aortic aneurysm [179]. Thus, the change in mechanical behavior 
seen following EFV-treatment may be an indicator of early vascular remodeling leading 
to dysfunction. Additionally, the alteration of axial force may even be a marker that 
precedes circumferential stiffening that is normally measured in the clinic. 
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Changes in aortic geometry have been reported due to treatment with AZT [12, 
83], and changes in carotid geometry have recently been associated with EFV treatment 
in a cross-sectional study (hypothesis 1). Aortic intima-media thickness was evaluated in 
mice treated with water or 10X EFV for 5 weeks. No significant differences were 
observed, suggesting that EFV plays no role in short-term thickening of the aortic wall. 
However, given the changes in mechanical behavior following 10X EFV treatment for 5 
weeks, the possibility of macroscopic remodeling following a longer treatment regimen 
cannot be discounted and warrants further investigation. 
 Plaque progression was analyzed as a function of duration of treatment as well as 
bolus concentration. For 5 weeks of treatment, 3 groups were analyzed: a control group, a 
group treated with 1X EFV, and a group treated with 10X EFV. Analysis was performed 
for thoracic aortas as well as aortic arches. Interestingly, plaque coverage tended to 
increase most in the 1X treated group rather than the 10X treated group in both vessel 
types. However, following a one-way ANOVA, no differences were observed between 
groups in either vessel type. Vessels from mice treated for 10 weeks with water or 1X 
EFV were also analyzed. Plaque coverage in all vessels was increased compared to each 
respective 5-week-treated group; however, differences between controls and EFV-treated 
mice at 10 weeks were not existent. Tohyama et al. showed that EFV treatment has a 
beneficial effect on reverse cholesterol transport and leads to a transient increase in HDL-
c in hA-I transgenic mice [175]. Such a finding may explain both the transient increase in 
plaque coverage of 1X EFV-treated mice compared to controls; however other studies 
have demonstrated no effect of EFV on cholesterol efflux from macrophages [246] or 
negative effects of EFV on lipid content in hepatic cells [11], so available results are 
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conflicting. The differential effects of EFV seen in this study (neutral or beneficial effects 
on plaque progression and deleterious effects on vascular remodeling) may be explained 
by different mechanisms acting along various pathways. Additional studies should be 
performed investigating the mechanisms of EFV-induced disease progression in vivo.  
It should be noted that the mice analyzed in this study were 11 or 16 weeks old 
upon completion of the study. In general, analysis of plaque progression requires that 
mice be much older as measureable plaque progression may normally occur as late as 30-
40 weeks of age. This study was aimed primarily at identifying accelerated development 
of preclinical markers of atherosclerosis; thus, younger mice were chosen in order to 
attenuate aging effects in the vasculature. Consequently, plaque coverage was low, 
consistently less than 10% in all vessels at all time points and often as low as 1%. 
Difficulties arise in the interpretation of these results due to the low signal-to-noise ratio. 
A more in-depth analysis of plaque progression at later developmental stages would be 
useful in future studies.   
Previous animal studies focusing on effects of EFV related to CVD have utilized 
concentrations comparable to our 1X group (approximately 10 mg/kg). However, 
differences in pharmacokinetic profiles between species following EFV administration 
have been shown in multiple studies (compare [247] and [248]) that suggest higher dose 
requirements in rodents to achieve plasma concentrations comparable to those in humans, 
leading us to utilize higher concentrations for our investigation of EFV-induced vascular 
remodeling. Additionally, many of these studies have simply included the substance in 
the food and estimated the dose based on consumption. Our study employs a more 
accurate methodology by providing a daily dose of EFV via oral gavage. The solubility 
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of EFV in water is low, and we consequently utilized sonication to ensure that the drug 
was evenly distributed in the medium; however, accuracy in concentration delivered to 
the animals is still lost in this case. Some have shown improved bioavailability of EFV 
using polymeric micelles for encapsulation [249], and this may be employed in future 
studies for increased accuracy in drug delivery to the animals. 
Additional limitations of this study arise in the use of an animal model that does 
not accurately recapitulate the physiologic environment of HIV-positive patients 
receiving HAART. These patients receive a cocktail of three drugs of various classes and 
remain chronically infected with HIV. Mouse models are useful in the context of 
identifying specific contributors to HAART-induced CVD; however, the additive effects 
of chronic infection and combined therapy are lost when utilizing animal models. 
Regardless, emerging clinical data surrounding EFV use and CVD progression highlights 
the need to better characterize the effects of EFV use on the vasculature, and the mouse 
model employed in this study provides such an opportunity. 
 These data taken together suggest that EFV may play a role in early vascular 
remodeling contributing to HAART-induced cardiovascular disease but does not 
independently contribute to late-stage atherosclerosis. Validation of a mouse model of 
EFV-induced preclinical markers of cardiovascular disease provides a platform for future 
studies investigating the specific mechanisms behind HAART-induced atherosclerosis. 
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                                                           CHAPTER 4 
MECHANICALLY-MEDIATED REMODELING OF 
LYMPHATIC TISSUE AS A DRIVER FOR LYMPHEDEMA  
4.1 Introduction 
 The lymphatic system is a robust network of vessels that plays a critical role in 
many functions including immune cell trafficking, transport of lipids from the gut to the 
bloodstream, and tissue fluid balance [250]. Each of these functions is directly dependent 
on the ability of lymphatic vessels to spontaneously and rhythmically contract to 
transport fluid against an unfavorable pressure gradient, a function which, if impaired, 
leads to lymphedema [123]. It is well known that the mechanical environment contributes 
significantly to their overall contractile function, leading many to study the relationship 
between intrinsic contractile function and mechanical cues such as magnitude and 
direction of flow, inlet and outlet pressure, or pressure gradient [13, 14, 141, 147]. Also 
directly related to contractile function is the ability of the vessel to distend appropriately 
in response to mechanical loading, and there have consequently been many studies 
characterizing the active and passive mechanical behavior of lymphatic vessels [126, 146, 
153, 251]. Confocal microscopy has also been reported to characterize the microstructure 
of the vessel in order to provide motivation behind the mechanical responses of the 
vessels [150, 153]. 
 Mechanically-mediated growth and remodeling is a well-documented 
phenomenon in biological tissue and is especially well-characterized in the field of 
vascular mechanics. However, growth and remodeling data relating to the lymphatic 
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vasculature is strikingly absent. Correlation between geometric changes in collecting 
lymphatic vessels and progression of lymphedema have only recently been reported in 
cancer patients [16], suggesting a possible role for growth and remodeling as an impetus 
for the development of lymphedema, but the mechanisms driving such remodeling are 
still vastly under-characterized. Models of growth and remodeling in the vascular 
literature suggest homeostatic shear and hoop stress states that drive remodeling 
behavior, thus implicating flow and pressure, respectively, as critical mediators of the 
process [117, 119, 121, 252]. Many fluid-structure interaction (FSI) models have been 
published that predict flow patterns (and consequently wall shear stress) in lymphatic 
vessels, but the solid mechanical properties are generally modeled empirically or without 
consideration for the nonlinear, anisotropic behavior of the material [152, 153, 156, 158, 
159], thus reducing the accuracy of hoop stress calculations obscuring the value of 
potential models of mechanically-mediated lymphatic growth and remodeling. There is a 
pressing need for a predictive microstructurally-motivated mathematical model that 
captures the key characteristics of the mechanical response, namely the material non-
linearity and anisotropy, in the framework of finite elasticity. Such a model represents a 
key step in exploiting important biomechanical frameworks for FSI and soft tissue 
growth and remodeling and holds the potential to advance our understanding of 
lymphatic function, dysfunction, and disease progression.  
 The purpose of this study is to develop a predictive mathematical model for 
passive and contractile mechanical behavior of the rat thoracic duct. We adapted our 
custom biaxial testing device [243] to support biaxial biomechanical testing and 
multiphoton microscopy of rat lymphatic vessels and performed parameter estimation 
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from these data for a four fiber family constitutive model and active contractile model. 
We describe here the incorporation of that model into an FSI model using Poiseuille flow 
assumptions and illustrate the role of various mechanical factors on growth and 
remodeling of a single lymphangion using the developed FSI model in conjunction with a 
simple model of volumetric growth. These illustrations motivate the need for specific 
experimental data to better understand the role of mechanics in lymphatic dysfunction as 
well as highlight key parameters that may play a role in mechanically-mediated 
development of lymphedema.  
4.2 Milestone 15: Quantify the active and passive mechanical properties of rat 
thoracic ducts using a microstructurally-motivated constitutive model in the context 
of finite elasticity. 
 The goal of this milestone is to characterize the mechanical behavior of rat 
thoracic ducts using standard biaxial biomechanical testing techniques and applying 
known constitutive models that account for collagen fiber angle orientation and muscle 
cell contraction. 




 Caulk AW, Nepiyushchikh ZV, Shaw R, Dixon JB, Gleason RL. Quantification of the passive and active 
biaxial mechanical behavior and microstructural organization of rat thoracic ducts. Revised and resubmitted 
to J Roy Soc Interface. Mar 2015.  
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4.2.1 Methods and Materials 
4.2.1.1 Vessel isolation 
 Male Sprague-Dawley rats (300 – 350 g) were obtained from Jackson 
Laboratories (Bar Harbor, ME) and kept on a 12-hour light/dark cycle in a temperature-
controlled room at 22°C. The animals were housed and cared for according to the 
guidelines set forth the by the National Institutes of Health (NIH) for the care and use of 
experimental animals. All experimental procedures were reviewed and approved by the 
Georgia Tech Institutional Animal Care and Use Committee (IACUC). Rats were 
anesthetized with a combination of diazepam (2.5 mg/kg body weight) and 
droperidol/fentanyl (0.3 mg/kg). Both drugs were administered via intramuscular 
injection. After the animals reached a surgical plane, the chest cavity was opened and the 
thoracic duct was visualized by removing surrounding tissue and organs. Care was taken 
to excise the vessel from the same location each time; however, priority was given to 
identifying a location that was without valves or branches in order to simplify the 
modeling process. The vessel was carefully excised and placed in physiologic saline 
solution (PSS) consisting of the following constituents (in mM) at room temperature: 
145.0 NaCl, 4.7 KCl, 2.0 CaCl2, 1.17 MgSO4, 1.2 NaH2PO4, 5.0 dextrose, 2.0 sodium 
pyruvate, 0.02 EDTA, and 3.0 MOPS (pH = 7.4 at 37°C). For passive mechanical tests, 
vessels were placed in Ca
2+
-free PSS, which contained all of the same constituents as 
PSS with the exception of replacing CaCl2 with 3.0 mM EDTA. Vessels were mounted 
on opposing cannula in a bath of PSS and carefully cleaned of all perivascular tissue. All 
chemicals were obtained from Sigma-Aldrich (St. Louis, MO). 
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4.2.1.2 Biomechanical testing 
 Single thoracic duct lymphangions (n = 6), excluding valves, were mounted on 
opposing glass cannula using silk suture (Figure 4.1) within a custom computer-
controlled biaxial testing device [243] in PSS in a temperature controlled incubator at 
37°C. The unloaded length was at least 10 times the unloaded radius and data were 
collected near the midpoint between mounting suture to sufficiently attenuate end effects 
during testing and isolate the mechanical response of a central region of the vessel. 
Vessels were visualized using an inverted microscope (2.5X magnification) and digital 
camera (Allied Vision Technologies, Marlin F-033B) while controlling the transmural 
pressure and axial length and recording the outer diameter and axial force measurements. 
Inlet and outlet pressure were measured using inline pressure transducers (Honeywell 
FPG 060-E418-11) and transmural pressure was calculated as the average of the inlet and 
outlet pressure. Outer diameter was recorded using an edge detection subroutine in 
Labview, axial length was controlled using linear actuators (Newport Precision LTA 
series) connected to the cannula, and axial force measurements were measured using a 50 
g load cell (Delta Metrics 99-2636-050G). Vessels were pressurized to just above 0 
cmH2O in order to prevent collapse, and the unloaded length and diameter of each vessel 
was determined using a custom program in LabView.  Vessels were then axially stretched 
to 30% beyond the unloaded length (λ = 1.3), pressurized to 3 cmH20, and given 30-60 




 Prior to data collection for this study, preliminary experiments were performed on 
five vessels to establish the experimental testing protocol. Axial force versus transmural 
pressure and transmural pressure versus diameter behavior demonstrated little variation 
for axial stretch values below 1.3; thus, the lower limit of axial stretch was chosen as 1.3. 
For axial stretches above 1.6, transmural pressure vs. diameter behavior became nearly 
linear, suggesting that collagen fibers had possibly become maximally engaged. After 
this transition to linear behavior, no differences were observed in transmural pressure vs. 
diameter behavior other than a reduction in diameter and increased slope. Thus, the upper 
limit of axial stretch for the testing protocol was chosen as 1.6. Also, from these 
preliminary experiments, vessels exhibited contractile amplitudes >25% of unloaded 
diameter at 3 cmH2O and an axial stretches of 1.30; thus, vessels that exhibited a 
contractile amplitude of <25% of the unloaded diameter were not considered 
representative (e.g., due to damage during isolation and mounting) and excluded from 
analysis. Note that the maintenance of basal tone was not evaluated as an exclusion 
criterion.  
Figure 4.1. Typical image of a rat thoracic duct mounted for mechanical testing at an 
axial stretch of 1.3. Vessels were mounted such that the unloaded length was at least 10 
times the unloaded radius in order to sufficiently attenuate end effects during testing.  
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 Once contractility was established, isobaric contractile function was assessed at 
transmural pressures of 3, 6 and 9 cmH2O. At each transmural pressure, the vessel was 
given a period of 5-10 minutes for equilibration. The same procedure was repeated for 
axial stretches of λ = 1.4 and 1.5. Temporal changes in end diastolic and systolic 
diameters were observed following changes in loading conditions; thus, data for analysis 
was taken only after the minimum and maximum diameters reached steady-state 
conditions.  
 After contractile function was assessed at fixed pressure, the PSS in the bath and 
the system was replaced with Ca
2+
-free PSS, which contained all of the same constituents 
as PSS with the exception of replacing CaCl2 with 3.0 mM EDTA, to inhibit vessel 
contractility and quantify the ‘passive’ mechanical response. Vessels were preconditioned 
by ramping the transmural pressure from 0 to 15 cmH2O at axial stretch values of λ = 
1.30, 1.35. 1.40, 1.45, 1.50, 1.55, and 1.60. Note that an axial stretch value of λ = 1.6 was 
excluded from passive testing in two samples because transmural pressure vs. diameter 
behavior transitioned to a linear shape at a stretch of 1.55, thus precluding the need test at 
higher values of axial stretch. Following preconditioning, vessels were subjected to three 
loading cycles of transmural pressure values from 0 to 15 cmH2O at axial stretches 
identical to those during preconditioning. Plots depicting transmural pressure vs. diameter 
and axial force vs. pressure were generated for all fixed length conditions. Axial force 
versus axial length data were generated for conditions of fixed transmural pressure. Axial 
force data was retrieved for values of transmural pressure at intervals of 1 cmH2O for 
each value of axial stretch, resulting in up to 16 curves each with 6 data points. 
 75
4.2.1.3 Multiphoton imaging 
The testing device was placed on an LSM 710 META inverted confocal 
microscope (Zeiss) to visualize the microstructure across the entire wall of live, unfixed 
lymphatic vessels [112]. The vessels were imaged using a 40X / 1.3NA immersion 
objective (Zeiss). The vessel, maintained in Ca
2+
-free PSS, was excited with an 800 nm 
two-photon laser, and collagen was visualized by detecting its second harmonic 
generation around 400 nm. Elastin emissions were detected by setting the META filter to 
a 500-550 nm bandpass configuration and using 488 nm excitation [253]. 
Z-stacks were collected under three loading conditions: a low-load condition (p = 3 
cmH2O, λ = 1.3), a medium-load condition (p = 9 cmH2O, λ = 1.45), and a high-load 
condition (p = 20 cmH2O, λ = 1.6 or maximum during passive testing). Orthogonal views 
of these z-stacks were then used to calculate vessel thickness in a loaded configuration. 
Unloaded vessel thickness was calculated from these values for each of the three 
conditions, assuming incompressibility, and the unloaded thicknesses used in modeling 
were calculated as the average of the unloaded thickness values determined from each of 
the three loading conditions. 
4.2.1.4 Quantification of collagen organization 
 The angular distribution of collagen fibers was quantified for each optical slice of 
the z-stacks using a custom MATLAB® program that utilizes a fast Fourier series 
algorithm as described previously [110]. Using a fast Fourier transform, a power 
spectrum was generated in order to provide a histogram of the frequency intensities 
between -90° and 90° at 4° increments (reported as “Normalized Intensity”). Note that an 
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angle of 0° corresponds to an orientation in the axial direction. The mean fiber angle 
distribution was determined by taking an average of each bin across all slices in a z-stack. 
4.2.1.5 Constitutive modeling 
We modeled the lymphatic vessels as an incompressible, thin-walled cylinder in 
the framework of finite elasticity such that the Cauchy stress can be defined by equation 
(4.1), 
  = − + 2  ! "  (4.1) 
where  is the Cauchy stress, p is the Lagrange multiplier that enforces incompressibility, 
 is the deformation gradient, W is the strain energy function, and " is the right Cauchy-
Green strain tensors. The components of the deformation gradient and the right Cauchy-
Green strain tensor for inflation and extension of an axisymmetric thin-walled tube are 
  = #$%&(' ,  , ))								and										" = #$%&.',  , )/	 (4.2) 
where ' = ℎ/1,  = %/2, and  ) = ℓ/4 where ℎ, %, and ℓ, and  1, 2, and 4 are the 
loaded and unloaded thickness, midwall radius, and axial length, respectively.  
Conservation of mass for the incompressible solid vessel wall requires that 
det78 = ') = 1, which leads to the constraint, 
 
 ℎ(% + ℎ)ℓ = 1(2 + 1)4 (4.3) 
Equilibrium requires that  
 9 = %ℎ = 9:,;< − ''  ! '' + 
 !  (4.4) 
 9)) = =)>ℎ(2% + ℎ) = −''  ! '' + ))
 ! )) (4.5) 
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where =) is the axial force,  is the luminal pressure, 9 and 9)) are the mean 
circumferential and axial components of the Cauchy stress, respectively, 9:,;< is a 
constitutive equation that describes the stress generated from ‘active’ muscle cell 
contraction, ?? 	(@ = A, B, C) are the in-plane components of " and ! = !(") is the 
strain energy density function that describes the ‘passive’ mechanical response. Note that 
=) = =D + >% where =D is the force measured by the load cell during testing, and the 
second term accounts for the end cap pressure. Due to the very small thickness of the 
vessel wall (average unloaded thickness of approximately 30 microns), a two-
dimensional framework was utilized such that stresses in the radial direction were 
assumed to be negligible in comparison to circumferential and axial stress. 
 We considered the four-fiber family strain energy density function of Baek et al. 
[254] which was adapted from the original function described by Holzapfel et al. [108]; 
namely,  
 ! = E(FG − 3) + I EJK4EK MNO7EK((K) − 1)8 − 1PKQJ,,R,S  (4.6) 
where E, EJK, and EK are material parameters, FG = TA(") = '' +  + )) is the first 
invariant of ", (K) =  sin(WK) + 2) sin(WK) cos(WK) + )) cos(WK) is the 
stretch of the Z[ fiber family, and WK is the angle between the axial and fiber directions. 
For inflation and extension tests (given appropriate material symmetry), ) = 0, so that 
(K) =  sin(WK) + )) cos(WK). We assume that fiber families one and two 
correspond to fibers oriented in the circumferential and axial directions, respectively, and 
are therefore prescribed as opposed to calculated. We also assume material symmetry 
 78
such that, WR = −WS ≡ W and EJR = EJS and ER = ES. Thus, equation (4.6) contains seven 
material parameters (E, EJK and EK with k = 1,2,3) and one structural parameter (W).  
 We employed the model of Rachev and Hayashi [111] for the active stress due to 
muscle cell contraction; namely,  
 9:,;< = 9;< ^1 − _` − ` − ab
c (4.7) 
where 9;< is a parameter dependent on the activation of the muscle cells, ` is the 
stretch at which the muscle contraction is maximum, and a is the stretch at which 
muscle-induced force generation ceases. Due to both tonic and rhythmic contraction of 
lymphatic muscle cells, the parameter 9;< was calculated for conditions describing the 
basal tone as well as the systolic contraction of the vessel, resulting in separate curves 
depicting maximum and minimum states of active contraction governed by equations 
9;<D;d = 9;<e;f + 9;<fgf	 and 9;<Dhi = 9;<e;f	, where 9;<e;f is the material parameter governing 
active stress in a diastolic state and 9;<fgf is the material parameter that governs the 
addition of active stress during systolic contraction. Note that “maximum” here refers to a 
physiologic systolic state and not maximal contraction as defined by applying 
depolarization solution together with a strong lymphatic muscle agonist, and “minimum” 
refers to a physiologic diastolic (or basal) state.  
 9;<e;f was calculated as a function of pressure to support the observation of a 
myogenic response. Constant values of 9;<e;f were determined for each loading condition, 
resulting in three values of 9;<e;f and three values of pressure. A linear regression was 
performed on the data to determine values for parameters % and E following the form 
9;<e;f = =() = % + E, thus characterizing 9;<e;f (and consequently 9;<D;d) as a function 
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of pressure. In some cases, regression yielded a nearly vertical line due to almost 
identical maximum radii in the diastolic condition, and therefore one point was excluded 
from the regression so as to ensure that calculated parameters indicated a positive linear 
relationship between 9;<e;f and pressure. Following linear regression, the MATLAB® 
subroutine lsqnonlin was used to calculate 9;<e;f for a range of pressure values for the 
purpose of plotting theoretical curves. A minimum of −E/% was imposed on the solver to 
prevent predictions of negative active stress. 
4.2.1.6 Parameter estimation 
 The passive mechanical parameters and structural parameter were determined 
using the MATLAB® non-linear regression function lsqnonlin and minimizing the 
error function 
 N = 12j kI lDmnop
h − odhqod r
i
hQJ +			I l
=Dmnoph − =odh=o̅d r
i
hQJ t (4.8) 
where n equals the number of data points acquired during biaxial testing, Dmnoph  and 
=Dmnoph  are the model prediction of pressure and axial force values for data point n, 
determined from equations (4.4) and (4.5), with 9;<=0 (and thus, 9:,;<=0). odh  and =odh  
are the measured pressure and axial force for data point n. qod and =o̅d are the average 
pressure and axial force values over all data points.  
 After the passive parameters were determined via regression with the passive 
data, the values of 9;<fgf and 9;<e;f were determined by minimizing equation (4.7) to the 
maximal contraction occurring during systolic contraction (9;< = 9;<fgf) and minimum 
contraction occurring during diastolic relaxation (9;< = 9;<e;f)	at pressure values of  = 
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3, 6, and 9 cmH2O. The parameter ` was prescribed as the maximum circumferential 
stretch achieved during passive testing plus 5%. The parameter a was prescribed as 5% 
less than the minimum circumferential stretch achieved during active testing. These 
parameters were prescribed in order to capture the entire working range of active 
contraction. All parameter values are reported for individual samples as well as in the 
form of the mean ± standard error of the mean (SEM). 
4.2.2 Results 
4.2.2.1 Passive and active mechanical response 
 Average unloaded thickness was 32.2 ± 1.60 µm, the average unloaded length was 
3.573 ± 0.173 mm, and the average unloaded radius was 240 ± 10.9 µm, respectively 
(Table 4.1); thus, the radius-to-thickness ratio of 13% in the unloaded thickness supports 
the thin wall assumption and the diameter-to-length ratio suggests that end effects may be 
neglected within a central region of the vessel (see Figure 4.1). Loaded geometry was 
used to determine unloaded thickness from the incompressibility assumption. Standard 
errors associated with the calculation of unloaded thicknesses, based on measurements 
from the low, medium, and high loading scenarios, averaged 2.67 µm, which is 8% of the 
mean unloaded thickness, and suggests that incompressibility may be a reasonable 
assumption. For a single value of axial stretch, the amplitude of spontaneous contractions 
decreased (i.e. the vessel becomes more like a conduit) as transmural pressure increased 
(Figure 4.2). Contractile amplitude was markedly diminished upon increasing axial 
stretch from λ = 1.3 to 1.5 (Figure 4.2C); contractile frequency, however, was not 
diminished (data not shown).  
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Figure 4.2. Contractile amplitude of lymphatic vessels as a function of time, 
transmural pressure, and axial stretch. (A) Active diameter measurements for specimen 
5 reveal a time-dependent contractile response following changes in transmural 
pressure at an axial stretch of 1.3. (B) Transmural pressure vs. circumferential stretch 
for specimen 5 at an axial stretch of 1.3. Contractile amplitude decreases as transmural 
pressure increases. End diastolic stretch increases to a lesser degree than end systolic 
stretch (less than 10% vs. more than 30%, respectively). Note that this plot 
corresponds to the time-dependent data in panel A. Data was included only after 
diameter measurements reached an equilibrium following changes in loading 
conditions. (C) Contractile amplitude data for all specimens at 3 values of transmural 
pressure and 3 values of axial stretch. Note that contractile amplitude was markedly 
decreased at axial stretch values of 1.4 and 1.5 compared to 1.3. Data are reported as 
the mean ± SEM. 
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 Passive mechanical behavior was observed and showed a stiffening response with 
increasing axial stretch, typical of soft tissues from the vasculature (Figure 4.3). Axial 
force measurements had little variation at the lower values of axial stretch but generally 
increased to maximum force values ranging from 4 to 15 mN at the highest stretch 
values. Qualitatively, isobaric axial force versus axial stretch curves consistently intersect 
at axial stretch values between 1.3 and 1.4; the intersection of isobaric axial force-stretch 
curves a characteristic response observed in blood vessels and often ascribed as the in 
vivo axial stretch [112, 255]. We did not measure the in vivo axial stretch of the rat 
thoracic ducts during excision; however, an axial stretch of 1.4 seems reasonable based 
on our qualitative observations. 
Table 4.1. Measurements and calculations of loaded and unloaded geometry for 
individual rat thoracic ducts. Vessels were mounted on a biaxial testing device and 
oriented in a stress-free condition. Unloaded length and outer radius were determined  
using a custom LabView program. Loaded thicknesses from three loading conditions 
were determined using confocal microscopy. The loading conditions consisted of low (p 
= 3 cmH2O, λ = 1.3), mid-range (p = 9 cmH2O, λ = 1.45), and high loading (p = 20 
cmH2O, λ = 1.6 or highest stretch value during passive testing) corresponding to hlow, 
hmid, and hhigh, respectively. Unloaded thickness (H) was calculated by applying the 
known loaded and unloaded geometry to the incompressibility assumption and averaging 
the unloaded thickness calculations from the low, mid, and high loading conditions. SEM 
for each calculation of the average unloaded thickness is also reported. 
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4.2.2.2 Material parameter calculation 
 Non-linear regression yielded material parameters that provided a good fit of the 
passive mechanical testing data (Table 4.2 and Figure 4.4).  In general, the majority of 
the error in the passive fits appeared to occur either in the toe region of the plots where 
the collagen fibers become engaged or in the higher values of axial stretch in which 
collagen fibers appear to be constantly engaged.  
Figure 4.3. Passive mechanical testing data for specimen 4 and transmural pressure 
vs. diameter data for all 6 specimens at an axial stretch of λ = 1.3. Transmural 
pressure vs. diameter (A) and axial force vs. transmural pressure (B) show progressive 
stiffening as axial stretch is increased. Lowest and highest values of axial stretch are 
denoted by arrows. (C) Isobaric axial force vs. axial length curves for specimen 4. The 
The intersection point of the curves has previously been used to estimate the in vivo 
axial stretch of arteries. (D) Transmural pressure vs. outer diameter data for 6 thoracic 
ducts at an axial stretch of 1.3. Note the large variability in geometry between 
samples. The maximum diameter for the largest vessel is approximately 50% larger 
than that of the smallest vessel (~800 µm compared to ~530µm). 
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 Regression yielded material parameters that provided a good fit of the contractile 
testing data (Table 4.3 and Figure 4.5). Average errors were calculated using Equation 8, 
and the values associated with the active parameters 9;<D;d and 9;<e;f were 6.6 ± 2.6% and 
6.8 ± 3.4%, respectively. The parameter % provides physical insight into the dependence 
of the basal parameter on transmural pressure. Calculation of this parameter showed 
relatively consistent basal tone in all samples with the exception of specimen 5, which 
had very little dependence on transmural pressure. Although a myogenic response was 
absent from this specimen, we believe this to be an indication of the variability in 
lymphatic behavior rather than an outlier in the data set, since the contractility for that 
specimen met the inclusion criteria defined in the methods. Note also that for specimen 3, 
a single data point was excluded from the error calculation in the basal condition due to a 
skewed error calculation. The inaccuracy was affected by the large slope of the basal 
curve (thus a very large change in transmural pressure is required for modest changes in 
diameter). Eliminating this data point from the error calculation had little effect on the 




Figure 4.4. Illustrative plots from parameter fitting results for specimen 4 using a four-
fiber constitutive model. (A) Transmural pressure vs. diameter plot for a range of axial 
stretch values. (B) Axial force vs. diameter plot for a range of axial stretch values. Note 
that axial force values in the modeling process exclude contributions from end cap 
pressure (i.e. =D is reported rather than =)). Open circles denote experimental data and 
solid lines denote theoretical predictions. 
Table 4.2. Passive material parameter calculations for rat thoracic ducts using a four-fiber 
constitutive model. Data are reported as the mean ± SEM. The family of parameters EJK
exhibit a much higher degree of variability than the family of parameters EK. The 
structural parameter exhibits consistency, and all parameters yield error values that 




Figure 4.5. Model simulations of transmural pressure vs. circumferential stretch 
behavior for specimen 2 at an axial stretch value of λ = 1.3. Theoretical simulation of 
transmural pressure vs. circumferential stretch behavior was calculated from the 
combination of passive plus active stress and provides a good fit of the active data. 
Contributions to the behavior from the basal (dashed line) and systolic (dotted line) 
parameters are denoted on the graph. Note that the maximal systolic condition is 
determined by the summation of the basal and systolic contributions. 
Table 4.3. Active material parameter calculations for rat thoracic ducts. Slope and 
intercept values for 9;<e;f were determined using linear regression. The parameters `
and a were prescribed based on experimental data. (†) Denotes sample with a single 
data point removed from error calculation. Removal of data point was due to the large 
slope of the basal curve resulting in excessively high errors that skewed the 
interpretation of the data. Removal of data point had no effect on parameter calculation 
or estimation of total stress. Data are reported as the mean ± SEM. 
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4.2.2.3 Collagen and elastin organization 
 A single outer layer of collagen and a single inner layer of elastin were 
consistently identified in all samples using confocal microscopy (Figure 4.6). Similar 
observation of the layered structure of lymphatic vessels was reported by Arkill et al. 
[150]. The fluorescence spectrum of elastin revealed a ‘fiber family’ oriented nearly 
circumferentially and another oriented nearly longitudinal. Collagen fibers showed a 
more undulated morphology at lower loading conditions and appeared to recruit fibers 
more gradually throughout the loading process, compared to elastin. Despite consistency 
in the elastin fiber orientations, significant differences in collagen fiber distributions were 
observed across samples, with all samples exhibiting differing degrees of material 
asymmetry (Figure 4.7).  
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Figure 4.6. Representative multiphoton images of specimen 3 at low, mid, and high 
loading conditions (A-C, respectively). Multiple images were taken in order to produce a 
three-dimensional representation of the vessel wall. Collagen fibers are denoted by red 
and elastin fibers are denoted by green. Note the presence of small, elongated elastin 
fibers and the much larger collagen fibers that have a wavier morphology. Scale and 
orientation are denoted in (A). (D) Representative orthogonal image of a vessel under 
high loading conditions including both collagen and elastin. The layered structure and 
curvature of the vessel are evident. Thickness of the vessel was determined from the 
cross-sectional view depicting the curvature. 
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Figure 4.7. Frequency intensity plots for low-, mid-, and high-loading conditions as a 
function of orientation angle for six rat thoracic ducts (A-F for specimens 1-6, 
respectively). An angle of 0 degrees denotes an orientation in the axial direction. Primary 
angle orientations were easily identified by a large peak in frequency intensity. Peaks 
associated with secondary angles were more difficult to interpret. Data suggests that 
material asymmetry exists in all specimens. Note that the highest normalized intensity 
values occur in the high loading conditions of every specimen, indicating increased 
alignment of collagen fibers as loading conditions are increased. 
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4.2.3 Discussion 
 Lymphatics play a key role in a diverse set of physiological functions, including 
tissue fluid balance, lipid absorption, and immune cell trafficking. As is the case for other 
soft tissues, mechanically-mediated biological mechanisms likely play a central role in 
lymphatic function (or dysfunction) and disease progression. Experimental studies have 
shown that lymphatic contractility is altered following changes in transmural pressure 
[145, 146] and changes in axial pressure gradients [13, 141], and clinical data has shown 
that lymphedema leads to dramatic changes in lymphatic vessel geometry (e.g. thickness, 
radius, lymphatic muscle hyperproliferation) [16]. While it is well known that tissues 
remodel in response to changes in their local mechanical environment, altered loading 
conditions such as those found in lymphedema have yet to be directly linked. To study 
mechanically-mediated remodeling of lymphatics, accurate quantification of the local 
mechanical environment of lymphatics is required; however, a critical gap remains in 
quantifying the biaxial mechanical response of lymphatic tissue and modeling the 
mechanical behavior in a framework that allows quantification of the local mechanical 
environment for relevant applied loads and vessel geometries. Such a model represents a 
critical step in the investigation of mechanically-mediated dysfunction and disease 
progression. To that end, we have identified material parameters, combining the models 
from Baek et al. [254] and Rachev and Hayashi [111], to accurately describes the 
mechanical behavior of rat thoracic ducts to passive cylindrical biaxial testing and 
spontaneous contraction. 
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4.2.3.1 “Microstructurally-motivated” passive constitutive model 
 The functional forms of the constitutive equations were motivated by the tissue 
microstructure; however, microscopy revealed both consistencies and inconsistencies 
between the microstructure captured in the constitutive model and that observed in the 
tissue. First, although elastin is often modeled as an isotropic material [109, 110, 119, 
256], elastin imaging revealed nearly circumferentially and nearly axially oriented fibers. 
Second, although we did not quantify their organization, there are nearly 
circumferentially oriented smooth muscle cells. Third, we observe collagen fibers 
oriented at off-axis angles. Fourth, in addition to these elastin structural components, 
collagen structural components, and smooth muscle cells, an amorphous, presumably 
isotropic mechanically significant solid, likely containing proteoglycans, 
glycosaminoglycans, water, and other ECM constituents, exists in which these structural 
components are embedded. Thus, the proposed four-fiber family model (Equation (4.6)) 
captures many of the key salient features of the observed microstructure. Namely, the 
axially fiber family captures, the contribution from the axially oriented elastin structural 
element (and perhaps the contribution from axial collagen components), the 
circumferential fiber family captures the combined role of passive smooth muscle and the 
circumferentially oriented elastin structural element (and perhaps the circumferential 
collagen components), the fiber-families at ±α capture the combined contribution of 
collagen fibers oriented off axis, and the isotropic term captures the contribution from the 
amorphous solid.  
 There are, however, several important inconsistencies between our 
microstructurally-motivated constitutive model and the observed microstructure. For 
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several vessels, the collagen fiber distributions were asymmetric, often with a single peak 
oriented off-axis (see Figure 4.7), suggesting material asymmetry. To accurately identify 
material parameters for an asymmetric material requires one to quantify both the shear 
strains and the torsional load during fixed length pressurization; more rigorously, one 
should also perform torque-twist tests on the tissue [257]. Although quantifying shear 
strains can be done via tracking of markers or particle image velocimetry, the 
measurement of applied torque is technically challenging and has not been reported for 
tissues of this caliber. Without this torsion boundary condition, proper analysis to identify 
material parameters for a proposed asymmetric constitutive model cannot be performed. 
Indeed, other asymmetries are also apparent; namely, the elastin fibers and smooth 
muscle cells are not oriented at exactly 0- and 90-degrees. Note that material asymmetries 
exist in most arteries, yet rarely are torsional loads quantified (particularly in small 
caliber vessels) and rarely are these material asymmetries incorporated into the functional 
form of the constitutive model, perhaps because the nominal values and biological 
significance of these shear strains and stresses are thought to be of secondary importance, 
compared to the normal strains and stresses. Thus, although our model is motivated by 
microstructure, we do not use measured microstructure as an input to the constitutive 
model. Despite the technical challenges required for such an effort, the results herein 
motivate the need for incorporating microstructural measurements into the constitutive 
model [110] and quantifying relevant boundary conditions and deformations so that such 
modeling efforts may be performed. 
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4.2.3.2 Sample-to-sample variations and material heterogeneity 
 We observed significant variations in mechanical response (Figure 4.3) and 
material parameters (Table 4.2 and Table 4.3), geometry (Table 4.1), and microstructural 
organization (Figure 4.7) across samples; such variability is not uncommon in the 
lymphatic circulation [143, 144, 258]. Loaded thicknesses in rat thoracic ducts reported 
in the literature are consistent with the present data [144, 153]; geometric and functional 
parameters generally show large standard errors, suggesting large sample-to-sample 
variations. Similarly, others have used confocal microscopy to quantify angle orientation 
in bovine mesenteric lymphangions, and report similar variability to that reported herein 
[150]. Geometric variability in human thoracic ducts as a function of longitudinal 
position has been reported [258] and we (data not shown) and others have reported 
heterogeneities in the microstructural organization along the length of a single 
lymphangion [153].     
 Such heterogeneities and sample-to-sample differences in geometry, 
microstructure, and mechanical behavior render quantifying a unified constitutive model 
for the rat thoracic duct challenging. Indeed, it further motivates the need for a 
constitutive model that links microstructural measurements to the tissue-level mechanical 
response. The goal of this milestone was to isolate the mechanical behavior of a central, 
nearly homogeneous region of a lymphangion, quantify the deformation and boundary 
conditions for this central region, identify an appropriate constitutive model for this 
homogeneous region that captures well the tissue level mechanical response, and quantify 
the microstructure of the same region. We submit that an accurate constitutive equation 
that links the microstructural architecture to the tissue-level biomechanical behavior for a 
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homogeneous region is a required first step, before the material heterogeneities can be 
accurately modeled. 
4.2.3.3 Sample-to-sample variations in passive material parameters 
 Passive parameters obtained via non-linear regression spanned multiple orders of 
magnitude (Table 4.2); such variations may be due to several factors. First, given that we 
observed significant sample-to-sample variations in the mechanical response, geometry, 
and microstructural organization, it is perhaps not surprising that there were also large 
variations in material parameters obtained via non-linear regression. Second, 
identification of material parameters for exponential constitutive models, via regression 
to biaxial mechanical testing data, often results in large deviations across samples [112, 
259, 260], even when sample-to-sample variations in mechanical behavior is low; non-
uniqueness may be a factor [108, 261]. Note, however, we were unable to identify models 
with fewer material parameters (e.g., two or three fiber-family models) that provided an 
adequate fit to data. All parameters were restricted to be positive, however, since our goal 
was to identify a model that provided the best fit to data, no other restrictions were placed 
on their value; we also surveyed a broad range of initial guesses during regression to 
ensure that a global minimum was identified. Restricting the values of material 
parameters in order to ascribe a more physical meaning and microstructural motivation to 
each may be an opportunity for future work [122]. 
4.2.3.4 Model spontaneous contraction and basal tone 
 Lymphatic muscle cells have characteristics in common with both smooth muscle 
cells, which exhibit tonic contraction, and cardiac muscle, which exhibit rapid and 
spontaneous contraction [125, 149]; both characteristics are observed here and are 
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captured in the active model. The contraction results suggest that the maximum 
contraction is captured well by the functional form of Rachev and Hayashi, but that the 
basal tone that occurs during the resting phase exhibited a pressure (or strain) 
dependencies, beyond that captured from the strain-dependent response captured in 
Equation (4.7); modeling a linear dependency between the basal parameter and 
transmural pressure provided a reasonable fit to data. In general, material parameters 
should not be prescribed as a function of applied loads (e.g., pressure), but rather as a 
function of an appropriate strain measure; this is a limitation of the current active model. 
However, with the data reported herein, at fixed length (i.e. fixed axial strain), the 
diastolic diameter (and circumferential strain) remained nearly constant with increasing 
pressure, presumably due to a myogenic response from the muscle cells; such 
singularities prohibit relating basal tone to strain using the original model in Equation 
(4.7) because the model cannot produce the highly nonlinear behavior necessary to 
recapitulate maintenance of load-dependent tone without prescribing unrealistic values 
for the parameters ` and a. Davis et al. reported myogenic responses in rat lymphatic 
vessels that are time-dependent following a step-change in transmural pressure [142] and 
reported a decrease in maximum diastolic diameter following an increase in afterload 
[13] in the rat mesentery. Gasheva et al. have reported increases in end diastolic diameter 
of rat thoracic ducts due to pumping-induced production of nitric oxide [124]. Further, 
these data suggest that contraction amplitude (Figure 4.7) and frequency (not shown) are 
highly dependent on the axial stretch; however, the current active model does not 
consider such axial dependencies. Developing a new functional form for the active stress 
as a function of appropriate circumferential and axial strain measures and material 
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constants (and performing a broader range of theoretically-motivated experiments to 
quantify these material constants for lymphatic vessels) should be a target of future work.    
  Taken together, these findings provide a framework for future investigations 
targeting lymphatic growth and remodeling as it relates to the progression of diseases 
such as lymphedema. Given that an important role of the lymphatic system is the 
transport of fluid from tissues to the venous system, many functional parameters that 
have been quantified in the literature relate directly to the ability of the vessels to 
transport fluid (e.g. contractile amplitude and contractile frequency). It is unknown how 
these functional parameters may be affected by the internal forces experienced in these 
vessels, and it therefore remains necessary to quantify these forces. It is well known that 
mechanical factors such as transmural pressure, stretch, and flow direct tissue growth and 
remodeling [118, 119, 121, 122, 252], and quantification of stresses in lymphatics will 
provide a foundation for simulating growth and remodeling in an effort to quantify the 
effect of mechanically-mediated geometrical changes on common functional parameters 
describing contractile behavior. This proposed model is the first to successfully simulate 
both the active and passive behavior of a lymphatic vessel using a microstructurally-
motivated model and provides potential for long-term predictions of mechanically-
mediated maladaptive remodeling as well as identification of primary parameters 
contributing to the development of diseases relating to the lymphatic vasculature. 
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4.3 Milestone 2: Establish a novel predictive framework characterizing the 
relationship between mechanically-mediated lymphatic growth and remodeling and 
time-dependent lymphatic pumping function in order to identify key parameters 
driving progression of lymphedema.  
 The goal of this milestone is to characterize lymph transport through a single 
actively contracting rat thoracic duct using experimentally-determined parameters from 
Milestone 1 in conjunction with a model of Poiseuille flow and adaptations of previously 
published models of volumetric mechanically-mediated growth and remodeling in order 
to identify potential key parameters driving the progression of lymphatic dysfunction and 
lymphedema. 
4.3.1 Methods and materials 
Constitutive model. Given the sufficiently small nature of lymphatic vessels, it is 
appropriate to begin mathematical modeling with the simple two-dimensional framework 
as described in section 4.2.1. We can consider a single lymphangion as a long, straight 
tube subjected to a prescribed luminal pressure and axial load. In the 2-D case, average 
stress values serve as suitable representations for the intramural stresses within the vessel 
because we assume the wall to be a thin membrane. We can impose a luminal pressure 
and axial load, and we can easily measure the outer radius of the vessel. Given isochoric 
deformation, it is then easy to calculate the inner radius and wall thickness in the loaded 
configuration, making experimental stress calculations straightforward. 
 For constitutive modeling, the Cauchy stress can be expressed as a function of the 
deformation gradient and the strain energy function following equation (4.2). For this 
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where A and y are the loaded and unloaded midwall radius, respectively, at an arbitrary 
point within the vessel wall, Θa is the opening angle of the vessel after making a radial 
cut in the unloaded vessel (defined by Chuong and Fung [103]),  and Λ are the loaded 
and unloaded lengths, respectively, and ', , and )  are the mean in-plane stretch ratios 
in the radial, circumferential, and axial directions, respectively. Note that the off-diagonal 
components are zero because we assume no shear deformation in an in vitro testing 
environment. For a normal carotid artery, residual stresses exist within the wall until a 
radial cut in a cross-sectional segment is made, allowing the vessel to spring open and 
create what is commonly called an opening angle. No data currently exists regarding 
opening angles of lymphatic vessels, so we have here assumed that there are no residual 
stresses within the wall of the vessel and consequently no opening angle, thereby 
reducing the in-plane circumferential component of the deformation gradient to  =
A/y. We consider this a reasonable assumption based on the sufficiently small thickness-
to-radius ratio observed in the previous section (approximately 13%).  
 For the passive mechanical behavior of lymphatic vessels, we considered the four-
fiber family strain energy density function in equation (4.6). We assume that fiber 
families one and two correspond to fibers oriented in the circumferential and axial 
directions, respectively, and are therefore prescribed as opposed to calculated. We also 
assume material symmetry such that, WR = −WS ≡ W and EJR = EJS and ER = ES. Passive 
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material parameters were experimentally determined based on isolated rat thoracic ducts 
in the previous section, and those parameters are utilized in these simulations. 
 For active contraction, we consider an adaptation of the model of Rachev and 
Hayashi [111] as described in the previous section. Note that active contributions are only 
considered in the circumferential direction due to the preferred alignment of smooth 
muscle cells in the circumferential plane. Active parameters experimentally determined 
for rat thoracic ducts were utilized in these simulations. In order to capture the cyclic 
contractile feature of the lymphangion, we have here prescribed a time-varying value of 
the parameter as an adaptation of the prescribed motion published by Bertram et al. [159] 
such that, 
 9;< = 9;<D;d1 − cos.2>=(T − T<)/ + 9;<e;f (4.9) 
where = is the frequency of the lymphatic contraction, T is the current time, and T< is the 
duration of the active contraction, and an additional parameter T' is defined as the 
refractory period or time separating contractile phases. Note that because of the cosine 
function, the maximum value of 9;< is equal to 29;<D;d + 9;<e;f, resulting in contractions 
stronger than expected based on experimental observations. This waveform was chosen 
partly based on previously proposed models. Because frequency has been shown to 
depend on transmural pressure [13, 262], frequency was prescribed based on the average 
basal transmural pressure and was defined based on equation (4.10), 
 = =  ∗ ; + e − ;2 + j (4.10) 
where  and j are parameters governing the shape and intercept of the curve, 
respectively. These values were determined by digitizing data from Figure 2C in the 
study from Davis et al. [13] and performing a nonlinear regression using the MATLAB 
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subroutine lsqnonlin. Results depicting the regression can be seen in Appendix B. 
The calculated values for  and j were 1.59 and 4.28, respectively. Note that this 
relationship forces a (nearly) maximum frequency value. Note also that the frequency can 
also be defined as the inverse of the sum of T< and T', and thus alteration of the frequency 
requires manipulation of either the duration of contraction, the refractory time, or both. In 
this study, we have assumed that the duration of contraction is constant, and thus the 
refractory time is the value adjusted in order to calculate the correct frequency based on 
equation (4.10), which is in agreement with observations reported on collecting rat 
lymphatics in vivo [263, 264]. Incorporation of the strain energy density function in 
equation (4.6) in conjunction with this theoretical framework can then provide us with a 
complete view of the mechanical environment in the vessel wall. 
 Lumped parameter model. In order to model lymph propulsion through a 
lymphangion, the vessel was modeled similar to that in Bertram et al. [159] such that the 
vessel can be considered a cylindrical, distensible tube with a valve at the proximal and 
distal end of the tube and fixed inlet and outlet pressures ; and e, respectively. 
Pressure within the vessel is divided into three nodes: J, D, and  which are the 
pressures immediately distal to the inlet valve, the luminal pressure halfway down the 
length of the vessel, and the pressure immediately proximal to the outlet valve, 
respectively. A graphical representation of the model of a lymphangion can be seen in 
Figure 4.8.  
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 Lymph propulsion through the tube was modeled as steady, fully-developed, 
unidirectional, axisymmetric flow such that the pressure drop across the length of the 
tube can be defined by equation (4.11), 
 Δ = 8)4>AhS  
(4.11) 
where Δ is the pressure drop across the length of the vessel,  is the dynamic viscosity 
of the fluid, ) is the axial stretch of the vessel, 4 is the unloaded length of the vessel,  
is the flow through the vessel, and Ah is the inner radius of the vessel. The assumption of 
Poiseuille flow from equation (4.11) has been demonstrated to be a reasonable 
approximation of the flow profile in areas away from the valves [154, 155]. If contraction 
of the vessel is assumed to be uniform throughout the vessel wall and the fluid is 
considered incompressible, bulk flow through the vessel can be defined as the change in 
volume per unit of time as seen in equation (4.12), 
  =   T = 2>Ah  Ah T )4 (4.12) 
Figure 4.8. Model of the relationship between pressure, flow, and diameter in a single 
lymphangion pump. The time varying values include the diameter D, the pressures pm, p1, 
p2, and the flow rates Q1, Q2. The valve resistances RV1 and RV2 are functions of the 
pressure drop (the difference between the inlet and the outlet pressure). The external 
pressure as well as each of the pressure reservoirs are fixed values, and pa is 
constitutively less than pb. 
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For the sake of simplicity, we assume here that the pressure drop across the vessel is 
linear such that the pressures J and  can be approximated by equation (4.13). 
 J = D + ∆2 , 						 = D − ∆2  (4.13) 
In this model, the transmural pressure D is calculated from the constitutive model 
previously described using the time-dependent 9;< term in equation (4.9) and Laplace’s 
Law following equations (4.4) and (4.5). Taken together, we can calculate the entire 
pressure profile of a single lymphangion. Using these pressures, the flow across the inlet 
and outlet valves can then be calculated using equation (4.14), 
  = hi − my  (4.14) 
where hi is the pressure on the proximal side of the valve, m is the pressure on the 
distal side of the valve, and y is the resistance of the valve as defined by equation 
(4.15), 
 y = yi + yd1 + NO.−m(Δ − Δm)/ 
(4.15) 
where yi is the resistance when the valve is fully open, yd is the resistance when the 
valve is fully closed, m is the valve opening slope, ∆ is the pressure drop across the 
valve (defined as hi − m), and ∆m is the pressure drop at which the valve opens and 
closes. It has been shown that this value is a function of transmural pressure and differs 
depending on whether the valve is opening or closing [126]. For simplicity’s sake, we 
have modeled the transition state as a fixed value of pressure differential for both opening 
and closing characteristics. Finally, conservation of mass dictates that 
 # = #,hi − #,m (4.16) 
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where # is the change in volume in the lumen of the vessel for a fixed time step, #T, 
#,hi is the volume of fluid taken in through the proximal valve for a fixed time step, 
and #,m is the volume of fluid expelled through the distal valve for a fixed time step. 
For modeling, the time-dependent active contraction was prescribed following equation 
(4.9) and the midwall radius was calculated at each time step by utilizing Equation (4.16) 
as the cost function and employing the MATLAB subroutine lsqnonlin. Following 
calculation of the inner radius, all other values can be calculated explicitly prior to 
moving forward to the next time step.   
 Various flow parameters have been previously utilized to quantify changes in 
lymphatic function. These metrics can be defined by the following equations: 
  = ( − )/ (4.17) 
  =  × = (4.18) 
 2 =  −  (4.19) 
  =  −  (4.20) 
where  is the ejection fraction,  is the fractional pump flow,  is the end 
diastolic diameter,  is the end systolic diameter, = is the contractile pumping 
frequency, 2 is the contraction amplitude,  is the stroke volume,  is the end 
diastolic volume, and  is the end systolic volume where the volume at any point in 
time is calculated as  = >Ah)4. 
 Time-dependent volumetric growth. The constitutive model describing the solid 
mechanical behavior of the vessel wall can be extended to include volumetric growth 
following the model proposed previously by Taber et al. [117]. To expand the model to 
support growth, the deformation gradient u must be reformulated to include a growth 
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term. To do so, an infinitesimally small element of an unloaded and stress-free body (in 
this case, the vessel wall) must first undergo growth before undergoing kinematic 
deformation such that the deformation gradient can be defined as u = u∗ ∙ u where u∗ is 
the kinematic deformation gradient tensor describing the deformation from an unloaded, 
grown state to a loaded grown state (i.e. the current state), and u is the growth 
deformation gradient describing the deformation from the original unloaded state to the 
current or grown unloaded state. With this framework in place, the in-plane stretch ratios 
can then be described by equations (4.21) - (4.23), 
 ' = '∗' = ℎ/1a (4.21) 
  = ∗  = A/ya (4.22) 
 ) = )∗) = /4 (4.23) 
where h∗ is the ratio of the current loaded length to the current unloaded length and h is 
the ratio of the current unloaded length to the original unloaded length, 1a and ya are the 
unloaded thickness and midwall radius prior to growth, respectively, and $ = (A, B, C). To 
accurately describe the growth behavior of the tissue with this framework, a growth law 
must be prescribed for each plane. However, data motivating lymphatic growth is largely 
absent in the literature. Consequently, growth laws are prescribed here to model the 
growth observed in arteries. Sustained increases in flow are known to induce an increase 
in radius with little change in thickness [265], whereas sustained increases in luminal 
pressure are known to induce an increase in thickness with little change in radius. It is 
widely believed that these changes occur in an effort for the tissues to reach homeostatic 
states of stress. Changes in the growth ratios h can be defined according to the 
following equations, 
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 #' = 1' ^
9 − 9,D9,D c ∗ #T 
(4.24) 
 # =  1 ^
9 − 9,D9,D c +
1 
 − DD  ∗ #T 
(4.25) 
 #) = 0 (4.26) 
where 9,D is the homeostatic circumferential stress,  is the luminal shear stress, D is 
the homeostatic shear stress, and ' and  are the time constants governing the speed of 
growth in the radial and circumferential directions due to sustained changes in 
circumferential stress, respectively,  is the time constant governing growth in the 
circumferential direction due to sustained changes in shear stress, and #T is the fixed 
change in time during growth. Note that #) is prescribed as zero for this study because 
growth in the axial direction is neglected. In this case the wall shear stress is defined by 
equation (4.27), 
  = 4>AhR  
(4.27) 
where  is the dynamic viscosity,  is the volumetric flow rate for a fixed change in time 
as calculated by equation (4.12), and Ah is the inner radius.  
 In order to properly predict growth and remodeling behavior, it is necessary to 
accurately assign time constants and homeostatic stress values that govern the growth 
behavior. In vascular function, circumferential stress can be calculated simply from the 
tonic contraction of smooth muscle cells in response to blood flow or increased blood 
pressure; however, the lymphatic vasculature experiences more variable circumferential 
and shear stress due to the spontaneous and rhythmic contraction of the muscle cells. 
Given this and the lack of experimental data motivating the concept of lymphatic growth 
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and remodeling, time-averaged stress values are considered here such that growth is 
calculated from equations (4.24) - (4.26) using the average stresses experienced over the 
course of a single contraction of a lymphangion, and the equilibrium values are assigned 
as the average stress values calculated prior to applying a step change to the system. 
4.3.2 Illustrative simulations 
 Material parameters. Active and passive mechanical properties of isolated rat 
thoracic ducts were quantified in Milestone 1, and the estimated values are used here to 
govern the mechanical behavior during simulation. A list of constants used during all 
simulations can be seen in Table 4.4.  
 Simulation 1 – Changes in short term lymphatic pumping function in response to 
elevated afterload. Let all growth terms equal ∞ such that no growth occurs in response 
to a change in the mechanical environment. Let the preload equal 3 cmH2O, and let the 
afterload experience a gradual, linear increase from 4 to 16 cmH2O. Time-dependent 
pumping behavior including radius, flow rate, and transmural pressure can be seen in 
Figure 4.9 for time points before and after an increase in afterload. Pumping metrics can 
be seen in Figure 4.10. Note that ejection fraction decreases following an increase in 
afterload, while ESD increases, inducing a decrease in contractile amplitude, in response 
to elevated afterload.  Note that the EDD does not change in this case because pumping 
pressure was assumed to be equal to the inlet pressure, which remains unchanged. 
Functional pumping metrics follow a pattern that is similar to that observed in Figure 2 of 
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Figure 4.9. Predicted time-dependent waveforms of a single pumping lymphangion 
under two different afterloads. (Top left) Outer radius measurements over the course of 
a single pumping cycle. Note that EDD does not change, but ESD increases following 
an increase in afterload, thus decreasing the contractile amplitude. (Top right) Flow 
rates are decreased over the course of a single pumping cycle following an increase in 
afterload. (Bottom left) Pressure waveforms range from the value of the preload 










































































































































Figure 4.10. Functional flow metrics for a single pumping lymphangion as a function of 
increasing afterload. (Top left) Ejection fraction decreases uniformly as afterload 
increases. (Top right) EDD is unchanging, and ESD increases, thus decreasing contractile 
amplitude as a function of increasing afterload. (Middle left) Contractile frequency 
increases with increasing afterload. (Middle right) Average flow rate initially increases 
and subsequently decreases as afterload increases. (Bottom left) Fractional pump flow 
increases initially and subsequently decreases as afterload increases. Note that although 




 Simulation 2 – Radial growth in response to elevated afterload. Let the afterload 
e experience a sustained increase from 4 to 16 cmH2O, let the time constant ' equal 5 
days, and let the time constants  and  equal ∞ such that growth occurs only in the 
radial direction. The “target” value of circumferential stress was here defined as the 
circumferential stress calculated prior to the step increase in afterload. Simulation results 
Constant Units
R 0 cm 240 240 240
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Table 4.4. Table of constants used for simulations illustrating the effects of various 
changes in mechanical loading on growth and remodeling behavior of a single lymphatic 
vessel. Simulations were performed using data obtained from a passive biaxial 
mechanical test of a rat thoracic duct. 
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suggest that the pressure profile is relatively unchanged, but EDD and ESD both decrease 
as the thickness increases in order to restore the circumferential stress to the target value, 
resulting in a decrease in bulk flow (Figure 4.11). Circumferential stress is restored to the 
homeostatic value with an increase of wall thickness of approximately 24% (40 µm 
compared to 32.2 µm), but note that shear stress is decreased and does not return to 
homeostatic values as growth in this simulation is not shear-dependent (Figure 4.12). 
Ejection fraction is initially decreased following a step increase in afterload (Figure 4.13). 
However, the value increases slightly as the vessel wall thickens, but the value remains 
significantly less than the original homeostatic value. Note that fractional pump flow 
follows the same pattern, and, despite the sustained increase in contractile frequency, also 


















































































Figure 4.11. Time-dependent waveforms of a single pumping lymphangion under 
initial homeostatic conditions and homeostatic conditions following mechanically-
induced vessel wall thickening. (Top left) EDD decreases and ESD increases due 
wall thickening following an increase in afterload. (Top right) Flow rates after 
reaching mechanical homeostasis are decreased. (Bottom left). Pressure profiles 
follow the preload and the afterload and appear relatively unaffected by the 
evolution of the thickness of the vessel wall. 
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Figure 4.12. Mechanically-mediated radial geometric evolution of a single pumping 
lymphangion in response to a sustained elevation in afterload. (Top left) 
Circumferential stress is initially elevated following an increase in afterload and 
subsequently approaches the target value as the vessel wall thickens. (Top right) The 
vessel wall thickens in response to a sustained elevation in afterload in order to 
restore circumferential stress. (Bottom left) Vessel cross-sectional area increases as 
thickness increases. Increases in cross-sectional area have been reported in lymphatic 
vessels from lymphedematous legs of human subjects in the literature. (Bottom right) 
























































































































Figure 4.13. Evolution of functional flow metrics following a sustained increase in 
afterload and subsequent radial growth of a vessel wall. (Top left) Ejection fraction 
decreases significantly following an increase in afterload and undergoes little change 
in response to radial growth. (Top right) FPF follows the same trend as ejection 
fraction despite a sustained increase in frequency. (Middle left) Contractile frequency 
increases following an increase in afterload. Note that frequency is not dependent on 
the unloaded geometry and therefore does not evolve with growth. (Middle right) 
EDD and ESD decrease with radial growth, but EDD is reduced compared to initial 
homeostatic values, whereas ESD is elevated compared to initial homeostatic values. 
(Bottom left) Average flow rate per contraction experiences an initial decrease due to 
increased afterload as well as further decrease following vessel remodeling. 
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 Simulation 3 – Radial and circumferential growth in response to elevated 
afterload.  Let the afterload e experience a sustained increase from 4 to 16 cmH2O, let 
the time constant ' equal 5 days, and let the time constants  and  equal 60 days and 
5 days, respectively such that growth occurs in the radial direction (i.e. thickness 
changes) in response to circumferential stress and growth occurs in the circumferential 
direction (i.e. radius changes) in response to circumferential and shear stress. Time-
dependent waveforms show a dramatic decrease in EDD, ESD, and contractile amplitude 
as compared to the homeostatic value prior to the increase in afterload (Figure 4.14). 
Bulk flow was decreased and the pressure waveforms were unchanged following 
geometric changes of the vessel. Circumferential stress was initially increased due to 
elevated afterload but experienced a sharp decrease as the vessel remodeled in response 
to the dominant shear term (Figure 4.15). Shear stress initially experienced a sharp drop 
and gradually increased as the vessel radius decreased. Vessel thickness and radius 
decreased by 25% and 33%, respectively. Note that without the inclusion of shear-
induced remodeling, thickness increases in order to re-establish a homeostatic value of 
circumferential stress, but inclusion of shear dominates the growth behavior and causes a 
sharp decrease in radius. Ejection fraction and fractional pump flow were both reduced in 
response to elevated afterload, and geometric remodeling induced a small increase in 
both values, but neither value reached the values associated with the original homeostatic 
configuration (Figure 4.16).  
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Figure 4.14. Time-dependent waveforms of a single pumping lymphangion following 
mechanically-mediated radial and circumferential growth. (Top left) EDD, ESD, and 
contractile amplitude are substantially reduced following growth induced by 
increased afterload. (Top right) Bulk flow is reduced following remodeling. (Bottom 
left) Pressure profiles are unchanged both before and after elevation in afterload. 
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Figure 4.15. Mechanically-mediated circumferential and radial growth of a single 
lymphangion in response to elevated afterload. (Top left) Circumferential stress 
undergoes an initial increase in response to the elevated load, but a subsequent 
decrease occurs as the shear stress term dominates the geometric changes of the 
vessel. (Top right) The vessel initial thickens but ultimately atrophies in response to 
elevated afterload. (Middle left) The vessel radius reduces in order to restore values of 
time-averaged shear stress. (Middle right) Vessel cross-sectional area decreases 
following remodeling. (Bottom left) Time-averaged shear stress restores to the initial 
homeostatic value following vessel atrophy. 
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Figure 4.16. Evolution of functional flow metrics following a sustained increase in 
afterload and subsequent circumferential and radial growth of a vessel wall. (Top 
left) Ejection fraction is initially reduced but is slightly increased in response to 
reduction of vessel thickness and radius. (Top right) Fractional pump flow follows 
the same pattern as the ejection fraction. (Middle left) Contractile frequency is 
increased in response to elevated afterload. (Middle right) EDD and ESD are both 
reduced compared to initial homeostatic values. (Bottom left) Average flow rate per 
contractile cycle decreases in response to vessel remodeling. 
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4.3.3 Discussion 
 Mechanically-mediated maladaptive growth and remodeling as it relates to 
disease development is a well-documented phenomenon, especially in the vascular 
mechanics literature; however, little is known regarding the relationship between the 
mechanical environment of lymphatic vessels and the progression of lymphedema. 
Consequently, the primary goals of this milestone were twofold: (1) to test the hypothesis 
that mechanics is a driver of the progression of lymphedema using a theoretical 
framework for mechanically-mediated volumetric growth, and (2) to highlight key 
parameters that can potentially be investigated as these motivators using available ex vivo 
testing techniques. We have here developed a microstructurally-motivated lumped 
parameter model that predicts diameter, pressure, and flow profiles for a single 
lymphangion that follows patterns seen in the literature [13] and utilized this model to 
predict long-term growth and remodeling in response to a sustained elevation of afterload 
under various growth considerations. These simulations suggest that radial growth can 
restore circumferential stress but that shear-induced remodeling leads to reduction of 
vessel radius and thickness in response to a sustained elevation in afterload. Such a 
finding suggests that shear stress may not be a mediator of the lymphatic growth 
observed in the lymphedema literature. 
 Results from simulation 1 demonstrate the ability of our model to recapitulate 
available data in the literature, specifically that from Davis et al. These simulations were 
performed for a thoracic duct (as opposed to mesenteric lymphatics), and thus the 
geometric predictions were much larger than those observed in the aforementioned study. 
However, functional pumping metrics (e.g. ejection fraction, fractional pumping flow) as 
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well as general contractile behavior (e.g. changes in EDD and ESD) in response to an 
elevated afterload were similar to those observed by Davis et al., thus lending credibility 
to the predictive capability of our model. It should be noted, however, that the peak value 
of the active parameter was larger than that determined in the previous study of this aim 
due to the chosen cosine waveform. This waveform was selected based on studies from 
Bertram et al. [159]. Scaling of the waveform was performed to more accurately 
recapitulate the results in this aim and resulted in pumping function that could not exceed 
normal values of afterload. This is perhaps a limitation of the solving techniques rather 
than the model itself, and additional work to address this limitation is ongoing. 
Simulations 2 and 3 suggest that thickening of the vessel wall may be exclusively due to 
the need for restoration of circumferential stress. Inclusion of shear-dependent growth 
suggests shrinking of the vessel in response to elevated afterload in order to increase the 
shear stress. This simulation does not follow the limited results that are reported in the 
literature that show narrowing of the lumen and thickening of the vessel wall. Time 
constants in all simulations were chosen based on the study from Taber et al. [117]; 
however, these time constants were prescribed for the case of aortic growth and could 
therefore take on any number of values for the lymphatic vasculature. Larger time 
constants suggest slower growth; consequently, the smaller time constant associated with 
shear-induced growth in simulation 3 dominated the growth process. Note that the time 
constants do not affect the homeostatic values of the unloaded geometry but rather how 
quickly the vessels remodel to achieve such homeostasis (data no shown). Thus, varying 
these parameters would have little effect on the ability of the model to recapitulate 
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geometric data in the literature, and because time-dependent remodeling data has never 
been reported, a sensitivity analysis of the time constants was not performed.  
 We assumed a target value of circumferential and shear stress for all simulations 
in this study based simply on the starting conditions of the vessel prior to the increase in 
afterload. To effectively test a hypothesis for mechanically-mediated growth and 
remodeling, it is critical that the hypothesis include a target value of stress for which the 
vessel to try to achieve. Homeostatic stress values in arteries have been proposed in 









 for shear stress; however, the stresses 
experienced by lymphatic vessels are notably lower than those in arteries and veins [146, 
154, 266]. Indeed, homeostatic circumferential stress values in this model were 3000 
dyne/cm
2
, and homeostatic shear stress values were 0.25 dyne/cm
2
. Future studies should 
investigate the homeostatic mechanical conditions of lymphatic vessels. Taken together, 
these results demonstrate a clear need for additional experimental data in the literature in 
order to better understand the role of mechanics in lymphatic remodeling and progression 
of lymphedema.  
 Although these simulations suggest a novel perspective, they should be 
interpreted with caution due to the large number of assumptions that must be made. First, 
the transport model contains many assumptions that may not in fact be true of normal in 
vivo lymphatics. To start, the model does not include the effects of gravity on overall 
lymph transport, thus limiting its application in studying lymphedema of the lower limbs 
in humans. With this assumption in mind, the model still adequately supports ex vivo 
testing of lymphatics as well as in vivo experimental models of lymphedema such as a 
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mouse tail model that does not require inclusion of gravity in its considerations [267]. As 
additional experimental data becomes available, expansion of the model can be 
performed in order to include the effects of gravity and better simulate the native 
environment of lymphatics of the lower limbs in humans.  
Valve behavior in lymphatics is known to be complex and has recently been 
quantified as a function of transmural pressure [159]. Transition properties of the valves 
are dependent on the pressure drop across the valves, and lymphatic valves have different 
properties depending on whether they are opening or closing. In most cases the valves are 
biased to remain in an open position (i.e. the valves remain open even when facing a 
small negative pressure drop) [126]. Valve behavior here was simplified to support valve 
opening properties that were constant rather than pressure-dependent in order to simplify 
model behavior. Constants were chosen to support the concept that valves should remain 
biased to stay open. Valve behavior is an important determinant in flow profiles within 
the vessel; however, the goal of this milestone was to develop a framework in which 
specific parameters could be identified as contributors to lymphatic dysfunction, and thus 
valve behavior was simplified with the assumption that future studies might include a 
more detailed analysis of the relationship between complex valve behavior and 
mechanically-mediated growth and remodeling. Additional assumptions of the transport 
model include a linear pressure drop across the vessel and Poiseuille flow, and although 
these may not represent exact behavior, it is unlikely that these assumptions would 
dramatically inhibit the utility of the model due to the low Reynold’s numbers generally 
observed in lymphatic flow (less than 1) [154].  
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 Many assumptions were made in order to predict growth and remodeling 
behavior. First, a volumetric growth model explicitly ignores the remodeling behavior of 
individual constituents of the microstructure (e.g. collagen and elastin). Growth and 
remodeling of arteries is a much larger field, and many have proposed constrained 
mixture models that propose differential growth behavior of individual constituents [118, 
120-122]. Lack of available data regarding microstructural organization and evolution of 
lymphatics makes such models too advanced. The volumetric model proposed here is 
similar to that proposed by Taber et al. [117], but other volumetric models have been 
proposed for arteries that have offered a wide range of utility in understanding 
cardiovascular disease development [116, 268-270]. Without a thorough understanding of 
stress-dependent microstructural behavior of lymphatics, a volumetric growth model is a 
suitable starting point in understanding mechanically-mediated disease development.  
 Due to the spontaneous and rhythmic contraction of lymphatic vessels, the 
mechanical environment is significantly more complex than that seen in arteries that 
exhibit only tonic contraction. Consequently, growth behavior was assumed to depend on 
time-averaged values of stress that occur over the course of a single contraction cycle of a 
vessel. This consequently makes growth and remodeling behavior dependent on the 
frequency of contraction. In this case, duration of contraction was assumed to be 
constant, whereas frequency (as determined by the addition of the duration of contraction 
and refractory period) was calculated as a function of the spatially averaged transmural 
pressure (i.e. the average of the afterload and preload). The relationship between the 
frequency and transmural pressure was determined from values in the literature; however, 
the data in the literature is noisy, and thus the model is very inaccurate. Fractional pump 
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flow is explicitly dependent on the contractile frequency, and in order to accurately 
calculate such a metric, the relationship between frequency and transmural pressure 
should be better characterized. It should be noted that Gasheva et al. have demonstrated 
that shear-dependent production of nitric oxide from spontaneous contractions 
contributes to the maintenance of contractile frequency in rat thoracic ducts [124], but it 
is unknown how the geometry of vessel contributes to this behavior. 
Mihara et al. have reported thickening of lymphatic vessels in patients with 
lymphedema, and although they report increased pressures associated with thickening, 
pressure values are not reported, and neither are geometric changes quantified [16]. 
Similar results have been shown by another group that demonstrate phenotypic changes 
of muscle cells as well as changes in cross-sectional area of lymphatics in progression of 
lymphedema [271], but this study also lacks pressure measurements in order to correlate 
mechanical load with geometric evolution. Phenotypic changes of muscle cells may be 
associated with decreased contractility. These simulations do not incorporate any changes 
in the material parameters governing the contractility of the vessel (e.g. 9;<D;d and 9;<e;f) 
and therefore assume a constant maximum value of contractility and basal tone. 
However, proliferation and phenotypic changes of muscle cells would likely inhibit 
contractility and consequently the time-dependent flow profiles of the vessel. Such a 
relationship should be experimentally investigated and included in future simulations. 
 These simulations predict growth and remodeling behavior in the face of a 
constant adverse pressure gradient. There have been a multitude of other experimental 
and computational studies that have investigated the behavior of lymphatics under 
varying axial pressure gradients. Notably, Quick et al. developed a computational model 
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similar to the one proposed here and applied it to simulations of a favorable pressure 
gradient [152]. The simulations presented here make no account for conduit behavior of 
lymphatic vessels, an assumption considered valid only for cases of an adverse pressure 
gradient. Additionally, the experimentally determined material parameters used in the 
proposed model were evaluated for a single lymphangion with an axial pressure gradient 
of 0 cmH2O. While material parameters that govern passive mechanical behavior and 
maximum contractility should generally remain constant independent of load, strong 
correlations between loading conditions and parameters such as contractile frequency 
have been repeatedly demonstrated in many studies.  
 The mechanical environment of a single lymphangion is difficult enough to 
quantify; however, the model should ideally be expanded to support the prediction of 
flow through a chain of lymphangions as this is more physiologically relevant. Adding 
vessels onto a chain creates additional complication in prediction of behavior because 
timing and magnitude of contractions affect the pressure profiles within each respective 
segment of the chain and consequently affect valve behavior and bulk flow. Expansion of 
the model to support a chain would not only create difficulties in the mathematical 
modeling but would also require additional information of the mechanical properties of 
the tissue at locations of valve insertion. The current model treats valve locations as two-
dimensional planes with built in variable resistance, an assumption that obscures the 
nuances of mechanical behavior in a single vessel, but mechanical behavior at valve 
insertion may induce more pronounced changes in the transport capability of a long chain 
of vessels. 
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 Model limitations aside, this study provides a novel framework for the 
investigation of mechanically-mediated lymphatic growth and remodeling. The transport 
model (excepting growth) accurately recapitulates experimental data available in the 
literature investigating the effects of changes in the mechanical environment on 
lymphatic function. The successful development of the transport model provided a 
platform for the incorporation of mechanically-mediated growth and remodeling behavior 
in an actively pumping lymphangion. Our simulations suggest that a sustained elevation 
in afterload induces geometric changes in an isolated lymphatic vessel that is associated 
with decreases in standard markers of lymphatic function (e.g. ejection fraction). This 
model offers a novel perspective on potential parameters driving the progression of 
lymphatic dysfunction and the progression of lymphedema and directly motivates future 
studies to investigate lymphatic growth and remodeling.  
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                                                                 CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS  
5.1 Summary 
 The overall purpose of this study was to utilize various modeling techniques in 
biomechanics to test hypotheses that would identify key parameters in mechanically-
mediated disease development in the context of understudied populations. Two separate 
modeling techniques were employed to study two different diseases of the vasculature. 
First, a common mouse model of atherosclerosis was used to test the hypothesis that EFV 
treatment leads to arterial stiffening, a hypothesis motivated by clinical studies that 
established a correlation between EFV treatment and vascular remodeling and 
dysfunction in an Ethiopian population of HIV-1+ adults. Second, a microstructurally-
motivated mathematical model of lymphatic mechanical behavior was developed in the 
context of finite elasticity to test the hypothesis that changes in the mechanical 
environment of the lymphatic vasculature lead to mechanically-mediated growth and 
remodeling.  
 Cross-sectional clinical studies were performed in adult and pediatric Ethiopian 
HIV-1+ patients in order to investigate the role of various antiretroviral drugs in the 
progression of preclinical markers of CVD. PWA and PWV were analyzed in all patients 
in order to quantify arterial stiffening in the aorta. Non-invasive ultrasound was 
implemented to quantify arterial stiffening and geometric changes in the carotid artery as 
well as flow-mediated dilation of the brachial artery. EFV treatment was associated with 
various markers of CVD in the adult population, most notably an increase in arterial 
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stiffness as measured by PWV in EFV-treated subjects compared to NVP-treated subjects 
and impaired FMD in EFV-treated subjects compared to NVP-treated and HAART-naïve 
subjects. Given the significant HIV burden in sub-Saharan Africa, the prevalence with 
which EFV is prescribed, and the lack of data investigating HIV-related CVD in 
Ethiopian populations, this study offered useful information that motivated the need to 
better characterize the role of EFV in the development of CVD. Consequently, we 
employed a mouse model of atherosclerosis to study the effects of EFV on vascular 
remodeling independent of HIV infection and the drug cocktails associated with 
treatment. Mice were treated with EFV for 35 or 70 days. Biaxial mechanical testing was 
performed on suprarenal abdominal aortas following 35 days of treatment, and early 
onset of plaque progression was also quantified for both 35 and 70 days of treatment. 
This study demonstrated that EFV treatment leads to aortic stiffening and remodeling as 
quantified by compliance measurements and alteration of axial force and in vivo axial 
stretch, respectively. However, plaque progression was not different between groups. The 
observation of decreased compliance in EFV-treated mice supports the correlation 
between EFV treatment and increased PWV in aortas that was established in the clinical 
studies. Animal models offer significant advantages when attempting to study the effects 
of a drug, especially as it relates to vascular mechanics. Mouse models offer the ability to 
isolate the effects of the drug from the context of HIV-infection and combined therapy as 
well as the ability to directly study the behavior of the vasculature (as opposed to the non-
invasive methods utilized in clinical studies).   
 A pronounced gap exists in the lymphatic literature describing the mechanisms 
driving the onset of lymphedema. Thus, we sought to develop a novel experimental / 
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theoretical paradigm describing mechanically-mediated remodeling of the lymphatic 
vasculature in order to provide a useful tool for the investigation of the relationship 
between mechanics and the onset of lymphedema. We first performed active and passive 
biaxial mechanical testing of rat thoracic ducts to quantify the mechanical environment of 
lymphatic vessels using a microstructurally-motivated mathematical model. This model 
successfully recapitulated the spatial mechanical behavior of rat thoracic ducts including 
passive transmural pressure vs. diameter behavior, maintenance of basal tone, and 
contractile amplitude as a function of transmural pressure. Confocal microscopy was 
performed, and fiber angle orientation was quantified. The results suggested material 
asymmetry and high degree of variability between specimens. A predictive model of 
lymph transport was developed that incorporated the material parameters determined 
from biaxial testing and simulated changes temporal contractile behavior of an isolated 
lymphangion in response to elevated afterload. Calculation of functional pumping metrics 
suggested that the predictive capacity of the model was reasonable. This model was then 
utilized in a model of mechanically-mediated growth and remodeling in order to postulate 
the effect of the mechanical environment on the progression of lymphatic dysfunction 
and lymphedema. Simulations suggest that circumferential stress may be the primary 
mediator of lymphatic growth; however, the model should be interpreted with caution 
until experimental data can confirm or refute the predictions of the model. 
5.2 Limitations 
 Many limitations in this project motivate the need to perform future studies that 
improve upon the current results presented here. George E.P. Box stated that, “all models 
are wrong, but some are useful,” and we have here employed models at multiple 
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experimental and theoretical models at various scales. Our clinical studies investigating 
the relationship between treatment with EFV and accelerated progression of CVD utilize 
statistical models with inherent limitations primarily because of the study design. The 
study was cross-sectional and therefore does not offer data regarding causal relationships 
between antiretroviral treatment and markers of CVD. Additionally, the HIV-negative 
control group in the adult population was recruited by word of mouth and may have been 
predominantly from the neighboring cardiac facility, thus potentially biasing the results, 
and the pediatric population was without a control group due to the difficulty of 
recruitment of children. In all cases, clinical studies contain inherent difficulties when 
attempting to isolate specific variables, and certainly the population characteristics in our 
study increase the difficulty in analysis; however, we do not believe that these limitations 
impede the utility of the data provided. Future clinical studies may include longitudinal 
data in similar cohorts in order to investigate a causal relationship between EFV 
treatment and progression of CVD.  
 On another length scale is the animal model utilized to establish a link between 
EFV treatment and arterial stiffening. In contrast to the clinical studies, animal models 
offer a significant advantage in isolating specific variables and carefully controlling the 
experimental environment. However, animal models also pose obvious difficulties when 
attempting to interpret data in a clinical light. Our study suggests that treatment with EFV 
(75 mg/kg) leads arterial stiffening in a mouse model of atherosclerosis. However, it is 
difficult to interpret data between small rodents and humans. Mice have a significantly 
higher metabolism than humans, and without a pharmacokinetic study, it is difficult to 
know that plasma levels of EFV in mice are equivalent to those seen in humans. It should 
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be noted that the concentration utilized was 10 fold higher than the typical human dose, a 
value that has been utilized in studies investigating the effects other antiretroviral drugs 
on vascular dysfunction. Similarly, the physiologic environment within the mouse is not 
the same as that found in chronically infected HIV-1+ patients receiving HAART. 
Without the infection and the combination therapy, the interaction between EFV and the 
vasculature cannot be fully characterized. Additionally, ex vivo experiments such as those 
performed on the murine arteries in specific aim 1 neglect contributions from the 
perivascular tissue to the mechanical behavior of the artery. In such a case, the in vivo 
geometry and mechanical behavior can only be inferred rather than directly calculated.  
 Similar ex vivo studies were performed with rat thoracic ducts in order to quantify 
the active and passive mechanical properties of the vessel. The limitations in this case, 
however, extend beyond simply neglecting the contributions of the surrounding tissue. 
Microstructurally-motivated mathematical modeling was employed to characterize the 
mechanical properties of this tissue, and the model contains limitations of its own. We 
modeled the tissue as a non-linear, pseudo-elastic material comprised of four 
symmetrically oriented families of collagen fibers and uniformly distributed, isotropic 
elastin. We also included a tonic and rhythmic contractile response from lymphatic 
muscle cells using an adapted constitutive equation of active stress. Confocal microscopy 
revealed that the microstructural organization of the tissue does not contain 
symmetrically oriented collagen fibers and likely consists of one or two families rather 
than four. Thus, while the model was capable of predicting bulk pressure vs. diameter 
and axial force vs. pressure behavior, it cannot truly be characterized as 
microstructurally-motivated because the material asymmetry is not considered. Material 
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asymmetry likely leads to a small degree of torsion, which was also neglected in this 
portion of the project. Future studies of the passive mechanical behavior of lymphatic 
vessels should seek to better quantify the microstructural organization of the tissue and 
include material asymmetry and torsional components in the mathematical model. Active 
stress contributions were considered only for a case without an axial pressure gradient. 
However, studies have shown that contractile parameters such as frequency, amplitude, 
and tone are dependent on not only the transmural pressure but also the axial pressure 
gradient. Future studies should seek to more accurately quantify the active mechanical 
properties using a model that can include the relationship between contractile parameters 
and axial pressure gradient. With these limitations in mind, we believe that the utility of 
the model is not diminished as it still accurately simulates passive and active mechanical 
properties of the rat thoracic duct and at least begins to bridge the gap between empirical 
and truly microstructurally-motivated modeling. 
 Predictive modeling of both lymph transport and lymphatic growth and 
remodeling contain significant limitations. Accurate prediction of lymph transport 
requires accurate characterization of contractile behavior and valve behavior as well as 
quantification of loading (e.g. in vivo axial stretch, preload, afterload), geometry (e.g. 
unloaded thickness and radius), and fluid properties (e.g. viscosity). All of these are 
difficult enough to accurately quantify, and this does not include any consideration of the 
biological signaling (e.g. intracellular calcium concentration, pH, production of growth 
factors, cytokines, etc.) that undoubtedly affect the mechanical behavior of the vessel. 
Biological signaling aside, we sought to predict lymph transport behavior using the 
experimentally derived parameters obtained from biaxial testing in conjunction with a 
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model of Poiseuille flow. Although we made many assumptions and simplifications such 
as uniform valve behavior, no dependence of tone on fluid shear stress, and no turbulent 
or backwards flow, our model was still capable of recapitulating data observed for a 
single isolated lymphangion in the literature. Similarly, growth and remodeling 
predictions require accurate quantification of the mechanical environment of the tissue, 
characterization of the microstructure, and ideally consideration of the biological 
response of each constituent in the microstructure to changes in the mechanical, 
biological, and chemical environment. A volumetric growth model such as the one 
proposed here does not account for differential growth patterns of collagen, elastin, and 
muscle cells. Even the constrained mixture models of in the literature are lacking 
considerable data because the process driving turnover and deposition of ECM proteins is 
not well understood. Without any data available addressing remodeling of lymphatics in 
response to altered loading, a model of growth and remodeling can only be a useful tool 
for motivating future experimental frameworks. Despite many of the limitations of our 
model, the theoretical framework motivates future studies on isolated lymphatics and 
holds the potential for the identification of key parameters driving the remodeling 
process. As additional data becomes available, the model can be adapted to better support 
and predict behavior in order to identify such parameters.  
 Taken together, the limitations of this project represent the myriad of limitations 
present in modeling techniques that span multiple length scales and experimental settings. 
Although there were many limitations, this project offers novel insight into the 
relationship between biomechanics and disease progression in fields which have 
significant need for additional attention. We have quantified arterial stiffening, a known 
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preclinical marker of atherosclerosis, using non-invasive techniques in a clinical 
population of HAART-treated HIV-1+ patients, and we have quantified similar markers 
using ex vivo testing techniques in a mouse model of atherosclerosis. We also used 
similar ex vivo testing techniques and theoretical computational modeling to quantify the 
passive and active mechanical properties of rat thoracic ducts and predict transport 
behavior and growth and remodeling of an isolated lymphangion.  
5.3 Future directions 
 The long-term goals of this project are to utilize various modeling techniques to 
parse out the mechanisms driving mechanically-mediated disease progression. An initial 
goal in this light is to develop tools and frameworks that support quantification of disease 
progression, and we have successfully developed such tools by providing a mouse model 
of EFV-induced arterial stiffening as well as an experimentally-motivated predictive 
theoretical framework describing lymphatic dysfunction. Studies in the immediate future 
should seek to add descriptive and predictive capabilities to each of these models. For the 
clinical model, longitudinal studies should be performed in order to establish a causal 
relationship between EFV treatment and development of CVD. For the mouse model, 
studies in the immediate future may include more in-depth quantification of the 
mechanical changes of the blood vessels in response to EFV treatment (e.g. opening 
angle, microstructural organization) as has been previously performed [12]. The mouse 
model also offers the ability to parse out mechanisms driving vascular remodeling. 
Recent studies have implicated cathepsins in HAART-induced vascular remodeling. 
Utilization of additional knockout mice, specifically ApoE
-/-
 mice crossed with cathepsin 
K, cathepsin L, or cathepsin S knockouts can serve as an ideal next step for the 
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investigation of cathepsin-induced vascular remodeling in association with EFV 
treatment. Long-term studies should address identification of specific parameters 
contributing to EFV-induced vascular remodeling and should be coupled with models of 
HIV infection and eventually quantified in a clinical setting. Clinical verification of 
mechanisms driving HAART-induced remodeling can ultimately lead to either additional 
pharmaceutical intervention or development of better antiretrovirals that avoid 
mechanisms of action that operate on pathways detrimental to vascular health and 
integrity. 
 Similarly, studies in the immediate future addressing lymphatic biomechanics 
should seek to build up the theoretical framework and more accurately quantify the 
mechanical environment. Experimental setups that support the measurement of torsion 
may be utilized to better quantify the mechanical behavior of actively contracting 
lymphatic vessels and would thus support a model that includes shear stress in the wall of 
the vessel. Additional studies may also seek to quantify the effect of axial stretch on the 
contractile function of these vessels, a consideration that was neglected in the first 
milestone of specific aim 2 (note that axial stretch was, however, considered in the 
passive properties), or studies may address the relationship between axial pressure 
gradient and contractile function.  
 It is important to note that quantification of growth and remodeling as it relates to 
transport function is the primary goal of specific aim 2, and thus the mechanical 
environment during actual lymph transport should be better characterized. Specifically, 
valve characteristics are complicated, and accurate quantification of valve characteristics 
and behavior are critical for the prediction of flow through a lymphangion. Experimental 
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studies should be performed, noting that some have already tried [126], in order to 
improve the predictive capability of the transport model. The model should also be 
expanded to support prediction of flow metrics in a chain of lymphangions rather than a 
single isolated lymphangion. Similarly, a striking gap exists in the literature describing 
remodeling of lymphatic vessels in response to altered mechanical loading despite 
clinical evidence of lymphatic remodeling in the context of lymphedema [16, 271]. 
Animal models of lymphedema are currently available and may be utilized to quantify 
changes in geometry, microstructural organization, and cellular phenotype in order to 
better motivate predictive models of growth and remodeling. Long-term studies may seek 
to investigate mechanically-sensitive proteins or genes that contribute to changes in 
lymphatic function and thus provide insight into mechanisms driving lymphatic 
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/uL] 6.01 (4.55 - 6.71) 5.40 (4.29 - 6.49) 5.69 (4.12 - 6.96) 4.86 (3.83 - 6.48) 4.95 (4.06 - 5.89)
Neu [%] 56.6 (46.6 - 63.3) 51.3 (42.9 - 60.5) 54.7 (41.6 - 63.9) 50.8 (42.3 - 59.6) 52.8 (43.3 - 62.7)
Lym [%] 34.4 (26.3 - 45.1) 34.9 (28.4 - 45.8) 33.9 (26.9 - 44.6) 39.2 (30.1 - 47.7) 37.2 (29.9 - 41.3)
Mon [%] 3.4 (2.6 - 5.6) 4.3 (2.8 - 6.0) 4.2 (2.9 - 6.6) 4.9 (2.8 - 6.7) 5.5 (3.6 - 7.4)
Eos [%] 3.5 (2.1 - 5.3) 3.9 (2.0 - 6.9) 3.5 (1.6 - 7.0) 3.7 (2.0 - 6.1) 4.1 (2.4 - 6.1)
Bas [%] 0.5 (0.4 - 0.8) 0.4 (0.3 - 0.6) 0.5 (0.3 - 0.6) 0.5 (0.3 - 0.7) 0.6 (0.4 - 0.8)
MID [%] 8.0 (6.2 - 11.1) 9.7 (7.0 - 13.8) 9.1 (7.3 - 13.4) 8.9 (6.8 - 13.3) 10.5 (8.5 - 13.4)
Neu # [10
3
/uL] 3.32 (2.01 - 4.48) 2.76 (1.80 - 3.86) 2.90 (1.83 - 4.28) 2.29 (1.71 - 3.17) 2.36 (1.70 - 3.18)
Lym # [10
3
/uL] 2.01 (1.59 - 2.31) 1.94 (1.39 - 2.42) 1.85 (1.50 - 2.20) 1.83 (1.37 - 2.31) 1.70 (1.37 - 2.32)
Mon # [10
3
/uL] 0.19 (0.15 - 0.31) 0.22 (0.17 - 0.31) 0.22 (0.14 - 0.36) 0.21 (0.14 - 0.35) 0.28 (0.15 - 0.35)
Eos # [10
3
/uL] 0.21 (0.10 - 0.35) 0.22 (0.09 - 0.37) 0.17 (0.09 - 0.37) 0.17 (0.07 - 0.29) 0.18 (0.11 - 0.33)
Bas # [10
3
/uL] 0.03 (0.02 - 0.04) 0.02 (0.0 - 0.0) 0.02 (0.01 - 0.03) 0.02 (0.01 - 0.04) 0.03 (0.02 - 0.03)
MID [#] 0.46 (0.37 - 0.64) 0.49 (0.35 - 0.75) 0.50 (0.34 - 0.71) 0.41 (0.30 - 0.67) 0.55 (0.37 - 0.69)
RBC [10
6
/uL] 5.14 (4.76 - 5.31) 4.84 (4.43 - 5.29) 4.40 (4.05 - 4.67)
A,B
4.07 (3.68 - 4.57)
A,B,D
4.33 (3.98 - 4.53)
A,B
HGB [g/dL] 15.3 (14.6 - 16.3) 14.9 (13.8 - 15.7)
a
15.0 (14.1 - 15.8) 15.0 (14.1 - 15.7)
a
14.4 (13.6 - 15.2)
A,d,e
HCT [%] 44.5 (43.2 - 47.9) 43.5 (40.2 - 46.1)
a
43.1 (41.2 - 45.0)
A
42.6 (40.5 - 45.6)
A
42.5 (40.0 - 44.4)
A
MCV [fL] 89.3 (86.6 - 92.4) 88.7 (85.8 - 92.5) 97.8 (91.6 - 105.2)
A,B
104.6 (97.5 - 113.8)
A,B,D
98.4 (95.1 - 103.6)
A,B,E
MCH [pg] 30.5 (29.7 - 31.6) 30.2 (29.1 - 31.6) 34.0 (32.0 - 37.1)
A,B
36.5 (33.3 - 40.2)
A,B,D
33.2 (32.2 - 36.6)
A,B,E
MCHC [g/dL] 34.4 (33.9 - 34.6) 34.1 (33.3 - 34.4) 34.5 (33.6 - 35.3)
b
34.7 (33.8 - 35.4)
a,B
34.2 (33.3 - 34.8)
d,E
RDW-CV [%] 12.2 (12.0 - 12.5) 12.6 (12.2 - 13.2)
a
12.9 (12.2 - 13.9)
A
12.1 (11.6 - 12.8)
B,D
12.6 (12.0 - 13.4)
e
RDW-SD [fL] 45.0 (43.4 - 46.6) 46.1 (44.6 - 47.9) 50.0 (47.6 - 52.7)
A,B
51.2 (47.5 - 55.0)
A,B
49.6 (47.4 - 54.5)
A,B
PLT [103/uL] 254 (213 - 282) 247 (206 - 275) 273 (233 - 331)
a,B
243 (197 - 279)
D
246 (210 - 281)
D
MPV [fL] 9.5 (9.0 - 10.2) 9.1 (8.7 - 9.9) 8.9 (8.0 - 9.6) A 8.8 (8.3 - 9.7) a 9.1 (8.7 - 10.1)
PDW 16.0 (15.7 - 16.2) 15.9 (15.8 - 16.1) 15.8 (15.1 - 16.1) 15.8 (12.2 - 16.2) 15.9 (15.6 - 16.2)
PCT [%] 0.238 (0.206 - 0.272) 0.220 (0.194 - 0.257) 0.250 (0.210 - 0.287)
B
0.209 (0.181 - 0.245)
a,D
0.218 (0.197 - 0.249)
D
HIV-Negative HAART Naïve Efavirenz (EFV) Nevarapine (NVP) Lopinavir/r (LPV/r)
6% 4% 8% 6% 11%
75% 63% 46% 44% 48%
3% 2% 0% 2% 0%
3% 4% 4% 2% 0%
3% 6% 3% 2% 2%
0% 4% 5% 4% 9%
3% 8% 7% 5% 2%
0% 2% 0% 3% 5%
0% 6% 4% 9% 14%
0% 0% 0% 0% 2%
6% 4% 12% 16% 11%
Table A.1. Lifestyle, personal and familial history of CVD, and complete blood count 
(CBC) analysis in an Ethiopian population. Continuous variables are reported as median 
(interquartile range). A, a = p<0.005 or p<0.05 versus HIV-negative controls, 
respectively; B, b = p<0.005 or p<0.05 versus HAART-naive, respectively; D, d = 
p<0.005 or p<0.05 versus EFV, respectively; E, e = p<0.005 or p<0.05 versus NVP, 
respectively. 
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Figure B.1. Confocal imaging results from 6 rat thoracic ducts at high 




Figure B.2. Non-linear regression results for contractile frequency vs. transmural 
pressure data from the literature. 
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